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1 Abbreviations 
This thesis uses the international one-letter amino acid code. 
 
ADC albumin, dextrose, catalase 
Ag85a/b Antigen85 a/b of M. tuberculosis 
Alexa# Alexa Fluor® # 
AmCyan Anemonia majano cyan fluorescent protein 
APC antigen presenting cell 
APC allophycoerythrin 
APC-Cy7 allophycoerythrinCychrome7 
ATP adenosine tri-phosphate 
BAK BCG activated killer cells 
BAL bronchoalveolar lavage 
BCG Mycobacterium bovis bacillus Calmette Guérin 
BCR B-cell receptor 
Bej M. tuberculosis Beijing 
BSA bovine serum albumin 
BSL3 biosafety level 3 (S3/L3 in Germany) 
CD# “cluster of differentiation” international nomenclature for 
cell surface molecules 
CFU colony forming units 
CTL cytotoxic T-lymphocyte 
DC dendritic cell 
d days 
DNA deoxyribonucleic acid 
DosR Dormancy survival regulator 
dp double positive 
ER endoplasmatic reticulum 
E:T effector:target ratio 
eGFP enhanced green-fluorescent-protein 
ELISA enzyme-linked immunosorbent assay 
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ESAT6_CFP10 6 kDa early secretory antigenic target_culture filtrate protein 10 
fusion protein of M. tuberculosis 
FACS fluorescence activated cell sorting, flow cytometry 
FCS foetal calf serum 
FITC fluoreszeinisothiocyanat 
FSC forward scatter, in flow cytometry 
GM-CSF granulocyte-macrophage colony stimulating factor 
h hours 
HIV human immunodeficiency virus 
Hsp# heat shock protein # of M. tuberculosis 
ICS intracellular cytokine staining 
IFNγ interferon gamma 
IL interleukin 
kDa kilo-Dalton 
LAK  lymphokine activated killer cell 
LPS lipopolysaccharide 
LTBI latent tuberculosis infection 
M mol/L 
M. tuberculosis Mycobacterium tuberculosis 
mAb monoclonal antibody 
MF macrophages 
MHC major histocompatibility complex 
min minutes 
MOI multiplicity of infection 
MTB-lysate M. tuberculosis whole cell lysate 
NO nitric oxide 
NK natural killer cell 
OADC oleic acid, albumin, dextrose, catalase 
OD# optical density, # indicates wavelength in nm 
PAMP pathogen associated molecular pattern 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
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PCR polymerase chain reaction 
Pe phycoerythrin 
Pe-Cy5 phycoerythrin-Cychrome5 
Pe-Cy7 phycoerythrinCychrome7 
PerCP peridinin-chlorophyll-protein complex 
PerCP-Cy5.5 peridinin-chlorophyll-protein complex-Cychrome5.5 
Pen Penicillin 
PHA phytohemaglutinin from Phaseolus vulgaris 
PPD purified protein derivative of M. tuberculosis 
Rif rifampicine 
RNI reactive nitrogen intermediates 
ROI reactive oxygen intermediates 
Rpf resuscitation promoting factor 
rpm rounds per minute 
RT room temperature 
SEB Staphylococcus enterotoxin B 
SSC sideward scatter 
sp single positive 
Strep Streptomycin 
TAP transporter associated with antigen presentation 
TB tuberculosis 
tp triple positive 
TCR T-cell receptor 
Th1 T-helper cell type 1 
Th17 T-helper cell type 17 
Th2 T-helper cell type 2 
TNFα tumour necrosis factor alpha 
TLR Toll like receptor 
Treg T-regulatory cell 
TST tuberculin skin test 
v/v volume per volume 
w/v weight per volume 
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2 Abstract 
Adaptive immune responses to Mycobacterium tuberculosis (M. tuberculosis) are crucial for 
an efficient containment of the pathogen and protection against secondary tuberculosis (TB). 
Although key mediators like the Th1 cytokines IFNγ and TNFα released by M. tuberculosis-
specific T cells are known, the immunological correlates determining the outcome of infection 
remain elusive. The vast majority of infected individuals is able to control TB by cellular 
immunity leading to latent tuberculosis infection (LTBI) while only ~10% will develop active 
disease. A better understanding of the underlying immune processes and the identification of 
protective biomarkers for TB are central aims of this thesis. 
To address these topics adaptive immune responses to M. tuberculosis were analyzed in 
healthy LTBI and patients with active pulmonary TB. The recognition of M. tuberculosis 
derived antigens was studied by measuring the expression of IFNγ in CD4+ CD45RO+ 
memory T cells. A special hallmark was the inclusion of latency proteins associated with 
dormancy, reactivation and resuscitation of the pathogen. Optimized assay conditions were 
needed to detect T-cell responses towards latency-associated antigens by intracellular 
cytokine staining (ICS). This type of response cannot be detected by conventional short-term 
restimulation. 
Seven days (d) in vitro incubation of PBMC and two rounds of restimulation followed by 
FACS analysis revealed T cell mediated recognition of the majority of tested latency-
associated proteins in donors with LTBI. Comparison between active TB and LTBI 
documented significantly higher T-cell responses against 7 of 35 tested M. tuberculosis 
latency-associated antigens in LTBI.  
Notably, T cells specific for one M. tuberculosis antigen, namely Rv3407, were exclusively 
detected in the subgroup of LTBI. Discrimination analysis revealed that the T-cell response 
against selected antigens with our novel assay is capable of distinguishing TB patients and 
LTBI with 82% accuracy using cross-validation. Again Rv3407 was by far the most 
influential component present in this cluster. Peptide pool stimulation in a similar fashion 
identified single distinct candidate epitopes within Rv3407 in four LTBI. Comparison of T-
cell responses after short-term versus long-term stimulation demonstrated different 
prerequisites for in vitro restimulation between common immunodominant and latency-
associated M. tuberculosis antigens. These differences argue for a different maturation stage / 
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cellular phenotype of CD4+ CD45RO+ memory T cells recognizing latency-associate M. 
tuberculosis antigens. 
Additionally, cellular cytokine secretion patterns of M. tuberculosis-specific T cells were 
studied to evaluate the quality of adaptive immune responses contributing to protection 
against TB. This analysis documented an increased amount of poly-cytokine producing T 
cells in LTBI compared to active TB. Especially the amount of IFNγ/TNFα double positive 
(dp) and IFNγ/TNFα/IL2 triple positive (tp) T cells was affected and treatment with low 
doses of IL7 further increased this T-cell proportion. The in vivo relevance of poly-functional 
T cell subsets cannot be addressed by cross-sectional clinical studies and lead to the 
establishment of a novel in vitro killing assay based on flow cytometry.  
The infection of human monocyte-derived macrophages with enhanced green fluorescent 
protein (eGFP) expressing mycobacteria allowed the investigation of functional properties of 
different autologous T-cell subsets. Preliminary experiments proofed the potential of the new 
assay to quantify intracellular mycobacteria by measuring the amount of eGFP+ macrophages 
directly. Moreover, the in vitro assay revealed dose dependent killing of intracellular 
mycobacteria after co-culture with autologous PBMC activated by M. tuberculosis whole cell 
lysate and IL2. The determination of viable macrophages by flow cytometry after co-culture 
documented fundamental differences regarding the killing mechanism carried out by both 
types of effector PBMC. The collateral damage to macrophages varied significantly 
depending on the stimuli used for activation of autologous PBMC. Clearly such differences 
would have been missed by conventional plating of mycobacteria to determine bacterial titers. 
Nevertheless, and probably due to heterogeneity within the macrophage population, 
substantial assay to assay variations afflict the potential use of the novel assay to study host / 
pathogen interactions in vitro.  
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3 Introduction 
3.1 The immune system 
The mammalian immune system plays an important role in tumor surveillance, but its major 
aim is protection of the host against invading microorganisms and pathogens. Due to the 
broad variety of possible targets like viruses, bacteria, fungi, protozoa and parasites, mammals 
evolved complex defense mechanisms which comprise soluble (humoral) as well as cellular 
components. The immune system can be separated into the innate and the adaptive part. 
While the innate immune system is based on recognition of conserved features of the invading 
organism, the adaptive immune system is able to specifically target unique structures. Despite 
all mechanistic differences, both arms of the immune system are intertwined in order to 
provide efficient and long lasting protection. 
 
3.1.1 Innate immune responses 
The innate immune system reacts independently from immunological memory and is initiated 
immediately after contact with foreign antigens. The type as well as the kinetics of the 
response is not altered by re-encountering the same pathogen. The advantage of such a pre-
programmed system is the ability to combat foreign organisms immediately without inducing 
more specific ways of host defense. The rapid reactivity of the innate immune system 
predestines it as a “first line of defense”, since full activation can be achieved without re-
encountering the antigen. Consequently most of the invading organisms are cleared from the 
body without the help of adaptive immune responses (Medzhitov and Janeway, 2000). In 
order to fulfill these requirements the responsible receptors of the innate immune system 
sensing “non-self” antigens are germ line-encoded with a genetically predetermined 
specificity. These receptors (e.g. Toll-like receptors; TLRs) recognize conserved pathogen-
associated molecular patterns (PAMPs) present amon groups of microorganisms.  
Classically such molecular targets are lipopolysaccharides (LPS) of Gram-negative bacteria 
and lipoteichoic acids of Gram-positive bacteria (recognized by TLR-4 and TLR-2), 
respectively. Double stranded RNA from certain viruses (TLR-3) as well as flagellin of 
flagella expressing bacteria (TLR-5) also represent important target structures. 
Microbial DNA is recognized by TLR-9 as unmethylated cytosine–guanosine dinucleotide 
sequences flanked 5' by two purines and 3' by two pyrimidines (CpG motifs). Hence pattern 
                                                                                                                                   Introduction 
 
 7
recognition receptors are able to discriminate between different types of pathogens resulting 
in the activation of conserved host defense signaling pathways. For TB the involvement of 
TLR-2 as well as TLR-4 has been proposed (Means, et al., 1999). At least for TLR-2 which 
can recognize the M. tuberculosis derived 19kDa lipoprotein a role in innate host defence 
against TB could be demonstrated (Reiling, et al., 2002). 
TLR mediated secretion of inflammatory cytokines plays an important role since it stimulates 
potent presentation of antigens which cross-links the innate immune system to adaptive 
immune responses. Recognition of microorganisms leads to a diversity of innate cellular 
defense mechanisms like phagocytosis, secretion of signaling molecules or release of toxic 
granules. Efficient effector cells of the innate immune system are neutrophils, dendritic cells 
(DC) and macrophages. Neutrophils patrol the body in high numbers and in most cases they 
are the first immune cells encountering an invading pathogen, followed by monocytes which 
migrate more slowly to the side of infection. Consequently these immune cells are have the 
first contact to M. tuberculosis after airborne infection.  
Both cell types are able to engulf and kill invading pathogens by phagocytosis. For that 
purpose macrophages possess specialized receptors like the mannose receptor recognizing 
carbohydrates which are normally not exposed on the surface of mammalian cells in order to 
discriminate between “self” and “non-self” molecules (Stahl and Ezekowitz, 1998). Another 
example is the so called scavenger receptor binding to modified low density lipoproteins 
(Bowdish, et al., 2007). Additional phagocytic receptors expressed on macrophages and 
neutrophils are specific for antibodies and complement allowing enhanced phagocytosis of 
opsonized pathogens. The uptake of mycobacteria is very diverse and involves a variety of 
receptors which have different consequences on the immune response (see 3.2.2 The immune 
response against M. tuberculosis). 
DC also take up pathogens or cell debris but their main function is to process foreign antigens 
and present them to cells of the adaptive immune system. Finally Natural-Killer (NK) cells 
are important for the removal of virus infected or malignantly transformed host cells by 
recognizing the “altered self” stage of their target cells (Guevara-Patino, et al., 2003).  
Since inflammatory responses and the underlying reaction cascades also damage host tissue 
and cause necrosis, the activation of the innate immune system has to be tightly controlled. 
Macrophages for instance require danger signals, e.g. activation  through TLR or cytokine 
receptors to develop their full antimicrobial potential. Crucial in this process is interferon γ 
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(IFNγ) since it potently activates macrophages and the resulting production of toxic molecules 
enhances killing of engulfed microorganisms. The group of effector molecules includes 
reactive oxygen intermediates (ROI), reactive nitric oxide intermediates (RNI), antimicrobial 
peptides and lysozyme. Simultaneously activated macrophages secrete different cytokines like 
tumor necrosis factor α (TNFα), interleukin 12 (IL-12), interleukin 18 (IL-18) and various 
chemokines. All together synergistically lead to local inflammation and migration of innate as 
well as adaptive immune cells to the side of infection. Here TNFα is a very efficient inducer 
of other chemokines and their receptors. Up-regulation of E-selectin, intercellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) by endothelial cells 
allow leukocytes to leave the blood vessel and migrate into the tissue (extravasation). By 
chemotaxis the leukocytes are able to travel along the chemokine gradient and finally reach 
the inflammatory side (Janeway, 2005). Especially for the host response against M. 
tuberculosis, IFNγ together with TNFα can be considered to be key cytokines since they 
allow killing of intracellular mycobacteria and potently promote the activation of infected 
phagocytes. 
 
In addition to the induction of inflammation, cytokines are also needed for the generation of 
adaptive immune responses. As mentioned above the DC is an important connection between 
the innate and the adaptive immune system. Immature DC constantly endocytose soluble and 
particular antigens as well as apoptotic material (Schaible, et al., 2003). However 
inflammatory signals (IFNγ and/or TLR activation) are required for maturation of the DC to 
become an antigen presenting cell (APC). In the course of differentiation it exposes foreign 
peptides loaded onto MHC-molecules (major histocompatibility complex) on its surface and 
migrates to the draining lymph node. In addition, the mature DC increases the surface 
expression of co-stimulatory molecules like CD40, CD80 and CD86. They provide 
appropriate signals for activation of antigen-specific T cells of the adaptive immune system. 
This takes place in the specialized environment of the secondary lymphoid tissue where naïve 
T cells “scan” MHC-peptide complexes on mature DC with their unique T-cell receptors 
(TCR). The T cell with the appropriate TCR for the foreign peptide-MHC complex will 
proliferate and mount a specific adaptive immune response. 
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3.1.2 Adaptive immune responses 
In contrast to the predetermined receptors of the innate immune system, the specificity and the 
“target structures” of the adaptive immune system are not germ line encoded. They evolve 
constantly by genetic rearrangement, clonal selection and hypermutation (only B cells)  
(Janeway, 2005). Despite the limited repertoire of genes, the diversity of adaptive receptors 
(BCR and TCR) even exceeds the whole number of host genes. This is achieved by 
recombination of different gene segments on a cellular level during development, covering the 
plethora of possible epitopes (Delves and Roitt, 2000). The broad epitope repertoire of the 
adaptive immune system comprehends the risk of generating self-reactive lymphocytes 
leading to autoimmunity. Therefore auto-reactive lymphocytes are negatively selected during 
development in primary lymphoid organs. In addition, T cells and B cells recognizing their 
cognate antigen without co-stimulatory “danger signals” become apoptotic or anergic and lose 
their effector functions (Wucherpfennig and Strominger, 1995). Another mechanism to avoid 
autoimmunity and to shut down inflammatory processes and is carried out by specialized 
regulatory T cells (Treg) which will be described in further detail later on. 
 
The major effectors of the acquired immune system are B- and T cells. While B cells 
recognize soluble antigens directly via the B-cell receptor (BCR), a membrane bound variant 
of an antibody, T cells depend on epitopes presented within MHC-peptide-complexes. This 
means that B cells can sense discontinuous (steric) epitopes while T cells are limited to linear 
epitopes. Both cell types undergo activation and clonal expansion after encountering their 
cognate antigen during infection. After antigen-specific proliferation the B cell transforms 
into an immunoglobulin M (IgM) secreting plasma cell. Somatic hypermutation further 
increases the affinity of the antibodies and B cells are able to produce antibodies of different 
isotypes (class switch) by T-cell help. Only a small fraction of the expanded B cells will 
survive the so-called contraction phase after fighting down the infection and contributes to a 
long lasting memory. This allows the adaptive immune system to react rapidly after re-
encountering the cognate antigen since memory cells do not follow the kinetic of naïve 
lymphocytes and can proliferate directly leading to the instant generation of effector cells. 
T-cells follow a comparable kinetic but possess different features and requirements. Their 
activation depends on proper presentation of antigens by MHC molecules and can be 
influenced by the cytokine signature accompanying infection (cytokine imprint). MHC class I 
                                                                                                                                   Introduction 
 
 10 
molecules present their cargo (in most cases peptides) to CD8+ T cells while loaded MHC 
class II molecules interact with T cells carrying the CD4 co-receptor. The MHC molecules are 
not equally distributed since class I is present on every host cell while class II is restricted to 
professional APC. 
 
 
Fig. 1: Antigen presentation pathways.  
Molecular mechanism for presentation of endogenous and exogenous antigens. a) Endogenous 
proteins are degraded by the proteasome and short peptides are actively transported into the lumen of 
the ER by TAP molecules. Peptides are loaded onto MHC-I molecules, reach the cell surface via the 
secretory pathway and can be presented to CD8+ T cells. b) Exogenous antigens are taken up by 
endocytosis, degraded inside the endosomes and finally antigenic peptides reach the MIIC/CIIV 
compartment. Here appropriate peptides can be loaded onto activated MHC-II complexes and are 
presented to CD4+ T cells on the cell surface. c) By cross presentation endogenous antigens can reach 
the MHC-I pathway and will be presented to CD8+ T cells. According to (Heath and Carbone, 2001) 
 
Classically cytosolic antigens, e.g. viral proteins, are degraded by the proteasome and small 
peptides are then shuttled into the lumen of the endoplasmatic reticulum (ER) by transporters 
associated with antigen processing (TAP). TAP is a member of the ABC transporter family 
and is a heterodimeric multimembrane-spanning polypeptide consisting of TAP1 and TAP2. 
The two subunits form a peptide binding site and two ATP binding sites that face the lumen 
of the cytosol. Inside the ER peptides which fulfill special criteria (anchor amino acids at 
position 2 and 9) are loaded onto MHC-I complexes. MHC class I molecules are 
heterodimers, consisting of a single transmembrane polypeptide chain (the α-chain) and a 
soluble β2 microglobulin (which is not encoded within the MHC gene locus). The α chain has 
three polymorphic domains, α1, α2, α3. Between α1 and α2 is the peptide-binding groove which 
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binds peptides derived from cytosolic proteins with a typical length of 8-9 amino acids. After 
assembly of the MHC-peptide complex the molecule reaches the cell surface via the secretory 
pathway. This passage includes a number of post-translational modifications, especially 
regarding N-glycans which mature inside the Golgi apparatus. 
In contrast to MHC-I molecules, the invariant chain (Ii) prevents MHC class II molecules 
from being loaded inside the lumen of the ER. Like MHC class I molecules, class II 
molecules are heterodimers, but they consist of two homologous peptides, an α and β chain, 
both of which are encoded in the MHC. Because the antigen-binding groove of MHC class II 
molecules is open at both ends it binds longer peptides with a typical size of 15-24 amino 
acids. The corresponding groove on class I molecules is completely embedded leading to the 
binding of shorter peptides. After passage of MHC-II-Ii complexes through the Golgi 
apparatus they reach the MIIC/CIIV compartment and the invariant chain is degraded. MHC-
II complexes are now able to bind antigenic peptides which enter the APC via the endocytic 
route. However the dogma of endogenous antigens presented via MHC-I and exogenous 
antigens presented via MHC-II does not hold true, because DC for instance can transfer 
exogenous antigens from other cells to their own MHC-I pathway in a process called cross 
presentation (Rock and Shen, 2005; Winau, et al., 2004). Although the details of this pathway 
remain elusive, specialized subcellular compartments bearing characteristics of both, the 
endoplasmic reticulum and the endosome, seem to be involved (Guermonprez, et al., 2003). 
TAP dependent TAP independent processes are crucial for this process which is in the focus 
of present immunological research (Burgdorf, et al., 2008). Since M. tuberculosis is 
internalized by phagocytes and resides inside a membrane bound vesicle, the most prominent 
T-cell response is carried out by CD4+ T cells which recognize mycobacterial antigens via 
MHC-II. Interestingly cross presentation to CD8+ T cells seem to be play a role in long term 
immunity to TB. It could be shown that apoptotic vesicles harbouring mycobacterial antigens 
are taken up by APC and lead to priming of CD8+ T cells (Schaible, et al., 2003). 
 
Once activated and expanded the effector cells of the adaptive immune system possess a 
functional diversity to fulfil their specific role. According to the recognition of cytosolic 
antigens the major task of CD8+ T cells is T-cell mediated killing of infected host cells. Such 
cytotoxic T lymphocytes (CTL) are important for the removal of virus infected cells, but also 
contribute to the defence against other intracellular pathogens as well as malignantly 
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transformed host cells (Bevan, 2004). CTL either induce programmed cell death by FAS 
(factor activating ExoS) – FAS ligand interaction (apoptosis) or initiate direct killing by the 
release of cytotoxic molecules like granzyme, perforin or granolysin (necrosis) (Barry and 
Bleackley, 2002; Masson, et al., 1986; Stalder, et al., 1994). These cytotoxic effector 
molecules can also act on intracellular pathogens. After killing of their host cell they are 
exposed to other components of the humoral and cellular immunity. 
The destiny of a CD4+ T cell after antigen-specific activation is even more diverse. The 
differentiation is influenced by the co-stimulatory signals as well as the cytokine environment 
produced by cells of the innate immune system upon infection (Feili-Hariri, et al., 2005).  
Today four distinct CD4+ T-cell lineages with different functional features are known – 
namely the Th1, Th2, Th17 and the Treg lineage.  
T-helper cells type 1 (Th1) are normally induced by IL12 or IFNγ during the early phase of an 
infection and act as pro-inflammatory mediators of the immune system. They are involved in 
the defence against many intracellular bacteria and protozoa since Th1 cells are potent 
activators of phagocytes, especially macrophages. Hereby the major effector cytokines are 
IFNγ and TNFα which synergistically stimulate macrophages and influence adjacent T cells 
to differentiate into Th1 cells (polarization). IL2 is also produced by activated Th1 cells. It 
serves as a growth factor for T cells in the periphery and supports the expression of other 
effector cytokines. Another important cytokine in this context is the granulocyte-macrophage 
colony stimulating factor (GM-CSF) which enhances microbicidal activity, oxidative 
metabolism and phagocytotic activity of neutrophils and macrophages. It also improves the 
cytotoxicity of these cells. More cytokines and chemokines are known to be produced by Th1 
cells representing the complexity of adaptive immune responses. All together the set of Th1 
related cytokines promote inflammation and cell mediated cytotoxic responses. 
The counterpart of the Th1 is the Th2 lineage which promotes a different cytokine milieu 
leading to humoral instead of cellular immune responses. Th2 cells are generated after 
encountering IL4 during interaction with the APC and react with the secretion of various anti-
inflammatory cytokines beneficial for humoral immune responses (antibody production). By 
release of IL4, IL5 and IL13 T helper cells of the Th2 subset activate mast cells, basophils as 
well as eosinophils which play a role in the defense against helminths (Cherwinski, et al., 
1987; Janeway, 2005; Jankovic, et al., 2001; Mosmann, et al., 1986; Mosmann and Coffman, 
1989; Romagnani, 1991). Although Th1 ad Th2 lineages represent antagonistic arms of the 
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adaptive immune system, many examples are known where both lineages are influenced and 
regulated (Maziak, 2003; Nabel, 2002; Szabo, et al., 2003). 
 
Fig. 2: T-cell lineages and their specific functions. 
Th1 and Th2 cells are counter-balanced parts of the immune system leading to inflammation and 
cellular responses on the one hand and humoral immunity on the other hand. While Th1 cells are able 
to activate macrophages (fighting intracellular bacteria / protozoa) Th2 cells are involved in the 
defence against helminths. The newly discovered Th17 cells represent another distinct lineage which 
activates neutrophils by the release of IL17 and IL22. Hereby Th17 cells contribute to protection 
against extracellular pathogens. To a variable degree the help of all sub-lineages is needed to promote 
humoral immune responses by B cells. Suppressive Treg cells needed for a tight control of cellular 
immune responses are not shown in this overview. According to (Medzhitov, 2007). 
 
Treg cells mostly share the CD4+ CD25+ phenotype, but can also be CD25- or CD8+. A more 
general feature is the expression of the transcriptional regulator forkhead box P3 (FoxP3). 
Their task is not only to maintain self-tolerance and homeostasis, Treg cells are also needed to 
terminate the immune response properly after the successful clearance of the pathogen. 
Similar to conventional T cells Treg cells develop in the thymus and expand in an antigen-
specific manner. They have been shown to prevent expansion of classical effector T cells in 
vivo and inhibit T-cell activation in vitro. The suppressor mechanism of regulatory T cells is 
not clearly understood but interleukin 10 (IL10), transforming growth factor β (TGFβ) and 
cytotoxic T-lymphocyte associated molecule 4 (CTLA-4) seem to be involved (Annacker, et 
al., 2001; Fontenot, et al., 2003; Hori, et al., 2003; Read, et al., 2000; Shevach, 2000). 
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Finally an additional T helper cell subset has been identified: Th17 cells were named 
according to the characteristic expression of IL17 upon specific stimulation. This cytokine 
fulfills an important effector function in host response to bacteria (e.g. the attraction of 
neutrophils to the site of infection) but can be also linked to autoimmunity (Kolls and Linden, 
2004). In the mouse system, IL6 and TGFβ syngergize to induce Th17 cells while their 
effector function is dependent on the presence of IL23 (Aggarwal, et al., 2003; Veldhoen, et 
al., 2006). In contrast to the murine system, the induction of human Th17 cells depend on 
IL1β and IL6, but not on TGFβ (Acosta-Rodriguez, et al., 2007). Of several known innate 
immune stimuli, bacterial peptidoglycan (PGN) was most potent at eliciting IL-17 production. 
Probably muramyl dipeptide, a product of PGN catabolism and a ligand for NOD2 
(nucleotide-binding oligomerization domain containing 2), is responsible for the observed 
production of effector cytokines. Remarkably NOD2 is often mutated in Crohn´s disease 
(CD), an autoimmune condition characterized by excessive intestinal inflammation (Meylan, 
et al., 2006). Moreover misregulation of IL-23 and the Th17 axis have been implicated in the 
pathogenesis of CD (Duerr, et al., 2006). The role of different T-cell subsets as well as B cells 
in host defense against TB will be described in the next chapter. In brief, CD4+ T cells of the 
Th1 lineage are key players and absolutely required for control of bacterial growth while Th2 
cells have adverse effects on the outcome of infection (Caruso, et al., 1999; North, 1998). The 
function of Th17 cells and B cells is not clearly understood. The absence of B cells within 
knock-out experiments in mice did not cause altered susceptibility to TB (Turner, et al., 
2001). Although IL17 is an important factor in inflammation and attracts neutophils as well as 
macrophages, its absence did not lead to a server immunopahology as long as Th1 cells are 
present (Khader and Cooper, 2008). Anyway Th17 cells may be important to orchestrate the 
immune response to TB since vaccinated animals lacking this T-cell subset showed a loss of 
protection (Khader, et al., 2007).  
 
3.2 Tuberculosis 
M. tuberculosis, the etiologic agent of TB in humans, causes 9.2 million new infections every 
year and 1.7 million deaths annually (WHO, 2008). Especially in high incident countries like 
Africa or Asia TB, also known as the wasting disease, is a major reason for morbidity and 
death. Acute infection goes along with fever, night sweat, weight loss, fatigue, lassitude, 
rheumatic pains, coughing, gastroenteritis and lethargy. Due to estimations of the World 
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Health Organization up to one third of the world’s population is latently infected with M. 
tuberculosis, underlining the fact that patients with acute disease only represent the tip of the 
iceberg (WHO, 2008). 
 
3.2.1 History and modern weapons 
Already in 1882 Robert Koch discovered the etiologic agent of TB which has been named M. 
tuberculosis later. The pathogen is a facultative intracellular bacterium with an extremely long 
doubling time up to 48 hours and a thick, waxy-like cell wall (Koch, 1882; Lehmann and 
Neumann, 1896). This unique cell wall contains a mycolic acid layer, connected via 
arabinogalactan polysaccharide to the conventional peptidoglycan layer (Barry, et al., 2007) 
and contributes to the special features of the pathogen to withstand host immune defense (see 
3.2.2 The immune response to M. tuberculosis).  
The early approaches by Robert Koch to establish a vaccine against TB based on tuberculin 
were not successful (Brock, 1988). Soon thereafter two French researchers, Albert Calmette 
and Camille Guérin, attenuated the related cattle pathogen Mycobacterium bovis and 
delivered it as a live vaccine. In 1921 the so-called M. bovis bacillus Calmette Guérin (BCG) 
was introduced to the public and provided protection against childhood TB which is 
associated with severe courses of disease like TB meningitis (infection of the meninges by M. 
tuberculosis) or military TB (disseminated infection) (Clarke and Rudd, 1992). Despite all 
advantages BCG immunization was not very popular in the beginning and this became worse 
after the disaster in Lübeck where in 1927 more than 70 infants died due to a contamination of 
M. tuberculosis within the BCG preparation (Moses, 1930). Meanwhile BCG has become a 
successful live-vaccine against TB in newborn and infants, but it remain ineffective against 
adult pulmonary TB (Reece and Kaufmann, 2008).  
Regarding the treatment of active disease a major breakthrough was the discovery of 
antibiotics and the usage of streptomycin to cure TB (Schatz, et al., 2005). Today the 
recommended drug regiment comprises four different first-line drugs which have to be taken 
for six up to nine months. These drugs are aiming at different molecular pathways of the 
pathogen: Isoniazid (Inh) exhibits its bactericidal effects by inhibition of cell wall mycolic 
acid synthesis and other basic metabolic activities. Rifampicine (Rif) inhibits specifically the 
RNA synthesis by targeting the RNA polymerase β subunit. Pyrazinamide (Pza) is a structural 
analogon of  
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nicotinamid and interferes with the membrane energy metabolism also leading to a disrupted 
membrane transport. The last drug in this scheme is ethambutol (Eth) which acts 
bacteriostatically by impairing the cell wall arabinogalactan synthesis (probably by blocking 
the underlying arabinosyl transferase which prevents cell wall arabinan polymerization) 
(Zhang and Amzel, 2002). In that regiment rifampicine is the only broad-spectrum drug since 
the other substances are TB specific. However the appearance of resistances against these 
first-line drugs either by incomplete treatment or spontaneous mutations is a serious problem. 
Multi drug resistant TB (MDR-TB) is characterized by lost effectiveness of at least isoniazid 
and rifampicine, the two most powerful anti-TB drugs (Zhang, 2005). The treatment requires 
prolonged and more expensive chemotherapy including second-line drugs, i.e. para-amino-
salicylate, kanamycin, cycloserine, ethionamide, amikacin, capreomycin, thiacetazone and 
fluoroquinolones (Zhang and Amzel, 2002). Recently extensively drug resistant (XDR) 
strains were identified. This means that such bacilli are even resistant to at least three of the 
six classes of second-line drugs. A well known example is the study of Tugela Ferry (South 
Africa) monitoring 544 patients of whom 221 suffered from MDR-TB including 53 cases of 
XDR-TB (Singh, et al., 2007). This forced the WHO to strengthen its efforts on TB leading to 
the release of new guidelines for treatment (DOTS-plus), public campaigns as well as 
improvement of health care systems. An additional part of the global STOP TB strategy 
launched in 2006 was to develop better drugs, diagnostics and vaccines (Torrelles, et al., 
2008; WHO, 2008). 
 
3.2.2 The immune response against M. tuberculosis 
The high rate of healthy individuals with LTBI can be explained by the typical course of 
infection. M. tuberculosis is being transmitted via aerosol from a person with active TB. By 
inhaling droplets the pathogen reaches the lung where it encounters the pulmonary innate 
immune system, the first line of defense against microbes entering via the respiratory route. 
As already mentioned the innate immunity is based on the broad recognition PAMPs. Due to 
the unique waxy cell wall structure of M. tuberculosis the pathogen is more resistant to 
soluble direct antimicrobial components like the pulmonary surfactant proteins A and D 
(Torrelles, et al., 2008). Consequently, phagocytes within the lung alveoli play a key role 
since their surface is rich in complement receptors and C-type lectin pattern recognition 
receptors (Torrelles, et al., 2008). Important for the internalization of M. tuberculosis are the 
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mannose-receptor, dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) and DC-
associated C-type lectin-1 (Dectin-1) on bronchoalveolar macrophages. These receptors can 
directly or indirectly bind to sugar residues within the cell wall of the pathogen (Aderem and 
Underhill, 1999) and contribute to the propagation of pro-inflammatory signals (Jo, 2008). 
Interestingly the recognition of M. tuberculosis components via TLR triggers intracellular 
signaling cascades that promote inflammation, but can also trigger signals that dampen the 
innate immune response (Jo, 2008). Consequently the interaction of M. tuberculosis with 
pattern recognition receptors leads to activation or suppression of the host immune system, 
depending on the entry route and the accompanying signals. 
The complement cascade is also involved in the uptake of mycobacteria. Activation via the 
alternative pathway leads to the deposition of C3b and C3bi on the bacterial surface which 
allows internalization by complement receptor 1 and 3 (Schlesinger, et al., 1990). 
Additionally the opsonization by C3b can be achieved by mechanisms which are specific for 
pathogenic mycobacteria, based on the formation of a C3 convertase after association of C2a 
with surface factors of the pathogen (Schorey, et al., 1997). 
 
Once internalized, M. tuberculosis is contained inside a membrane bound vacuole. Classically 
the pathogen is believed to actively interfere with phagolysosomal fusion by immune evasion 
mechanisms (Hart, et al., 1972). It has been proposed that a lack of acidification based on the 
impaired recruitment of proton-ATPases is responsible for the inhibited maturation of 
phagosomes (Sturgill-Koszycki, et al., 1994). More recent studies could even show that M. 
tuberculosis is able to maintain intrabacterial pH under acidified lysosomal conditions 
(Vandal, et al., 2008). However, the pathogen is able to reside and proliferate inside these 
early phagosomes.  
Within the alveolar phagocytes M. tuberculosis reaches the lung parenchyma and later the 
draining lymph nodes where macrophages and DC present mycobacterial antigens to T cells 
(Kaufmann and McMichael, 2005). At the site of infection dying macrophages attract 
monocytes and other immune cells leading to inflammation and formation of a local lesion. 
The whole process involves the release of TNFα and results in the secretion of chemokines as 
well as the up-regulation of chemokine receptors. The help of the adaptive immune system is 
needed to fully activate macrophages to kill intracellular mycobacteria (fig. 3). Important for 
the generation of an adaptive immune response are DC which can take up bacilli via DC-
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SIGN. They are also crucial for cross-presentation of mycobacterial antigens to T and B cells 
by processing apoptotic vesicles (Winau, et al., 2006). Initial studies with B cell deficient 
mice could not demonstrate a higher susceptibility to aerogenic infection with M. tuberculosis 
than wildtype mice based on the survival time (Turner, et al., 2001). Nevertheless, more 
recent studies observed higher bacterial titers and an exacerbated immunopathology with 
enhanced recruitment of neutrophils in these knock-out mice compared to wildtype 
(Maglione, et al., 2007). Hence, the role of antibody-mediated immunity to TB in humans is 
not completely understood and needs further investigation. 
In contrast CD4+ as well as CD8+ T cells are essential for the host defense against M. 
tuberculosis infection. Mouse strains deficient for HLA-II or CD4 molecules die shortly after 
M. tuberculosis infection (Caruso, et al., 1999) while in vivo depletion of CD8+ T cells 
impairs the long-lasting containment of the pathogen rather than the acute immune response 
(van Pinxteren, et al., 2000). As already mentioned the cytokine milieu which is produced 
upon TLR activation and intracellular infection of macrophages/DC is dominated by TNFα 
and other pro-inflammatory cytokines like IL12 and IL18. This cytokine environment leads to 
the biased differentiation of CD4+ T cells into Th1 cells. Following recognition of cognate 
mycobacterial antigens via their TCR within the lymphoid tissue they undergo clonal 
expansion and maturation. Fully activated Th1 T cells start to modify their homing receptors, 
migrate to the side of infection and directly exert effector functions after re-encountering their 
specific antigen presented on MHC-II complexes. 
Major effector cytokines in this process released by T cells are IFNγ and TNFα. Both are 
actively secreted by effector CD8+ T cells as well as CD4+ T cells of the Th1 lineage. IFNγ as 
well as TNFα have broad effects on mammalian host cells, but in case of M. tuberculosis 
infections their most important functions are activation of phagocytes and tissue remodeling.  
The IFNγ receptor consists of two different membrane bound subunits (R1 and R2) which are 
ubiquitously expressed on mammalian cells with the exception of erythrocytes. After homo-
dimerization of IFNγ-R1 the complex associates with IFNγ-R2 leading to Janus-Kinase (JAK) 
mediated activation of signal transducer and activator of transcription 1 (STAT1). Active 
STAT1 translocates to the nucleus and induces transcription of direct response genes and 
more than 40 transcription factors resulting in a cascade like regulation of secondary response 
genes (Foxwell, et al., 1992). Despite broad effects on cell cycle regulation and apoptosis 
IFNγ acts more specifically on phagocytes. The bactericidal capacity of macrophages is 
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increased by generation of RNI / ROS mediated by the induction of the inducible nitric oxide 
synthase (iNOS) and assembly of the enzyme complex phagocyte oxidase (phox), 
respectively. IFNγ signals also promote phagosome-lysosome fusion and hereby overcome 
the immune evasion mechanisms of M. tuberculosis (Boehm, et al., 1997; Bogdan, et al., 
2000). A general feature of IFNγ-receptor signaling is the up-regulation of MHC-I molecules 
on immune cells as well as MHC-II on nucleated cells to improve antigen presentation. In 
parallel the processing of antigens is optimized by induction of specialized proteasome 
subunits (immunoproteasome) and increased levels of TAP molecules (Kloetzel, 2001). 
Additionally the expression of adhesion molecules like ICAM-1 on vascular endothelial cells 
is increased. Together with the INFγ induced release of IP10 (interferon inducible protein 10), 
I-TAC (interferon-inducible T-cell alpha chemoattractant / CXCL11) and Mig (monokine 
induced by gamma-interferon / CXCL9) this leads to infiltration of CXCR-3 expressing 
leukocytes (macrophages, neutrophils, activated T cells) into the tissue (Boztug, et al., 2002; 
Dufour, et al., 2002).  
 
 
Fig. 3: Interaction of T cells with M. tuberculosis infected macrophages.  
After phagocytosis M. tuberculosis resides in a unique membrane-bound vacuole and prevents phago-
lysosomal fusion. To overcome this situation T-cell help and activation of the macrophage is required. 
Macrophage activation by IFNγ and TNFα promotes phagosomal maturation, vacuole acidification 
and the production of antimcrobial molecules, such as reactive nitrogen intermediates (RNI) by nitric 
oxide synthase 2(NOS2), reactive oxygen intermediates (ROI) or antimicrobial peptides. The release 
of the pro-inflamatory cytokines TNFα, IL18 and IL23 by activated macrophages also controls 
intracellular replication of mycobacteria, while IL12 promotes the secretion of IFNγ. Modified 
according to (Monack, et al., 2004). 
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The importance of IFNγ for host defense against infections becomes obvious in humans with 
hereditary IFNγ receptor deficiency. The ineffective immune response causes death by 
otherwise harmless intracellular bacteria. Even BCG vaccination in that scenario can be lethal 
(Jouanguy, et al., 1997). Various studies with knock-out mice also proved the fundamental 
role of IFNγ which in synergy with TNFα and IL18 orchestrates the immune system (Cooper, 
et al., 1993). TNFα is also released by Th1 cells upon antigen-specific stimulation and can be 
secreted by macrophages/monocytes, neutrophils and NK cells after encountering bacterial 
lipopolysaccharides. The main receptors for TNFα are two high affinity subtypes (TNF-R1 
and TNF-R2; also known as CD120a and CD120b) present on all somatic nucleated cells. The 
C-terminal intracellular region of TNF-R1 contains a so-called death domain, which is 
involved in signaling events leading to programmed cell death. The death domain of TNF-R1 
interacts with a variety of other signaling adaptor molecules, including TRADD (TNF-R1-
associated death domain protein) and RIP (receptor interacting protein) leading to the 
activation of the transcription factor NF-kappa-B (nuclear factor kappa B). NF-kappa-B 
responsive genes include those coding for a number of cytokines and growth factors, cytokine 
receptors, receptor signaling proteins, cell adhesion molecules and many other proteins 
involved in various processes (Baldwin, 1996). In resting macrophages TNFα induces the 
synthesis of IL1, prostaglandin E2 and stimulates phagocytosis. Like IFNγ TNFα causes up-
regulation of cellular adhesion molecules and attracts immune cells to the side of infection. 
The dramatic influence of this key cytokine can be observed during anti-TNFα therapy in 
patients with arthritis leading to significant reactivation of TB in LTBI (Brassard, et al., 
2006). 
In summary, the local secretion of IFNγ and TNFα synergistically activates phagocytes to kill 
intracellular mycobacteria, attracts leukocytes (macropahges, neutrophils, activated T cells), 
promotes antigen processing and presentation as well as tissue remodeling. 
 
3.2.3 Granuloma formation 
Waves of infiltrating immune cells wall off infected macrophages and the resulting structure 
is called granuloma. It consists of central necrosis with is characterized by hypoxic conditions 
at later stages of infection. The granuloma contains M. tuberculosis infected phagocytes, 
surrounded by macrophages and leukocytes which probably try to kill the pathogen. 
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Consequently it has been speculated that inflammation, tissue damage and necrosis is limited 
to the granulomatous structure. The caseous granuloma can also be identified by X-ray 
examination and still contributes to diagnosis of clinical TB. The majority of infiltrating cells 
are CD4+ T cells but also γδ T cells, unconventional CD1 restricted T cells and B cells are 
present within the granuloma and its periphery (Ulrichs and Kaufmann, 2006). The granuloma 
is a highly organized structure with a characteristic composition of cells present within 
different foci (fig. 4). The inner layer next to the central necrosis is rich in CD4+ T cells as 
well as CD68+ macrophages, while CD8+ T cells are rare. Epithelioid cells and Langhans 
giant cells are also present in this area. The adjacent outer layer consists of massive 
lymphocyte infiltrations with high amounts of CD4+ and CD8+ T cells. While the inner layer 
seems to be the side of action for effector T cells and phagocytes, the outer layer is 
characterized by different lymphocyte subsets and may contribute to vigorous T cell priming.  
 
Fig. 4: Schematic overview of the lung granuloma architecture.  
The hypoxic area of the central necrosis contains mycobacteria and oxidative stress signals drive M. 
tuberculosis into the dormant stage of its life cycle. The surrounding inner layer is rich in CD4+ T 
cells as well as macrophages (CD68+), while CD8+ T cells are rare. The outer layer also harbors CD8+ 
T cells and is less dense compared to the inner layer which walls of the central necrosis. Within the 
active centers in the periphery of the granuloma cross-talk of B-cells, T-cells and APC takes place. 
According to (Ulrichs, et al., 2004). 
 
Interestingly the active centers surrounding the granuloma contain high amounts of B cells, T 
cells and M. tuberculosis infected APC. Histological analysis revealed that the B cells 
comprised different states of B-cell differentiation, containing both naïve (CD23+) B cells and 
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memory (CD27+) B cells as well as antibody-secreting plasma cells (Ulrichs, et al., 2004). 
The presence of different maturation stages is reminiscent of B-cell follicles in lymph nodes. 
Strong proliferation within the active centers and the outer layer of the granuloma in close 
proximity to professional APC emphasize the important role of granulomatous structures to 
promote cross-talk and priming of T and B cells. In the later stages of infection the granuloma 
will be surrounded by a fibrotic wall and gain a lymphoid follicular structure (Kahnert, et al., 
2007). It has been proposed that the cell aggregates in the tissue surrounding granulomatous 
lesions in TB assume the structure and function of secondary lymphoid follicles, which ensure 
orchestration of the complex and long-lasting immune response to TB (Ulrichs, et al., 2004). 
Despite joint efforts of the innate and acquired immune system the host is not able to 
eradicate the pathogen completely. Oxidative stress signals in the central area drive the 
pathogen into the dormant stage of its life cycle and lead to the upregulation of dormancy-
associated proteins. The shifdown of M. tuberculosis from active replication to dormancy can 
be separated into at least two steps. Within the first phase the pathogen changes from fast to 
slow replication while the second step is leading to a complete shutdown of replication 
(Wayne, 1994). Dormancy is characterized by low/absent metabolic activity and survival 
under hypoxic conditions. Dormant mycobacteria contribute to a long lasting reservoir of 
infectious bacteria leading to the latent stage of infection (see 3.2.4 Latency versus active 
disease). 
 
3.2.4 Latency versus active disease 
As already mentioned the vast majority of M. tuberculosis infected individuals will not 
develop active TB but remain latently infected for the rest of their lives. Only 5-10% of all 
infected individuals will suffer from active disease and 50% of them will develop TB within 
the first three years after infection. Although potent host defense mechanisms against M. 
tuberculosis and other intracellular pathogens exist, the course of diseases is marked by a long 
lasting balance between protective immune responses on the one hand and immune evasion of 
the bacilli on the other hand. Normally the primary infection takes place within the central 
part of the lung (Ghon complex) from where bacteria can spread through the lymphatic 
system to the blood and finally re-infect the lungs. This leads to the formation of secondary 
lesions and in case of immune-competent individuals the pathogen can be contained within 
granulomatous structures. Generally the primary infection can be fought without symptoms of 
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disease but for unknown reasons M. tuberculosis is not eradicated completely. The underlying 
mechanisms are still unclear, but M. tuberclosis possesses a variety of immune evasion 
strategies which seem to play a role.  
Some mycobacterial genes like noxR1, noxR3, ahpC (Rv2428) and glbN (Rv1542c) are 
known to act against ROS and RNI either by neutralization or interference with metabolic 
pathways involved in generation of these toxic molecules (Bryk, et al., 2002; Ehrt, et al., 
1997; Ouellet, et al., 2002; Ruan, et al., 1999). In this connection the phagosomal arrest is 
also important, although it can be reverted by IFNγ. Responsible is the block of acidification 
by exclusion of the vacuolar proton pump from the phagosomal membrane (Ferrari, et al., 
1999) together with ESAT-6 (6kDa early secretory antigenic target) which interferes with the 
phagosomal membrane and causes membrane lysis (de Jonge, et al., 2007). Even antigen 
processing and presentation by APC can be influenced since various molecules of the 
pathogen lead to decreased surface expression of MHC-II molecules (Singh, et al., 2006).  
A remarkable feature of M. tuberculosis is its ability to survive under hypoxic and nutrient-
poor conditions (e.g. within the granuloma and activated macrophages) in a dormant stage 
which allows the pathogen to persist. This “life cycle” of the pathogen is characterized by 
extremely low metabolic activity and an altered proteomic profile. Important in this process 
are enzymes mediating an alternative energy metabolism [i.e. isocitrate lyase and glycine 
dehydrogenase; (Graham and Clark-Curtiss, 1999)] as well as thickening of the cell wall 
possibly mediated by PcaA, CmaA1, CmaA2 (Cole, et al., 1998) and/or the 16-kDa alpha 
crystalline (hspX) (Cunningham and Spreadbury, 1998) 
To investigate the behavior of non-replicating mycobacteria under such conditions an in vitro 
model has been introduced by Wayne et. al. based on the incubation of M. tuberculosis in 
sealed containers leading to starvation and gradual depletion of oxygen (Wayne, 1994). 
Subsequent adaption of the bacilli leads first to a microaerophilic and later to an anaerobic 
stage with changes in gene expression as well as drug susceptibility (Wayne and Hayes, 
1996).  
A number of different factors is involved in the persistence under hypoxic conditions and 
transcriptomic microarray studies revealed a set of 48 genes being differentially regulated 
(Sherman, et al., 2001). Among this set of response genes a two-component transcription 
factor, namely Rv3133c, has been identified to be responsible for the induction of all these 48 
genes and is therefore referred to as dormancy survival regulator (DosR) (Boon and Dick, 
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2002). By targeted deletion of the DosR locus it had been shown that DosR is essential for the 
pathogen response to hypoxia and needed for persistence (Park, et al., 2003). The genes 
regulated by DosR are clustered in nine distinct modules within the bacterial genome and 
form the so-called DosR regulon. Recently it has been shown that Rv3132c (DosS) and 
Rv2027c (DosT) encode sensor kinases which can phosphorylate DosR in vitro, thus 
initiating the dormancy response (Voskuil, et al., 2003). The sensor involved seem to be a 
heme-containing protein with specificity for oxygen as well as nitric oxide (Voskuil, et al., 
2003). 
Although the DosR regulon can be linked to virulence (present in M. tuberculosis, M. 
smegmatis and partially in BCG) there is no evidence so far about the metabolic stage of M. 
tuberculosis during latent infection. Latency simply describes an infected individual without 
symptoms of disease and does not refer to distinct stages of the pathogen life cycle. Since the 
tuberculous granuloma is characterized by hypoxia and bacterial numbers correlate well with 
the degree of oxygenation, it is still tempting to speculate that the majority of the bacilli are 
dormant and express DosR regulated genes.  
 
Fig. 5: The life cycle of M. tuberculosis and host/pathogen interactions.  
The colonization of alveolar macrophages (MΦ) is the first stage upon airborne infection. 
Contribution of T-helper cells lead to the activation of phagocytes by IFNγ and TNFα which act 
synergistically. Next the formation of a tuberculous granuloma occurs and oxidative stress signals 
induce the expression of DosR encoded proteins. M. tuberculosis enters its dormancy stage 
characterized by slow or absent bacterial replication. After receiving appropriate “wake-up” signals 
the persisting bacteria up-regulate Rpf and become metabolic active again. Consequently replicating 
mycobacteria begin to disseminate leading to reactivation of disease. Modified according to (Ulrichs 
and Kaufmann, 2006). 
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In addition to mechanisms driving M. tuberculosis into dormancy it is fundamental to 
understand the processes which facilitate the recovery from dormancy and promote active 
replication. Various mechanisms have been discussed in the literature and it is known that 
culture supernatant can reverse dormancy (Sun and Zhang, 1999). In this connection a group 
of five secreted proteins has been identified recently (Biketov, et al., 2000).  
One of these so-called resuscitation promoting factores (Rpf) shows homology to lysozymes 
and it has been speculated that peptidoylcan lysis and the resulting remodeling of the bacterial 
cell call could provide “wake up signals” (Cohen-Gonsaud, et al., 2005; Keep, et al., 2006). 
Reactivation of TB in latently infected humans is not clearly understood, although various 
exogenous and endogenous factors promoting active disease are known (malnutrition, absence 
of medical care, drug abuse, age, HIV/AIDS, immunosuppressive therapy etc.). Most of them 
leading to an impaired adaptive immune response and consequently containment of the 
pathogen gets lost. But not in every case reactivation can be explained by a brake down of 
proper immune surveillance and it remains elusive whether appropriate “wake up signals” are 
needed or resuscitation is simply a matter of statistical probabilities (Chan and Flynn, 2004; 
Saunders and Britton, 2007).  
 
3.2.5 Vaccines and biomarkers 
The most efficient way to fight TB globally is the generation of improved vaccines which 
provide better protection against adult pulmonary TB than BCG does. As already mentioned 
BCG vaccination in newborns confers protection against severe forms of childhood TB (i.e. 
TB meningitis and miliary TB) but is less efficient in adults (Trunz, et al., 2006). As part of 
the global STOP TB initiative financial support has been provided for the development of 
new anti-TB vaccines. Basically five different strategies evolved: the use of recombinant 
BCG, generation of attenuated M. tuberculosis vaccine strains, subunit vaccines, viral vector 
delivery systems and DNA vaccination. 
One recombinant BCG strain expressing the M. tuberculosis-specific antigen Ag85b is 
already in clinical trial phase I (Horwitz and Harth, 2003) and complementation of BCG with 
genes of the region of difference 1 (RD1) has also been reported (Pym, et al., 2003). Despite 
efforts to express otherwise absent or rare M. tuberculosis proteins it is also possible to alter 
the immune response elicited by BCG. This approach was followed by engineering a 
recombinant ureaseC deficient BCG strain expressing membrane-perforating listeriolysin. By 
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this means protein antigens should be able to pass from the phagolysosome to the cytosol 
leading to an increased generation of CD8+ cytotoxic T-cell responses. Indeed induction of 
better protection against aerogenic challenge with M. tuberculosis than the parental strain 
could be shown in mice. Especially at late stages of infection this recombinant BCG was 
much more effective (Grode, et al., 2005). 
Attenuated strains of M. tuberculosis have been developed and prominent examples are non-
replicative auxotroph mutants with targeted deletions in genes involved in pantothenic acid 
synthesis (Sambandamurthy and Jacobs, 2005) and strains lacking the virulence associated 
gene PhoP (Asensio, et al., 2008). Due to the use of attenuated M. tuberculosis strains as live 
vaccines instead of complementing BCG with antigens safety issues may arise.  
Subunit vaccines aim at boosting the BCG prime by delivering M. tuberculosis components 
(mostly proteins) together with an adjuvant. Latest subunit vaccines encompass Hybrid-1 
(Ag85b_ESAT-6), HyVac-4 (Ag85b_TB10.4) and Mtb72F (Mtb39_Mtb32) which already 
passed clinical trial phase I (Dietrich, et al., 2005; Skeiky, et al., 2005; Weinrich Olsen, et al., 
2001). Another possibility is the delivery of antigenic proteins by viral vectors; in this context 
a modified Vaccinia virus Ankara expressing Ag85a is already in phase I now (McShane, et 
al., 2004). Last but not least the principle of DNA vaccination can be combined with the other 
strategies to achieve better protection. In brief a DNA plasmid coding for antigenic proteins 
can be injected directly and is able to elicit robust Th1, Th2, CTL as well as antibody mediated 
immune responses (Tang, et al., 1992). The coding DNA fragment also contains a strong 
eukaryotic promoter, e.g. from cytomegalovirus, a terminator of transcription, e.g. the polyA 
sequence from bovine growth hormone, and components for expression and selection in 
prokaryotes during plasmid generation (i.e. origin of replication and resistances). Especially 
DNA vaccination against viral infections proved to be protective in animal models (Robinson, 
et al., 1993). Meanwhile a variety of DNA constructs have been tested alone or as part of a 
prime-boost scenario and most of these approaches confer more or less to protection in animal 
models (Orme, 2006).  
Nevertheless and despite all efforts there is still no protective vaccine against adult pulmonary 
TB available. The beneficial effect of recent candidates which were selected due to reduced 
bacterial titers in animals has to be finally evaluated in humans. Another problem is the high 
number of LTBI since none of the new vaccines was efficient in post-exposure settings within 
animal experiments. It is worth to mention that all these candidates rely on classical 
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immunodominant antigens of M. tuberculosis which are expressed under normal, replicative 
conditions. The inclusion of antigens associated with dormancy, reactivation and resuscitation 
may be a promising vaccination strategy to drive the pathogen more into latency or even 
achieve complete bacterial clearance (Roupie, et al., 2007) 
(http://www.gcgh.org/CureInfection/Chal-lenges/ImmunologicalMethods/Pages/PostExposureTB.aspx). 
Moreover the typical course of disease with a long lasting period of latency necessitates long 
term observations to follow the effect of vaccination. The direct analysis of vaccination 
success is still problematic since no molecular correlates of protection are known. This means 
that the induction of T-cell responses, the associated cytokine pattern as well as antibody 
levels can be measured easily but the contribution of such parameters to protection remains 
elusive. It has been proposed that the release of the key cytokine IFNγ by antigen-specific T 
cells could serve as a surrogate marker of protection, but more recent studies clearly showed 
that the magnitude of the adaptive immune response  alone (measured by IFNγ) is insufficient 
(Mittrucker, et al., 2007). Therefore the hunt for new protective biomarkers for TB is still 
ongoing. Possible implications are not limited to vaccination studies; prognostic markers for 
the outcome of infection as well as therapeutic markers to monitor the success of treatment 
are urgently needed. Finally the diagnosis of clinical TB is based on X-ray examination, 
identification of the pathogen in patient’s samples and modern interferon γ release assays 
(IGRA). Such IGRA detect antigen-specific memory responses of the host towards the unique 
protein antigens ESAT-6 and CFP10 of M. tuberculosis. Since these assays cannot 
discriminate between latent infection and active disease, a potent molecular biomarker would 
provide solutions for common day-to-day problems of physicians and patients in the field 
(Menzies, et al., 2007).  
The situation is even more complicated since TB in animals is very different from human 
infection and unfortunately appropriate in vivo latency models are still missing. In mice for 
instance granuloma formation is different and the bacilli are able to replicate continuously 
without any dormancy. Even in more resistant mouse strains a persistent M. tuberculosis 
infection is characterized by high bacterial burden in various organs, which is in contrast to 
humans (Orme, 2003). A pragmatic solution could be the evaluation of beneficial and adverse 
effects of different T-cell signals and stimuli in in vitro assays. Such assays could directly 
measure the influence of T-cell help on the activation of infected phagocytes and their ability 
to kill intracellular mycobacteria. However one should admit that the artificial in vitro 
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situation can be very different from real in vivo conditions. Moreover no standardized 
protocols exist and the common read-out method for determination of viable mycobacteria 
still relies on bacterial growth analysis on plates. 
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4 Aims of this study 
TB together with AIDS and Malaria is the major cause of death and morbidity worldwide 
(WHO, 2008). Co-infection with HIV leads to a dramatic course of disease and endangers 
public health in high incident countries (Kaufmann and McMichael, 2005). The evolvement 
of new MDR and XDR strains impairs the efficiency of present drug regiments (Singh, et al., 
2007). In combination with the vast number of LTBI the need for a protective vaccine against 
adult pulmonary TB becomes obvious. Animal models fail to mimic the latent stage of 
infection and reliable correlates of protection against TB are still to be defined. Therefore this 
thesis investigated adaptive immune responses against M. tuberculosis in humans and tried to 
characterize these cellular immune responses in further detail. These issues were be addressed 
by three independent approaches: 
 
1. Identification of new M. tuberculosis key antigens contributing to protection by 
comparing their T cell mediated recognition in healthy LTBI and TB patients 
2. Further characterization of involved T-cell subsets in order to evaluate qualitative 
differences in immunity to TB among both study groups 
3. Investigation of the functional properties of different M. tuberculosis-specific T-cell 
populations based on a novel flow cytometry assay 
 
1. Adaptive cellular immune responses to TB are crucial for the outcome of infection and the 
help M. tuberculosis-specific T cells is needed to guarantee long lived protection against 
disease outbreak. Although unconventional antigens of M. tuberculosis are known, e.g. the 
CD1d restricted presentation of lipids or glycolipids (Schaible and Kaufmann, 2000), the most 
prominent immune response of CD4+ as well as CD8+ T cells is directed against peptides 
(Kawamura, 2006). Due to differences in the local cytokine/chemokine milieu, altered protein 
expression of the pathogen and HLA polymorphism of the host the spectrum of recognized 
antigens vary among individuals. Consequently identification of key antigens correlating 
either with protection or susceptibility would have great impact on diagnosis, monitoring of 
treatment and vaccination strategies. Adaptive immune responses towards M. tuberculosis 
derived proteins covering the whole bacterial life cycle (fig. 10) were studied in healthy LTBI 
and patients with active pulmonary TB. The antigens tested in the present study can be linked 
to active replication (immunodominant proteins), dormancy (DosR encoded proteins), 
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reactivation or resuscitation (Rpf and “Wayne antigens”). Special feature of this approach was 
the inclusion of latency-associated proteins of M. tuberculosis. We intended to document 
differences among both study groups to define correlates of immunity and new biomarkers for 
latent infection. In case of successful identification of promising candidates the immunogenic 
epitope within the antigen should be pinned down. 
In parallel to distinct proteins fractionated M. tuberculosis whole cell lysate will was used to 
identify completely new antigens. Most studies regarding the recognition of mycobacterial 
antigens in TB patients and LTBI rely on known immunodominant proteins. Prominent 
examples are ESAT6-CFP10, TB10.4 or Ag85a/b which elicit robust IFNγ responses in 
infected individuals. It is important to mention that the restriction to already described 
antigens will limit the potential of a descriptive study and reduces its sensitivity. In order to 
perform unbiased clinical studies we replaced recombinant proteins by individual fractions of 
M. tuberculosis whole cell lysate. 
2. To characterize the quality of the adaptive immune response to TB different parameters of 
M. tuberculosis-specific memory T cells were analyzed on a cellular level. This part of the 
thesis mainly focuses on the analysis of cytokine expression pattern by antigen-specific T 
cells in LTBI and TB. There is increasing evidence that the amount of poly cytokine 
producing T cells correlates with protection against viruses and other infectious diseases 
(Seder, et al., 2008). Hence detailed cytokine profiles were measured within different 
experimental setups. In this context the stimulatory effect of IL7 on poly-functional T cells 
was investigated since this cytokine is known to boost Th1 T cell responses (van Roon, et al., 
2003) and increased survival of M. tuberculosis infected mice after donation of IL7 (Maeurer, 
et al., 2000) has been reported, as well.  
3. Although cross-sectional studies based on patients´ material may allow the identification of 
candidate biomarkers, the in vivo relevance for the outcome of infection cannot be addressed 
within such a clinical study. Therefore the impact of different T-cell populations was 
evaluated by a novel flow cytometry-based in vitro killing assay. It relies on the infection of 
human monocyte-derived macrophages with eGFP expressing mycobacteria followed by co-
culture with autologous effector PBMC. The assay should allow rapid and reliable 
quantification of intracellular bacilli as well as evaluation of side damage to macrophages. 
Functional properties of different T-cell subsets were examined to enlighten the underlying 
processes responsible for killing of intracellular mycobacteria and the contribution of T cells. 
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5 Material and Methods 
5.1 Material 
5.1.1 Human subjects 
Peripheral blood (40 ml) was obtained from 22 LTBI, recruited among health care workers at 
the Respiratory Diseases Clinic Heckeshorn, Department of Pneumology, HELIOS Klinikum 
Emil von Behring, Berlin, Germany. Diagnosis of latent M.tuberculosis infection was based 
on positive Tuberculin Skin Test (TST > 10 mm) verified by positive T-Spot TBTM (cut-off 7 
spots, in accordance with manufacturer’s guidelines). Peripheral blood from 20 patients with 
clinical pulmonary tuberculosis was collected at the Respiratory Diseases Clinic Heckeshorn, 
Department of Pneumology, HELIOS Klinikum Emil von Behring, Berlin; at the Department 
of Internal Medicine/Infectious and Pulmonary Diseases, Charité, Berlin; and at the Asklepios 
Professional Clinic München-Gauting, Centre for Pneumology and Thorax Surgery, Munich, 
Germany. Blood samples were taken either before drug treatment or shortly after beginning of 
treatment before sputum conversion unless otherwise noted. Ten uninfected donors (TST 
negative) were recruited among volunteers of the Max Planck Institute for Infection Biology, 
Berlin, Germany. All donors were Caucasians. There was no bias in gender or age among all 
study groups (fig. 16). All donors gave written informed consent. The local ethics committee 
approved this study (205-18.1; 205-18.2; 205-18.3). 
 
5.1.1 Proteins and peptides  
Recombinant M. tuberculosis proteins (immunodominant antigens, dormancy-, reactivation- 
and resuscitation-associated proteins; Figure 10) were kindly provided by Prof. Dr T.H.M. 
Ottenhoff, Leiden University Medical Centre, The Netherlands (Kana, et al., 2008; 
Mollenkopf, et al., 2004; Park, et al., 2003; Wayne and Hayes, 1996). All proteins were 
expressed in, and endotoxin-free purified from, Escherichia coli. All peptides used for in vitro 
restimulation were purchased from JPT Peptide Technologies GmbH, Berlin, Germany in 
crude purity (>80%). Aliquots of 10-2 M stock solutions were stored at -20°C until use. 
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5.1.1 M. tuberculosis / M. bovis strains 
The bacterial strains M. tuberculosis H37Rv (originally obtained from J.K. Seydel, 
Forschungsinstitut Borstel, Germany) and M. tuberculosis Beijing (RIVM No. 17919, country 
of isolation: Mongolia) were used for lysate generation. The recombinant eGFP expressing M. 
bovis BCG for the in vitro infection assays was kindly provided by Dr. Nathlie Winter, 
Mycobacterial Genetics Unit, Institut Pasteur, France. In brief M bovis BCG Pasteur 1173P2 
was transformed with Ms6-derived integrative vectors11 expressing the Aequoria victoria 
egfp gene. 
 
5.1.1 Equipment 
Flow cytometer FACSCantoTMII and LSRII Becton Dickinson 
ELISA-reader SpectraMAX190 Molecular Devices 
Bio-PlexTM System BioRad 
MultiScreen Filtration System Millipore 
FAST-PrepTM System Bio 101 Savant 
Ultra-sound bath Sonorex RK100 Bandelin 
CO2-Incubator Binder 
Incubator Memmert 
Microcentrifuge Biofuge fresco Heraeus 
Megafuge 1.0R (sepatech#2704 rotor) Heraeas 
Multifuge 4KR (LH4000 rotor) Heraeus 
Biological Safety Cabinets Class II  
(NUAIRE and HeraSafe) Heraeus 
Vortex MS1 Minishaker IKA Labortechnik 
Electronic pipetter Pipetboy acu Integra Biosciences 
pH-meter 761 calimatic Knick 
Lab-Shaker Lab-Therm 
Microscopes Leica 
Cell counting chamber Neubauer improved Brand 
Scales Sartorius 
Water purifier Millipore 
 
5.1.1 Kits 
IFNγ / TNFα / IL2 Secretion Assays Miltenyi 
CytoFix/CytoPerm Kit BD 
Human IFNγ ELISA BD 
Human TNFα ELISA BD 
Bio-PlexTM human Th1 cytokine Kit BioRad 
Bio-PlexTM human IL17 cytokine Kit BioRad 
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5.1.2 Antibodies 
Tab. 1: Fluorchrome-labeled antibodies used in this thesis.  
 
All conjugated antibodies for FACS analysis were purchased by Becton Dickenson (BD),  
eBioscience and Miltenyi, respectively. 
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5.1.3 Other material 
Addresses and contact information for suppliers are listed in the appendix. Standard 
laboratory chemicals used to prepare buffers, staining solutions and the like, were purchased 
from Sigma, Merck or Roth in per analysis quality. 
PARAFILM® Brand 
Cell strainer (40μm) BD 
Syringes B.Braun 
Steritop Sterile Filters Millipore 
Millex Syringe Driven Filter Units Millipore 
Sterile filters and membranes Schleicher & Schüll 
CombiTips Eppendorf 
Disposable Scalpels  B.Braun 
6-well / 24-well / 48-well / 96-well  
Flat Bottom Plates NUNC 
96-well Round Bottom / V Bottom Plates NUNC 
12-well / 96-well Ultra Low Attachment Plates Corning 
ELISA-plates Immuno Maxi-Sorp Nunc 
CryoTubes 1.8ml NUNC 
Filter plates for Bio-PlexTM MultiScreen®-BV Millipore 
FACS Tubes 5.0ml Sarstedt 
Cluster Tubes 1,8ml Thermo Fischer 
Disposable Transfer Pipette BD 
Steripette (5.0ml/10ml/25ml/50ml) Costar 
Disposable Inoculating Loops NUNC 
Bradford Assay reagent BioRad 
Bovine Serum Albumin (BSA) Serva 
Brefeldin A Invitrogen 
Staphylococcus enterotoxin B (SEB) Invitrogen 
Phytohemaglutinin (PHA) Invitrogen 
Recombinant cytokines  
(IL2, IL7, IFNγ, TNFα, GM-CSF) all Invitrogen 
Tuberculin PPD Batch RT50 Satents Serum Institute 
Streptavidin-PE (1mg/ml) Invitrogen 
UltraPURE Water Invitrogen 
Plasticware  Corning, Sarstedt or TPP 
Glassware Schott 
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5.1.4 Buffers and solutions 
Solutions were made up in H2O prepared with a Millipore water purifier, unless otherwise 
noted. Where indicated (*), solutions were sterilised by autoclaving for 25min at 121°C, or 
filter-sterilised through a 0.2μm membrane. 
 
Cell culture media 
FCS-RPMI medium*: 10% (v/v) FCS 
 1.0mM L-glutamine 
 100U/ml penicillin 
 100µg/ml streptomycin 
 10mM HEPES Buffer 
HS-RPMI medium*: 10%(v/v) heat inactivated human AB Serum 
 1.0mM L-glutamine 
 100U/ml penicillin 
 100µg/ml streptomycin 
 10mM HEPES Buffer 
 
 
Bacterial culture media  
Middlebrook 7H9 broth*: 4.7g DifcoTM Middlebrook 7H9 powder 
 2ml glycerol 
 900ml water 
Added after autoclaving:   
 100ml BBLTM Middlebrook 
 10% (v/v) ADC enrichment 
 0.05% (v/v) Tween80 
 
 
7H11-agar plates*: 21g DifcoTM Mycobacteria 7H11 agar 
 5ml glycerol 
 900ml water 
Added after autoclaving: 100ml BBLTM Middlebrook 
 OADC enrichment 
Optional: 50mg/l kanamycine were added after cooling. 
(50g/l stock solutions of kanamycine were stored at –20°C) 
 
PBS/Tween (PBST)*: 0.5% (v/v) Tween80 in PBS 
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Buffers for ELISA, Bio-PlexTM and flow cytometry  
Phosphate buffered saline (PBS): 8g NaCl 
 0.2g KCl 
 0.2g KH3PO4 
 1.3g Na2HPO4 
 
ELISA coating buffer: 100mM Na2CO3 
 100mM NaHCO3 
 titrated to pH9.6 
ELISA wash buffer: 0.1% (w/v) BSA 
 0.05% (v/v) Tween 20  
 in PBS 
ELISA blocking buffer: 5% (w/v) BSA in PBS 
ELISA stop solution: 3M NaOH 
Bio-Plex assay buffer A: 1% (w/v) BSA 
 0.05% (v/v) Tween 20 
 in PBS 
Bio-Plex wash buffer A: 0.5% (w/v) BSA 
 0.05% (v/v) Tween 20 
 in PBS 
FACS buffer (PBS/B)*: 10% FCS in PBS 
 
5.1.5 Software 
Tables, calculations, statistic and graphics 
GraphPad Prism 4.0 GraphPad Software 
Excel 2007 Microsoft 
Photoshop Adobe Systems 
 
Flow cytometric analysis 
FCS Express 3.0 De Novo Software 
FACSDiva v5.0.2 BD 
FACS data Analyser (v0.9.8) Christian Köberle 
 
Bio-Plex analysis 
Bio-Plex Manager 4.1.1 Bio-Rad 
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Text 
Word 2007 Microsoft 
References 
Endnote X Thomson 
 
5.1.6 Web resources 
Sequence information on M .tuberculosis genes: 
http://genolist.pasteur.fr/TubercuList/ 
 
Information on cytokines and chemokines: 
http://www.copewithcytokines.de/cope.cgi 
 
 
5.2 Methods 
5.2.1 Cell culture for intracellular cytokine analysis 
PBMC were isolated by density centrifugation (Biocoll, Biochrom) following manufacturer’s 
instructions. Cells were resuspended in RPMI-1640 (GIBCO, Invitrogen) supplemented with 
10% AB Rh-positive heat-inactivated human serum (Sigma-Aldrich), 100U/ml penicillin, 
100µg/ml streptomycin (PAA), 1mM L-glutamine (PAA) and 10mM HEPES (PAA). 2×105 
PBMC per well were seeded in 96-well round bottom plates (NUNC) in 200µL medium. 
Cells were cultured at 37°C / 5% CO2 with medium alone or together with 1µg/ml 
Staphylococcus enterotoxin B (SEB, Sigma-Aldrich), 10µg/ml purified protein derivative 
(PPD) from M. tuberculosis (Statens Serum Institute), 5µg/ml recombinant M. tuberculosis 
proteins (fig. 10) either for 16h or 7d. In order to identify the immunogenic epitope of Rv3407 
we designed overlapping peptide pools and tested these pools in the 7d two rounds of 
restimulation assay. Each 15-mer peptide was added at a final concentration of 5µg/ml. The 
pools were designed as matrix pools as described before (Maecker, et al., 2001). In brief, 15-
mer peptides with a shift of 3 amino acids along the primary sequence represent the whole 
protein and allow mapping of CD4+ as well as CD8+ T-cell responses. For a complete list of 
all tested peptides see figure 19. A second restimulation with the respective antigen was 
performed for the long-term assay at day 6. In both cases, 10µg/ml of the secretion inhibitor 
brefeldin A (Sigma-Aldrich) was added 12h before analysis to avoid release of cytokines by 
the Golgi apparatus. Subsequently, cells were fixed and permeabilized using cytofix/cytoperm 
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(100 µl) (BD Biosciences) for 30min at 4°C. Treatment with Cytoperm/wash (150µl) (BD 
Biosciences) was applied twice before staining with fluorochrome-labeled antibody mixtures 
(mAb). Staining antibodies were used in different combination and a complete list of FACS 
antibodies is given as figure 1. After staining for 45min at 4°C, cells were washed twice in 
Cytoperm/wash, resuspended in phosphate-buffered saline (PBS, Gibco) containing 10% fetal 
calf serum (FCS, Invitrogen) and analyzed using a FACS-LSRII (BD Biosciences).  
 
5.2.2 Cytokine analysis in the culture supernatant by ELISA 
Due to the accumulation of IFNγ and TNFα in the supernatant during prolonged in vitro 
stimulation the initial number of PBMC per well for ELISA has been reduced down to 5*104 
cells in 200µL medium. Following the described protocol (see 5.2.2 Cell culture and 
intracellular cytokine analysis) cells were stimulated at day 0 and day 6 under the same 
conditions. In contrast to the former approach no secretion inhibitor was added and 110µL of 
cell culture supernatant was harvested at day 7. To evaluate the impact of the doubled 
restimulation, supernatants were also harvested early at day 6 for some individuals. The 
remaining cells were used for the proliferation assay. Commercially available IFNγ and TNFα 
ELISA´s (BD Biosciences) were performed according to manufacturer’s guidelines. In brief, 
96 well flat bottom plates (NUNC) were coated overnight at 4°C with a primary catch mAb 
directed against the respective cytokine. After blocking with 10% FCS/PBS either 50µL of 
cell culture supernatant or different dilutions of the reference cytokine standard was applied. 
After extensive washing wells were incubated with a biotinylated secondary mAb together 
with Streptavidin-horseradish peroxidase. Finally tetramethylbenzidine substrate solution 
(BioRad) was added and the enzymatic reaction was stopped with 1M phosphoric acid. Plates 
were analysed by measuring extinction at 450nm using an ELISA plate reader (Molecular 
Devices). 
 
5.2.3 Proliferation analysis by [3H]-Thymidine incorporation 
After harvesting supernatants for ELISA 50µL medium containing 3H-labeled thymidinee 
(1,25 µCi) was added and cells were incubated at 37°C for 6h. After the incorporation period 
cells were frozen at -20°C thawed and transferred to 96 well Unifilter plates using a harvester 
(both PerkinElmer). Plates were then dried at 50°C for 30min and 40µL of Liquid 
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Scintillation Cocktail (MicrosCint, PerkinElmer) was added. The sealed plates were finally 
analyzed by using a TopCount reader (PerkinElmer). 
5.2.4 In vitro killing assay 
Buffy coats from the blood donor service of the Charité University Hospital, Berlin were used 
for isolation of PBMC in high numbers as already described.  
Macrophage generation and infection with mycobacteria: Monocytes were separated by 
adherence to plastic by incubation for 12h at 37°C and 5% CO2 in presence of 50U/ml 
recombinant GM-CSF (Invitrogen) in RPMI-1640 (GIBCO, Invitrogen) supplemented with 
10% AB Rh-positive heat-inactivated human serum (Sigma-Aldrich), 1mM L-glutamine 
(PAA), 100U/ml penicillin, 100µg/ml streptomycin (PAA) and 10mM HEPES (PAA). To 
detach adherent monocytes from the bottom of 75cm2 cell culture flasks they were washed 
with PBS (Gibco) and treated with 2mM EDTA. Residual cells were mechanically detached 
by a cell scraper if needed. Monocytes were then centrifuged and 7,5*104 cells were seeded 
into 96 well round bottom ultra-low-attachment plates (ULA plates, Corning) in 100µL 
RPMI-1640 supplemented with 10% human serum (see above). To allow differentiation of 
monocytes to macrophages the cells were incubated at 37°C and 5% CO2 for further 4d. For 
infection of macropahges with mycobacteria eGFP expressing BCG were grown in 
Middelbrook 7H9-broth medium supplemented with 10% ADC enrichment at 37°C with 
shaking until bacterial growth reached an OD600=0.7, corresponding to a cell density of 
approx. 108cells/ml. These mid-logarithmic cultures were harvested by centrifugation, washed 
twice with PBS and homogenized by transfer through a 26G needle. BCG were counted by 
using a Neubauer Improved Chamber and applied at an MOI 5 and 20. Infection took place at 
37°C, 5% CO2 and moderate shaking for 4h. After infection medium was removed and 
marcophages were washed four times with 200µl preheated RPMI-1640 (GIBCO, Invitrogen) 
supplemented with 10% AB Rh-positive heat-inactivated human serum (Sigma-Aldrich), 1 
mM L-glutamine (PAA) and 10 mM HEPES (PAA). After each washing step plates were 
centrifuged and the supernatant was flipped on absorbing paper. Finally 100µL medium was 
added. 
Generation of autologous effector PBMC: PBMC were incubated at a final concentration of 
1*106cells/ml in upright 20cm2 cell culture flasks 37°C and 5% CO2 in RPMI-1640 (GIBCO, 
Invitrogen) supplemented with 10% AB Rh-positive heat-inactivated human serum (Sigma-
Aldrich), 1 mM L-glutamine (PAA), 100 U/ml penicillin, 100 µg/ml streptomycin (PAA) and 
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10 mM HEPES (PAA). To promote their effector function for the later assay M. tuberculosis 
whole cell lysate (10µg/ml), different concentrations of recombinant IL2 (Invitrogen), 
recombinant GM-CSF (Invitrogen), recombinant IFNγ (Invitrogen) or phytohemaglutinin (10 
µg/ml) (PHA, Invitrogen) were added. After the first 24h 10U/ml recombinant IL2 was given 
to promote mid-term survival of PBMC. After additional 4d of incubation cells were washed 
with PBS and resuspended in 100µL RPMI-1640 (GIBCO, Invitrogen) supplemented with 
10% AB Rh-positive heat-inactivated human serum (Sigma-Aldrich), 1 mM L-glutamine 
(PAA), and 10 mM HEPES (PAA). For co-culture of infected macrophages and autologous 
PBMC, effector cells were adjusted at different effector:target ratios and incubated at 37°C 
and 5%CO2 for 16-36h. 
For FACS analysis palates were centrifuged and surface staining for prominent lineage 
marker was performed in 100µl PBS containing 10% FCS and 2mM EDTA. After incubation 
at 4°C for 30min cells were washed twice with 10% FCS / PBS, resuspendend in 100µl 10% 
FCS / PBS and analysed using a LSR II (BD Bioscience). If CFU were performed in parallel 
plates were centrifuged and cell lysis was achieved by addition of 0.5% EDTA in PBS. Serial 
dilutions were performed in 0.5% Tween / PBS and 50µl volume were plated on 7H11 agar 
plates (diameter 10cm) which were sealed with PARAFILM® and wrapped in aluminium 
foil. After three weeks of incubation at 37°C cfu were counted. 
 
5.2.5 Bio-Plex Assay 
The Bio-PlexTM Human Cytokine Th1 panel and IL-17 Assay were performed according to the 
manufacturer’s instructions (BioRad) with some slight modifications. Only 0.5μl beads in 
50μl Assay buffer A, 0.15μl (50x concentrated) or 0.075μl (100x concentrated) of the 
detection antibodies in 25μl Assay buffer A and 0.2μl Streptavidin-PE (1mg/ml) in 50μl 
Assay buffer A per well were used. Beads as well as detection antibodies from all kits were 
mixed together in order to analyze all cytokines in parallel within the same sample. 
 
5.2.6 Lysate generation 
M. tuberculosis was grown under BSL3 conditions in Middelbrook 7H9-broth medium at 
37°C with shaking until bacterial growth reached an OD600=0.7, corresponding to a cell 
density of approx. 108cells/ml. These mid-logarithmic cultures were harvested by 
centrifugation, washed twice with PBS and lysed using the FastPrepTM homogenizer 
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technology (Savant). Following the manufactures’ protocol for protein isolation Matrix B 
columns were used to disrupt bacilli by two 45 s pulses at 6,000 x g. The lysate was 
centrifuged and the debris-free supernatant was collected. The supernatant mainly contains M. 
tuberculosis cytosolic components including the fraction of cytosolic proteins. Finally the 
lysate was applied to a steril filter (20µm) and the protein yield was determined by Bradford 
assay. 
 
5.2.7 Bradford assay 
Bradford Assay was used to determine the total protein concentration of M. tuberculosis 
lysate and separate Beijing fractions after gel filtration. Basically the absorbance maximum 
for an acidic solution of Coomassie Brilliant Blue G-250 (BioRad) shifts from 465nm to 
595nm when binding to protein occurs. Serial dilution of BSA was used as standard for 
absolute determination of the protein yield. The absorbance was measured at 600nm using an 
ELISA plate reader (Molecular Devices). 
 
5.2.8 Gel Filtration 
To separate the cytosolic proteins according to their particular molecular size the Beijing 
lysate was applied to an Amersham Superose 12 gel filtration column with a fraction range 
from 1kDa to 300kDa. Basically smaller molecules show a more intense interaction with the 
gel matrix than larger molecules. Consequently it needs more time to elute them from the 
column and by subsequent collection of the flow (PBS, Gibco) molecules of different sizes 
can be separated. The chromatography of each fraction can be used to determine the 
absorption at 280nm. Since this is the characteristic absorption maximum for aromatic amino 
acids (tryptophan, tyrosine, phenylalanine) it reflects the total protein load of the single 
fraction. 
 
5.2.9 Analysis procedures and statistics 
For analyses memory T helper cells (we have previously identified this T-cell subpopulation 
as the major producers of cytokines in this assay (Mueller, et al., 2008)) were gated according 
to size, granularity, CD3, CD4, and CD45RO expression (fig. 11). Absolute numbers and 
proportions of cytokine expressing cells were determined. The Mann-Whitney U-test was 
used to determine significant differences between study groups and T-cell subpopulations. For 
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the individual comparison (fig. 15) a paired t-test was used. Nominal two-sided p-values are 
given and considered significant if P < 0.03 (*); P < 0.01 (**); P < 0.0001 (***). 
 
5.2.10 Discrimination analysis 
The discriminatory power for classifying TB patients and healthy LTBI was investigated 
using random forest analysis (Breiman, 2001). The classification was based on the proportion 
of IFNγ expressing CD4+, CD45RO+ T cells against of 14 selected stimuli (i.e. SEB, PPD, 
ESAT-6_CFP10, Rv0569, Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, 
Rv1884c, Rv2450c and Rv3407). We determined the relative feature importance for 
discrimination using a leave-1-out cross validation for all possible combinations of genes and 
assessed the proportion of correctly classified patients in the left-out group.  
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6 Results 
Working hypothesis of this thesis is the assumption that differences in the adaptive immune 
response either lead to long-lived protection against secondary tuberculosis or to an impaired 
containment of the pathogen with reactivation of disease. In order to identify such differences 
the adaptive immune response against M. tuberculosis will be compared between two study 
groups; on the one hand HIV negative patients with active pulmonary tuberculosis (the 
immune system failed to contain the pathogen) and on the other hand healthy donors with 
long lasting latent M. tuberculosis infection (proper containment). 
Possible distinctions between both sub-groups will be addressed by the analysis of M. 
tuberculosis antigens recognized and by cellular cytokine expression patterns of M. 
tuberculosis-specific CD4+ T cells. Finally functional properties of different T cell subsets 
will be studied by a newly developed in vitro assay based on monocyte-derived macrophages 
infected with mycobacteria. General focus is on the identification of key factors relevant for 
the outcome of infection. 
 
6.1 Identification of relevant M. tuberculosis antigens 
As already mentioned the presentation of M. tuberculosis derived antigens by APC and the 
generation of adaptive immune responses are crucial for robust and long lived immunity to 
TB (see 3.2.2 The immune responses to M. tuberculosis). Although unconventional antigens 
of M. tuberculosis are known, e.g. CD1d restricted lipids or glycolipids (Schaible and 
Kaufmann, 2000), the most prominent immune response of CD4+ as well as CD8+ T cells is 
directed against peptides (Kawamura, 2006). Since the entity of M. tuberculosis antigens 
represent “molecular targets” mediating recognition of infected host cells the identification of 
relevant protein-antigens will rely on two parallel approaches: 
 
i) Fractionated M. tuberculosis lysate will be used for restimulation of PBMC from 
LTBI and TB patients in order to characterize completely new antigens. 
ii) The adaptive immune response towards a panel of recombinant latency-associated 
proteins of M. tuberculosis will be analyzed in healthy LTBI and TB patients. 
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6.1.1 Fractionated M. tuberculosis lysate 
Most studies regarding the antigen recognition of TB patients and LTBI depend on known 
immunodominant proteins. Prominent examples are ESAT6, CFP10, TB10.4 or Antigen85a/b 
which elicit robust IFNγ responses in infected individuals. The restriction to known antigens 
limits the potential of a descriptive study. In order to perform unbiased clinical studies we 
intend to replace recombinant proteins used as antigens by distinct fractions of M. 
tuberculosis whole cell lysate. Instead of the commonly used lab strain H37Rv of M. 
tuberculosis we decided to perform this experiment with a hyper-virulent clinical isolate 
called Beijing (Wong, et al., 2007). This should mirror the real clinical situation in high 
endemic areas. In a first approach to separate the cytosolic proteins according to their 
particular molecular size a crude whole cell lysate of the Beijing strain was applied to a gel 
filtration column. The chromatography of this gel filtration is shown in figure 6. 
 
Fig. 6: Gel filtration of M. tuberculosis whole cell lysate.  
Cytosolic whole cell lysate of the hypervirulent Beijing strain was applied to an Amersham Superose 
12 column with a fraction range from 1 kDa to 300kDa. The x-axis shows the flow volume in ml and 
the typical size of molecules which can be eluted with that volume (arrows). The blue curve of the 
chromatography indicates absorption at 280nm. The number of each separate fraction is depicted in 
green and red-labeled fractions were selected for restimulation assays due to high protein yield. 
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The overall flow volume is indicated in ml at the bottom of the graph as well as the typical 
molecular size of “reference molecules” applied to the same column. The blue curve 
represents absorption at 280nm. Since this is the characteristic absorption maximum for 
aromatic amino acids (tryptophan, tyrosine, phenylalanine) it reflects the protein yield. At the 
top the number of each individual fraction is indicated and protein-rich fractions selected for 
restimulation assays are labeled in red. For each fraction the individual protein concentration 
was determined by Bradford assay. 
In order to evaluate the reproducibility of this method two independent batches of Beijing 
lysate were applied to the same gel filtration column. For both batches the chromatography is 
shown in figure 7. The characteristic absorption profile at 280nm (blue curve) is identical for 
both samples. Since this is no proper way of “quality control”, the problem of reproducibility 
was avoided by using the same batch of Beijing fractions for the following study. 
 
 
Fig. 7: Gel filtration of two different batches of M. tuberculosis lysates.  
Cytosolic whole cell lysates of two different batches of the Beijing strain were applied to the same 
column (as described before). The characteristic absorption profile at 280nm is indicated by the blue 
curve. 
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To measure the adaptive immune response towards the Beijing fractions an in vitro 
restimulation assay was used. In brief PBMC from healthy LTBI (T-Spot TB positive), 
patients with active pulmonary tuberculosis and uninfected controls (TST negative) were 
incubated for 16h with each separate fraction. 12h prior to analysis the secretion inhibitor 
brefeldin A was added to inhibit cytokine release. Finally cells were fixed and stained for 
intracellular cytokines as well as phenotypic markers. In this assay only memory T cells 
which were already primed by the same antigen will express characteristic effector cytokines. 
FACS analysis focused on CD3+ CD4+ lymphocytes for the detection of antigen-specific T-
helper cell responses. The analysis includes the specific activation marker CD154 to avoid the 
detection of unspecific activation (TLR or bystander activation) which could be due to non-
protein components within the lysate. CD3+ CD4+ T cells were then analyzed for the 
expression of IFNγ, TNFα, IL2 and GM-CSF. Parallel analysis of CD8+ T cells revealed no 
detectable cytokine expression (IFNγ, TNFα, IL2, GM-CSF) in any case. 16h in vitro 
restimulation was performed for two TST negative controls, four LTBI and five patients with 
active TB before/within the first week of treatment (fig. 8).  
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Fig. 8: ICS after 16h of in vitro incubation revealed T-cell mediated recognition of Beijing 
fractions in LTBI and TB patients.  
Fractionated Beijing whole cell lysate (10µg/ml) was used to restimulate 5*105 PBMC in 200µl RPMI 
containing 10% human serum. After 4h of incubation the secretion inhibitor brefeldin A was added at 
a concentration of 15µg/ml. Following additional 14h of incubation at 37° and 5 % CO2 cells were 
fixed, permeabilized, stained and analyzed by 6-colour flow cytometry. Results are shown for a) two 
non-M. tuberculosis infected donors b) four latently infected donors and c) five patients with active 
pulmonary TB. Background values of unstimulated controls were subtracted during data analysis. 
Numbers of Beijing fractions are indicated at the x-axis and percentage of CD3+ CD4+ T cells is 
shown on the y-axis. For each fraction and donor the amount of IFNγ single positive cells (sp, red 
dots), IFNγ/CD154 double positive cells (dp, blue squares) and CD154 sp cells (green triangles) is 
depicted. 
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Data analysis was done for CD3+ CD4+ T cells and discriminated between IFNγ/CD154 
double positive (dp), IFNγ single positive (sp) and CD154 sp cells. Individual background 
values for unstimulated medium controls were always subtracted. For uninfected donors IFNγ 
as well as CD154 expression was not detectable. Therefore cytokine expression by LTBI or 
TB patients can be considered antigen-specific. All four LTBI showed detectable proportions 
of IFNγ/CD154 dp cells for the vast majority of Beijing fractions. In most cases slightly 
elevated levels of CD154 sp cells were measured. IFNγ sp cells were only detected at low 
frequencies underlining the value of CD154 as a marker for antigen-specific activation of 
CD4+ T cells. Regarding the quantity and the quality of the immune response no differences 
between the separate fractions could be observed by using this assay. For LTBI CD4+ T-cell 
response seems to be independent from the particular Beijing fraction. Consequently we failed 
to identify specific fractions which elicit more prominent T-cell responses in LTBI. 
In patients with active TB the frequencies of activated CD4+ T cells were generally higher 
compared to LTBI. Similar to LTBI the highest frequencies were detected for IFNγ/CD154 dp 
cells, but also detectable amounts of CD154 sp cells were measured. In contrast to LTBI in a 
few cases IFNγ was detected without co-expression of CD154. This could be explained by 
bystander activation due to high cytokine levels before addition of the secretion inhibitor. An 
additional observation is the broader range of T-cell frequencies for TB patients compared to 
LTBI (higher variability). In summary, no consistent pattern regarding the recognition of 
Beijing fractions could be found for the five TB patients. 
For a single patient we had the possibility to collect peripheral blood at the beginning of 
treatment and four weeks later after sputum conversion (fig. 9). Before therapy the TB patient 
showed a pronounced IFNγ response mediated by CD4+ T cells towards some of the Beijing 
fractions (Frak8; 9; 10; 11). The analysis at the later time point revealed a general increase in 
CD4+ T-cell responses which were now directed against the majority of the Beijing fractions. 
11 out of 14 fractions now elicited high frequencies of IFNγ+ T cells. Moreover the cellular 
activation/cytokine pattern seems to be altered since the absolute increase in T-cell 
frequencies also caused an increase in the relative amount of CD154 sp cells (orange bar in 
figure 9a and 9b). The cellular cytokine secretion pattern in context of these Beijing fractions 
will be discussed in further detail later in this thesis. 
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Fig. 9: Increased proportions of specifically activated CD4+ T cells after 4 weeks of treatment 
measured by ICS.  
Fractionated Beijing whole cell lysate was used to restimulate PBMC from a patient with active 
pulmonary TB as already described. Peripheral blood was drawn a) before beginning of treatment and 
b) after four weeks of first line antibiotic treatment (including isoniazid, rifampicine, pyrazinamide 
and ethambutol). Background values of unstimulated controls were subtracted during data analysis. 
Numbers of Beijing fractions are indicated at the x-axis and percentage of CD3+ CD4+ T cells is 
shown on the y-axis. For each fraction the amount of IFNγ sp cells (blue bars), IFNγ/CD154 dp cells 
(red bars) and CD154 sp cells (orange bars) is depicted. 
 
 
6.2 Latency-associated antigens 
This parallel approach is focused on the detection of adaptive immune responses towards 
recombinant M. tuberculosis proteins associated with dormancy, reactivation or resuscitation 
(fig.10). For comprehensibility reasons these proteins will be termed “latency-associated” 
from now on since they are unregulated by M. tuberculosis during the latent stage of disease. 
Despite the efforts to identify new biomarkers for latent M. tuberculosis infection (correlate of 
protection) it is worth to speculate that T-cell responses towards latency-associated antigens 
actively contribute to immunity to TB (correlate of immunity). This is a first step to verify the 
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hypothesis that T-cell responses towards latency-associated antigens are essential for the 
outcome of mycobacterial infections.  
 
 
Fig. 10: Complete list of recombinant M. tuberculosis proteins tested. 
Recombinant proteins of M. tuberculosis tested in in vitro restimulation assays. Known 
immunodominant proteins (1.xx) as well as DosR regulon encoded proteins (2.xx), resuscitation 
promoting factors (4.xx) and proteins associated with reactivation (3.xx + 5.xx) were included. 
 
The panel of tested M. tuberculosis proteins represent the complete life cycle of the pathogen 
(fig. 5) with a focus on the latent stage of disease. The list of 35 recombinant M. tuberculosis 
proteins includes known immunodominant antigens (1.xx), DosR encoded proteins (2.xx) and 
proteins associated with resuscitation or reactivation (3.xx, 4.xx, 5.xx). More details about the 
role of these proteins can be found in the Introduction of this thesis.  
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6.2.1 Assay optimization and candidate identification 
In a first step 16h in vitro restimulation was used as already described. This method is based 
on short term incubation of PBMC in medium supplemented with proteins / antigens of 
interest. To inhibit the release of cytokines a secretion inhibitor, e.g. brefeldin A, was added 
to the cells 12h prior to analysis. Finally, PBMC were fixed and stained for phenotypic 
markers and intracellular cytokines. Due to the short-term restimulation only cells which were 
already primed in the host (i.e. memory cells) will express cytokines and can be detected by 
flow cytometry. To verify that the responses are carried out by specific memory T cells an 
unstimulated medium control as well as the memory marker CD45RO is included. 
 
Fig. 11: Gating strategy for FACS analysis after in vitro restimulation and ICS.  
2*105 PBMC from a LTBI were restimulated with PPD from M. tuberculosis (10µg/ml) in 200µl 
medium containing human serum for 16h. After 4h the secretion inhibitor brefeldin A was added 
(15µg/ml) and cells were finally fixed and stained. First lymphocytes were gated due to characteristic 
size (forward scatter, FSC) and granularity (sideward scatter, SSC). In a second gating step T-helper 
cells were selected by the expression of CD4. Next memory T cells (CD4+ CD45RO+) were analyzed 
independent form naïve T cells (CD4+ CD45RO-) for the expression of IFNγ and TNFα. 
 
Post-acquisition analysis of FACS data is demonstrated in figure 11 for a latently infected 
donor and 16h restimulation with purified protein derivative (PPD) of M. tuberculosis. 
Lymphocytes are selected by their characteristic size (FSC) and granularity (SSC). Only 
CD4+ T cells were chosen for further analysis and studied separately according to their 
expression of CD45RO. Finally the expression of IFNγ and TNFα was measured on a cellular 
level. For individual experiments GM-CSF, IL2, CCL4 or CD154 were included to analysis.  
The expression of tested cytokines was restricted to CD45RO+ CD4+ T cells, which is 
representative for all experiments performed with PPD, recombinant proteins or synthetic 
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peptides. Detectable expression of cytokines for CD45RO- and CD8+ T cells could only be 
observed after incubation with the superantigen staphylococcus enterotoxin B (SEB), which 
serves as a positive control in this study. Moreover a strong correlation of the expression of 
IFNγ and TNFα could be documented. The proportion of IFNγ expressing T cells is shown in 
all the following figures. The vast majority of cytokine expressing CD4+ T cells were also 
positive for the antigen-specific activation marker CD154 (data not shown). 
 
The first step was to verify the recognition of latency-associated proteins of M. tuberculosis in 
LTBI before comparing these responses to patients with active TB. The results of ICS and 
FACS analysis for 11 healthy latently infected donors are shown in figure 12. Diagnosis of 
LTBI is based on a positive TST skin test verified by T-Spot TB (for details and cut-off 
values see Material and Methods). The amount of IFNγ expressing cells is given as 
percentage of all CD4+ CD45RO+ T cells. Each stimulus used for restimulation is indicated on 
the x-axis. Individual background values of unstimulated medium controls were already 
subtracted during data analysis. 
For all 11 donors the incubation with the superantigen SEB led to IFNγ production ranging up 
to 10% of all CD4+ CD45RO+ cells. In all but one case the incubation with PPD also caused 
detectable IFNγ production which sometimes reached levels comparable to those of the 
superantigen SEB. After restimulation with ESAT6_CFP10 (1.01) and TB10.4 (1.02) the 
majority of LTBI showed detectable but low frequencies of IFNγ expression. The median of 
T-cell frequencies after incubation with the remaining immunodominant antigens were even 
lower and Hsp65 (1.06) did not induce IFNγ expression in any of the 11 LTBI.  
Regarding the DosR regulon only proteins 2.06; 2.10; 2.17 and 2.18 elicited low cytokine 
responses next to detection limits in one or two donors. The other members of the DosR 
family (2.xx) as well as the reactivation associated proteins 3.01 / 3.02 did not induce T 
memory responses above detection limits. The resuscitation related proteins (4.xx) and the 
reactivation antigen Rv3407 (5.01) led to IFNγ production in some donors but the frequencies 
of CD4+ IFNγ+ memory T cells were also close to unspecific background levels. 
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Fig. 12: ICS after 16h in vitro incubation of PBMC from LTBI.  
2*105 PBMC from 11 LTBI were restimulated for 16h with 1µg/ml SEB, 10 µg/ml PPD or 5µg/ml M. 
tuberculosis proteins (see fig. 10 for nomenclature). IFNγ expression is depicted for each stimulus as 
percentage of CD4+ CD45RO+ memory T cells. Individual background values of unstimulated 
controls were subtracted during data analysis.  
 
There is increasing evidence that short-term assays efficiently detect recent M. tuberculosis 
infection while in vitro stimulation for several days is more sensitive for LTBI (Arend, et al., 
2007; Cehovin, et al., 2007). Since previous experiments indicated that a 16h restimulation 
before measurement is optimal for intracellular cytokine detection (Mueller, et al., 2008), 7d 
of stimulation were combined with a restimulation 16h prior to analysis. For eight LTBI the 
result of the long-term stimulation followed by ICS were compared to conventional IFNγ 
ELISA of the supernatant and measurement of proliferation by incorporation of radioactive 
labeled thymidine (fig. 13). In all approaches the incubation period was 7d and the protein 
concentration was 10µg/ml for PPD as well as the recombinant M. tuberculosis proteins. ICS, 
ELISA and proliferation assays were able to detect T-cell responses after incubation with 
classical as well as latency associated antigens (fig. 13a, b, c). Moreover the results of all 
three methods correlated. IFNγ responses and proliferation were detectable after incubation 
with PPD and all of the immunodominant antigens in the majority of LTBI. Compared to the 
short-term ICS assay the frequencies of IFNγ expressing CD4+ CD45RO+ T cells for PPD and 
immunodominant proteins, e.g. ESAT6_CFP10 or TB10.4, were significantly increased after 
prolonged stimulation. In contrast to the 16h time point (DosR responses were generally 
absent) DosR regulon encoded proteins elicited cytokine responses in the majority of LTBI. 
After 7d of incubation with latency-associated proteins (2.xx) the frequencies of IFNγ 
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expressing memory T cells even exceeded those of known immunodominant antigens. The 
reactivation and resuscitation associated proteins (3.xx, .xx, 5.01) showed a similar 
distribution. Exceptions are 2.01 and 2.15 which did not induce IFNγ production higher than 
unspecific background. The same pattern was measured by determination of IFNγ in the 
supernatant and proliferation-assays. The exception is Rv3407 (5.01) leading to discrepancy 
between ICS and ELISA/proliferation-assays. For the remaining 34 immunodominant and 
latency-associated proteins the same tendency could be observed by ELISA and proliferation-
assays. 
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Fig. 13: ICS, IFNγ ELISA and proliferation assay after 7d in vitro incubation of PBMC from 
LTBI revealed amplified T-cell responses.  
2*105 PBMC from eight LTBI were restimulated for 7d with 10µg/ml PPD or 5µg/ml M. tuberculosis 
proteins (see fig. 10 for nomenclature). A second round of restimulation with the respective antigen 
was performed on day 6 as well as the addition of 1µg/ml SEB which served as a positive control. 
Individual background values of unstimulated controls were subtracted during data analysis. a) ICS 
after addition of 15µg/ml brefeldin A 12h prior to FACS analysis. IFNγ expression is depicted for 
each stimulus as percentage of CD4+ CD45RO+ memory T cells. b) Commercially available ELISA 
detecting extracellular IFNγ in the cell culture supernatant after 7d incubation and two rounds of 
restimulation. IFNγ concentrations are shown for each stimulus. c) Measuring proliferation by 
incorporation of [3H]-labeled thymidine using the 96well Unifilter/TopCount system. Counts per 
minute (cpm) are depicted for each stimulus. 
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Since there is the unlikely possibility that prolonged co-culture of PBMC and antigenic 
proteins could generate “memory-like” T cells in vitro, it was essential to ensure that the 
observed cytokine responses were due to a priming of T cells in the host and no artifact of the 
long-term stimulation. Therefore the same experiment was performed with non-M. 
tuberculosis infected donors having a negative TST skin test. The results for parallel ICS, 
ELISA and proliferation are depicted in figure 14. Cellular analysis by ICS revealed IFNγ 
expressing T-cell frequencies close to detection limits for the eight uninfected controls. Only 
a single donor showed weak T-cell responses against 2.09, 2.18 and 2.21. In contrast, IFNγ 
was detected in the supernatant for the majority of LTBI and the majority of M. tuberculosis 
derived proteins. This also held true for the determination of proliferation by measuring the 
incorporation of radioactive thymidine.  
Crucial for the development of a new assay is the signal-to-noise ratio. In our study the signal 
is represented by the specific T-cell responses towards latency-associated antigens and the 
noise can be interpreted as the unspecific background for each particular protein after 
stimulation of PBMC from uninfected donors. All three techniques detected the specific 
“signals” of PBMC from latently infected donors. Nevertheless ELISA and proliferation 
assays both detected T-cell activation in uninfected donors as well. Therefore these methods 
are suboptimal to detect latency-associated T-cell responses after long-term stimulation and 
ICS turned out to provide the highest sensitivity and specificity. 
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Fig. 14: ICS, IFNγ ELISA and proliferation assay after 7d in vitro incubation of PBMC from 
TST negative donors.  
2*105 PBMC from eight non-M. tuberculosis infected donors (TST neg.) were restimulated for 7d 
with 10 µg/ml PPD or 5µg/ml M. tuberculosis proteins (see fig. 10 for nomenclature). A second round 
of restimulation with the respective antigen has been performed on day 6 as well as the addition of 
1µg/ml SEB. Individual background values of unstimulated controls were subtracted during data 
analysis. a) ICS after addition of 15µg/ml brefeldin A 12h prior to FACS analysis. IFNγ expression is 
depicted for each stimulus as percentage of CD4+ CD45RO+ memory T cells. b) Commercially 
available ELISA detecting extracellular IFNγ in the cell culture supernatant after 7d incubation and 
two rounds of restimulation. IFNγ concentrations are shown for each stimulus. c) Measuring 
proliferation by incorporation of [3H]-labeled thymidine using the 96well Unifilter/TopCount system. 
Counts per minute (cpm) are depicted for each stimulus. 
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There was the possibility to directly compare T-cell frequencies after 16h and 7d for the same 
eight LTBI. In order to elucidate the underlying mechanisms the amplified response towards 
immunodominant antigens after 7d was compared to the response elicited by latency-
associated antigens. Basically two explanations may account for differential IFNγ expression 
between the 16h short-term assay and the novel 7d assay: (i) The prolonged stimulation 
period followed by a second restimulation boosted weak T-cell responses agianst latency 
antigens which were below detection limit after 16h; (ii) T cells recognizing subdominant 
latency antigens in LTBI are at a different maturation stage compared to T cells specific for 
immunodominant proteins and require a second round of restimulation for optimal activation 
and cytokine expression.  
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Fig. 15. Absolute and relative increase of IFNγ expressing T cells from 16h to 7d.  
Box plots compare relative and absolute increase of IFNγ expressing CD4+ CD45RO+ T-cell 
proportions. Pair-wise comparisons for six LTBI are shown. The values for PPD are depicted on the 
left side, three selected immunodominant proteins ESAT6_CFP10, TB10.4, and Ag85a in the middle 
panel, and three latency-associated proteins Rv0569, Rv1734, and Rv2003 in the right panel. a) 
Individual relative increase (ratio of 7d-response / 16h-response) as percentage of the initial 16 h-
response. b) Individual absolute increase (difference between 7d- and 16h-responses) of IFNγ 
expressing CD4+ CD45RO+ memory T cell proportions. P value for *** = 0.0002 using the two-sided 
paired t-test. 
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As an initial step to address this question the relative and the absolute changes in the 
proportion of cytokine expressing T cells induced by different stimuli between 16h and 7d 
were compared in individual donors. Figure 15 indicates the relative increase (ratio of 7d-
response / 16h-response) and the absolute increase (difference between 7d- and 16h-
responses) of IFNγ expressing CD4+ CD45RO+ memory T-cell proportions. Three 
immunodominant antigens (left panel) and three latency-associated antigens (right panel) 
which elicited the highest frequencies of IFNγ expression are shown. The relative increase in 
terms of percentage of the 16h response was significantly higher in subdominant latency 
antigens as compared to immunodominant antigens (p = 0.002; fig. 15a). On the opposite, the 
absolute increase in T-cell proportions induced by subdominant latency antigens was 
comparable to that of immunodominant antigens (Fig. 15b). 
 
6.2.2 Clinical study of selected candidates 
The vast majority of the selected antigens are associated with latent stages of M. tuberculosis 
infection. Consequently, the question whether these antigens are differentially recognized by 
T cells from patients with active pulmonary TB and donors with LTBI arises. For this study 
the optimized long-term stimulation protocol was used together with the eleven subdominant 
antigens that induced the strongest responses in LTBI in the former experiments. The 
characteristics of 22 LTBI, 20 patients with active pulmonary TB and 10 TST negative 
controls included in this study are given in figure 16. 
 
 
Fig. 16: Characteristics of LTBI, TB patients and non-infected donors.  
Overview of total numbers, gender and age of donors included to the cross-sectional study. For each 
of the 52 donors the 7d in vitro restimulation assay was performed with a selection of latency-
associated proteins of M. tuberculosis. For further details about study group criteria see Material and 
Methods. 
 
There is no bias in age or gender among all three study groups. Diagnosis of LTBI is based on 
a positive TST skin test verified by a positive T-Spot TB. TB patients were HIV negative and 
blood was drawn either before beginning of drug treatment or before sputum conversion. 
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Further details and cut-off values are part of the Material and Methods section (see 5.1.1 
Human subjects).  
The amount of IFNγ expressing CD4+ CD45RO+ T cells after 7d incubation and two rounds 
of restimulation with the respective antigen are depicted for non-infected controls, LTBI and 
TB patients (fig. 17.). Individual background values of unstimulated controls were already 
subtracted during data analysis. All three study groups showed comparable amounts of IFNγ 
expressing T cells after incubation with the superantigen SEB. The proportion of IFNγ+ CD4+ 
CD45RO+ T cells after 7d of restimulation with PPD reached high levels in LTBI and TB 
patients comparable to those of SEB. There was no significant difference among patients and 
LTBI.  
CD4+ CD45RO+ T cells from TST negative controls showed no detectable expression of 
IFNγ after incubation with PPD. The same held true for restimulation with ESAT6_CFP10. 
For the vast majority of LTBI and TB patients, CD4+ T cell mediated IFNγ responses were 
detectable but generally lower compared to those induced by PPD. There was no significant 
difference among both sub-groups and IFNγ producing memory T cells were absent after 
incubation of PBMC from TST negative donors with ESAT6_CFP10. 
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Fig. 17: ICS after 7d in vitro incubation of PBMC from LTBI, TB patients and uninfected 
donors.  
2*105 PBMC from 22 LTBI (blue squares), 20 patients with active pulmonary TB (red triangles) and 
10 TST negative donors (green diamonds) were restimulated as already described. Either 5µg/ml of 
recombinant M. tuberculosis proteins, 1µg/ml SEB or 10µg/ml PPD were used. IFNγ expression is 
depicted for each stimulus as percentage of CD4+ CD45RO+ memory T cells. Individual background 
values of unstimulated controls were subtracted during data analysis. Nominal two-sided p-values for 
the Mann-Whitney U-test are indicated for the relevant groups (LTBI vs. TB patient) as follows: * p < 
0.03, ** p < 0.01 and *** p < 0.001. 
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Seven out of eleven latency-associated antigens induced significantly higher T-cell responses 
in LTBI compared to tuberculosis patients (P < 0.03). The difference in T-cell recognition 
among LTBI and TB patients for five of them (Rv1733c, Rv2003, Rv2005c, Rv0140, 
Rv3407) can be considered highly significant since the particular p-values were below 0.001. 
Moreover Rv3470 (5.01) exclusively stimulated T-memory cells in LTBI but did not induce 
detectable IFNγ expressing T cells in diseased patients. The frequency of IFNγ+ memory T 
cells after incubation of PBMC from TST negative donors with latency-associated antigens 
was either not detectable or next to unspecific background values. 
 
Figure 18 shows the same data sets for SEB, PPD and the three latency-associated antigens 
showing highly significant differences among TB patients and LTBI. This time a box-and-
whiskers plot is used to illustrate the differences in T-cell mediated recognition for LTBI and 
TB patients. Arithmetic median, interquartil range as well as overall range are depicted for 
each data set. Cellular cytokine expression is illustrated as log2 of the percentage of IFNγ+ 
CD4+ CD45RO+ T cells. By the box-and-whiskers plot the significant higher T cell 
frequencies for LTBI compared to TB patients for the three latency-associated antigens 
become obvious. For Rv3407 and Rv0140 there is no overlap in the interquartil range. 
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Fig. 18: Significantly higher T-cell responses after 7d incubation with latency-associated 
antigens in LTBI compared to TB patients.  
2*105 PBMC from 22 LTBI (blue), 20 patients with active pulmonary TB (red) and 10 TST neg. 
donors (green) were restimulated as already described. IFNγ expression is depicted for each stimulus 
as log2 of percentage of CD4+ CD45RO+ memory T cells as box plots. Stimulation with SEB; PPD 
and latency-associated proteins with highly significant differences in the recognition among LTBI and 
TB patients (p values below 0.001, fig. 17) are shown. The horizontal line indicates arithmetic median 
and the box represents the interquartile range of each dataset. The length of the whisker displays 
overall range (scatter) of each dataset. Individual background values of unstimulated controls were 
subtracted during data analysis. Nominal two-sided p-values for the Mann-Whitney U-test are 
indicated for the relevant groups (LTBI vs. TB patient) as follows: * p < 0.03, ** p < 0.01 and *** p < 
0.001. 
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Most striking was the complete absence of recognition of Rv3407 by T -helper cells among 
all 20 patients with TB whereas approximately half of the healthy LTBI group showed high 
frequencies of IFNγ producing T-memory cells after restimulation with this protein. 
 
6.2.3 Immunogenic epitopes within Rv3407 
In order to identify immunogenic epitopes within Rv3407, synthetic overlapping peptide 
pools of this protein were generated (for details see Material and Methods). A complete list of 
the synthetic peptides representing Rv3407 and their amino acid sequence is shown in figure 
19. The matrix design of the overlapping peptide pools lead to six ‘vertical’ and five 
‘horizontal’ pools. Each of the 29 peptides of Rv3407 is present in two pools. 
a
b
 
 
Fig. 19: Design of synthetic peptide pools representing Rv3407.  
a) Overlapping 15mer peptides with a shift of 3 amino acids along the primary sequence of Rv3407 
have been designed. All 29 peptides represent the whole protein and were synthesized with a purity of 
> 80% using combinatory chemistry. b) After synthesis 11 pools were generated following a matrix 
design. Hence a single peptide is present in one “vertical” (light grey) and one “horizontal” (dark 
grey) pool. 
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In six out of ten LTBI which were preselected for their profound response against Rv3407, a 
minimum of 0.2 % IFNγ expressing CD4+ T cells was detected after stimulation with at least 
two of the peptide pools (fig. 20 a – f). In four LTBI (A - D) a major immunogenic epitope 
could be identified (Fig. 20 a – d) while in two LTBI (E, F) with the weakest response against 
the Rv3407 protein no prominent responses were observed (Fig. 20 e – f).  
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Figure 20. ICS after 7d and two rounds of restimulation with overlapping peptide pools 
representing Rv3407.  
PBMC from six LTBI with Rv3407-specific T cells were restimulated with 15-mer synthetic peptide 
pools for 7d including two rounds of in vitro restimulation. IFNγ expressing CD4+ CD45RO+ T cells 
measured by FACS are shown after incubation with peptide pools 1 to 6 (grey bars) and pools 7 to 11 
(black bars). Each peptide is part of one pool within pools 1 to 6 and of one pool within pools 7 to 11 
(see fig.19). Based on the most prominent T-cell responses against the resulting peptides are 
highlighted for four donors. The horizontal line indicates the arbitrary threshold for positive responses 
as described in the text. Background values of non-stimulated controls were subtracted for each 
individual donor. 
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Notably the peptide 6 identified in LTBI A induced 0.97 % of CD8+ IFNγ-producing T cells 
as well (data not shown). Aside from this peptide no CD8+ T cells specific for Rv3407 could 
be identified. 
 
6.2.4 T-cell response under drug treatment 
For four patients with active pulmonary TB CD4+ T-memory responses could be measured 
before beginning of drug treatment (1st time point) and at week six of treatment after sputum 
conversion (2nd time point). The results are shown for the tested proteins in terms of 
percentage of IFNγ expressing T cells among all CD4+ CD45RO+ cells (fig. 21). In all 
patients and at both time points incubation with SEB and PPD induced substantial amounts of 
IFNγ producing T cells. In most cases detectable frequencies of IFNγ expressing T cells were 
measured after incubation with ESAT6_CFP10. Only two patients (fig. 21 c + d) had low T-
cell frequencies after incubation with ESAT6_CFP10 which were close to detection limits at 
the 1st time point; for both donors increased T-cell frequencies after stimulation with 
ESAT6_CFP10 were measured at the later time point. PPD mediated responses were also 
increased at the end of hospitalization for two patients (fig. 21 a+c), while PPD induced T-cell 
frequencies remained at the same level for the other two patients (fig. 21 b+d).  
Regarding the latency-associated proteins a heterogeneous situation was observed. Generally 
frequencies of IFNγ expressing CD4+ CD45RO+ T cells after incubation with these antigens 
were below detection limits before drug treatment and remain low till week six of treatment. 
Donor b had low but detectable amounts of IFNγ producing T cells before beginning of 
treatment after incubation with at least three of the eleven proteins (Rv0569, Rv1734, 
Rv2005c). IFNγ+ CD4+ CD45RO+ T-cell frequencies of this patient were increased at the later 
time point after co-culture with four of the eleven proteins (Rv0569, Rv1734, Rv2003, 
Rv0140). The strongest increase was observed for Rv0569. Interestingly two out of three 
proteins eliciting IFNγ expressing T cells at the 1st time point also showed increased T-cell 
frequencies at the 2nd time point. The remaining patients showed a similar kinetic. 
Frequencies of IFNγ expressing CD4+ memory cells were below or close to detection limits 
and increased at the later time point for some of the latency-associated proteins. Such an 
increase was observed with Rv1734, Rv2003, Rv2005c, Rv1009 for patient c and with 
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Rv2003, Rv2006, Rv2450c for patient d. Remarkably all three patients possessed increased 
IFNγ expressing T-cell proportions after incubation with Rv2003 at the 2nd time point. 
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Fig. 21: T-cell response during drug treatment measured by ICS after 7d in vitro incubation.  
PBMC from four different patients with active pulmonary TB (a-d) were restimulated as described. 
Blood was drawn before/within the first week of drug treatment (time point 1) and at week six of 
treatment after sputum conversion (time point 2). IFNγ expression is depicted for each stimulus as 
percentage of CD4+ CD45RO+ memory T cells. Individual background values of unstimulated 
controls were subtracted during data analysis. 
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6.2.5 Childhood tuberculosis 
Tuberculosis in children is different from the typical course of disease in adults. Since severe 
disseminated tuberculosis (miliary TB) and TB meningitis are more common among children 
and small infants, diagnosis of LTBI in these patients goes along with prophylactic treatment 
with first line antibiotics. This and other dissimilarities regarding the immature immune 
system lead to an altered “latency” stage different from adults. To investigate the recognition 
of the latency-associated antigens peripheral blood samples from five healthy children with 
LTBI and six diseased children with clinically active pulmonary TB were collected. All 
children were below the age of six. 
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Fig. 22: ICS after 7d in vitro incubation of PBMC from children with TB and children with 
LTBI. 
PBMC from six children with active pulmonary TB (age below 6 years) and five children with LTBI 
(age below 6 years) were restimulated as already described. Either 5µg/ml of recombinant M. 
tuberculosis proteins, 1µg/ml SEB or 10µg/ml PPD were applied. Blood was drawn before/within the 
first week of treatment. IFNγ expression is depicted for each stimulus as percentage of CD4+ 
CD45RO+ memory T cells. Individual background values of unstimulated controls were subtracted 
during data analysis. 
 
For SEB and PPD a similar situation compared to adults could be observed (fig. 22): all LTBI 
and TB patients showed high frequencies of IFNγ expressing memory T cells and differences 
among both study groups were absent. Incubation with EAST6_CFP10 did also elicit high 
amounts of IFNγ producing T cells but the median of CD4+ mediated T-cell responses was 
higher for TB patients than for LTBI. With regard to the latency-associated antigens IFNγ 
expressing T cells were detectable for the vast majority of proteins and donors. Five antigens 
(Rv1734, Rv2005c, Rv0140, Rv2450c, Rv3407) did not induce significantly different 
frequencies of IFNγ producing memory T cells in LTBI and TB patients.  
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Moreover the median of T-cell responses measured by IFNγ for the six remaining latency-
associated proteins (Rv0569, Rv1733c, Rv2003, Rv2006, Rv1009, Rv1884) was higher in 
diseased children than healthy LTBI. This is an inverse situation compared to adults where the 
arithmetic median was lower for TB patients compared to LTBI. 
 
6.3 Characterization of T-cell subsets 
The recognition of different M. tuberculosis antigens and the absolute frequency of specific 
T-helper cells are not the only important key factors. A matter of particular interest is the 
cellular phenotype and other functional properties of antigen-specific T cells involved in 
eliminating the pathogen. To address this issue single-cell cytokine expression pattern of M. 
tuberculosis-specific CD4+ T cells as well as the stimulatory effect of IL7 were measured in 
TB patients and LTBI. 
 
6.3.1 Cytokine profiles 
The analysis of cellular cytokine secretion patterns became a new focus of immunological 
research since there is evidence that the amount of poly-cytokine producing T cells may be 
crucial for protection against viruses and other infectious diseases (Seder, et al., 2008). Our 
own department recently discovered that the amount of poly-functional T cells in mice vary 
according to the particular vaccination strategy against tuberculosis and may have an impact 
on the outcome of infection (unpublished work by C. Desel et. al.). Hence cellular cytokine 
profiles for each particular M. tuberculosis Beijing fraction were studied in patients with 
active pulmonary TB and healthy LTBI. First two prominent T-helper cytokines were 
analyzed on the cellular level. An extended staining panel allowed the analysis of three 
different cytokines later. 
 
Simultaneous analysis of two cytokines 
In a first step cellular cytokine secretion pattern of CD3+ CD4+ CD154+ cells were 
investigated for two Th1 effector cytokines; either IFNγ and TNFα or IFNγ and IL2. For each 
case figure 23 and figure 24 illustrate data analysis after in vitro restimulation with Beijing 
whole cell lysate or medium alone (unstim.). PBMC from a patient with active TB were 
incubated for 16h as already described and finally stained for phenotypic markers, CD154 
expression and IFNγ/TNFα or IFNγ/IL2. The results are representative for three patients with 
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active tuberculosis. Measurement of the unstimulated medium control show low unspecific 
background levels close to detection limits. For all three cytokines a strong cellular expression 
which correlated with the expression of CD154 was detected. Based on the data sets generated 
by flow cytometry the cellular cytokine pattern has been calculated and is shown as a pie 
chart.   
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Fig. 23: Cellular T-cell cytokine profiles after 16h of restimulation with Beijing whole cell lysate. 
PBMC from a patient with active pulmonary TB were restimulated with Beijing whole cell lysate as 
already described and analyzed by flow cytometry. Dot plots are gated on CD3+ CD4+ T cells either 
for unstimulated PBMC or PBMC incubated with Beijing whole cell lysate. a) CD154 expression is 
shown on the x-axis and IFNγ expression on the y-axis. b) CD154 expression is shown on the x-axis 
and TNFα expression on the y-axis. c) Calculation of cytokine profiles for CD3+ CD4+ CD154+ T 
cells. Pie chart represents percentage of CD4+ CD154+ T cells expressing IFNγ (IFNγ sp), TNFα 
(TNFα sp), both cytokines (IFNγ/TNFα dp) or none of these cytokines (CD154 sp). 
 
The entity of antigen-specific CD4+ CD154+ T cells (activated PBMC) can be divided into 
three categories: i) cells expressing only one of the cytokines, ii) cells expressing both 
cytokines simultaneously, iii) cells negative for both of the cytokines expressing only CD154. 
The simultaneous cellular analysis of IFNγ and TNFα (fig. 23) revealed that the majority of 
specifically activated T-helper cells (CD3+ CD4+ CD154+) co-express both cytokines after 
stimulation with M. tuberculosis whole cell lysate. Still one fourth of all CD154+ cells do not 
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express any of these cytokines. The other fourth either express TNFα or IFNγ alone. Notably 
the amount of TNFα sp cells is approximately two times the amount of IFNγ sp cells. 
Analysis of cytokine profiles based on the expression of IFNγ and IL2 (fig. 24) documented a 
slightly altered distribution. Again the majority of antigen-specific CD4+ T cells 
simultaneously express both cytokines. The percentage of cells which do not express the 
cytokines (CD154 sp) is slightly reduced, but the most dramatic differences could be observed 
for IFNγ sp and IL2 sp cells. Taken together they still reach ~25% of all CD3+ CD4+ CD154+ 
cells, but the amount of IL2 sp cells is drastically reduced. 
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Fig. 24: Cellular T-cell cytokine profiles after 16h of restimulation with Beijing whole cell lysate. 
PBMC from a patient with active pulmonary TB were restimulated with Beijing whole cell lysate as 
already described and analyzed by flow cytometry. Dot plots are gated on CD3+ CD4+ T cells either 
for unstimulated PBMC or PBMC incubated with Beijing whole cell lysate. a) CD154 expression is 
shown on the x-axis and IFNγ expression on the y-axis. b) CD154 expression is shown on the x-axis 
and IL2 expression on the y-axis. c) Calculation of cytokine profiles for CD3+ CD4+ CD154+ T cells. 
Pie chart represents percentage of CD4+ CD154+ T cells expressing IFNγ (IFNγ sp), IL2 (IL2 sp), both 
cytokines (IFNγ/IL2 dp) or none of these cytokines (CD154 sp). 
 
In a next step the cytokine secretion pattern after restimulation with the Beijing fractions was 
analyzed in the same way. For the cellular expression of IFNγ and TNFα the results are 
shown in figure 25 for three healthy LTBI and four patients with active pulmonary TB. 
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Fig. 25: Cellular T-cell cytokine profiles after 16h of restimulation with Beijing fractions. 
PBMC from a) four patients with active pulmonary TB and b) three LTBI were restimulated with 
fractionated Beijing whole cell lysate as already described and analyzed by flow cytometry. For each 
individual fraction the percentage of CD4+ CD154+ T cells expressing IFNγ (IFNγ sp), TNFα (TNFα 
sp), both cytokines (IFNγ/TNFα dp) or none of these cytokines (CD154 sp) is shown. Bars indicate 
arithmetic mean and error bars represent standard deviation.  
 
For each fraction the relative amount of IFNγ sp, IFNγ/TNFα dp, TNFα sp and CD154 sp 
cells is shown as percentage of CD3+ CD4+ CD154+ events within the leukocyte gate. In 
LTBI the distribution is very similar to former experiments; IFNγ/TNFα co-expressing cells 
are the majority while CD154 sp approximately represent one fourth. The remaining PBMC 
are either TNFα sp or IFNγ sp.  
                                                                                                                                           Results 
 
 71
For LTBI T-cell responses against different Beijing fractions were similar with regard to their 
cellular cytokine profile. In contrast, TB patients possessed unique cytokine patterns 
depending on the particular Beijing fraction. In case of all but one fraction the relative amount 
of IFNγ/TNFα dp cells was reduced while the amount of CD154 sp cells expressing neither 
IFNγ nor TNFα was increased. In other words a reduced relative amount of poly-functional 
CD4+ T cells expressing IFNγ/TNFα in TB patients compared to LTBI was found for the 
majority of Beijing fractions. This reduction indicates a modified cytokine profile, which was 
not observed by incubation with Beijing whole cell lysate. 
Due to limitations in patients’ material the same assay with staining for IFNγ and IL2 could 
only be performed for a single donor with LTBI and two TB patients. The results are depicted 
in figure 26 showing the relative amount of IFNγ sp, IFNγ/IL2 dp, IL2 sp and CD154 sp cells 
among all CD3+ CD4+ CD154+ PBMC. Different to the analysis of IFNγ/TNFα the sub-group 
of LTBI shows a cytokine profile which differs depending on the Beijing fraction used for 
restimulation. Some fractions elicited very low poly-functional T-cell responses with 
IFNγ/IL2 co-expression. Instead the relative amount of CD154 sp cells was increased. Even 
though the cytokine profiles were different depending on the Beijing fraction, no differences 
could be observed among LTBI and TB patients. In contrast to the former experiment each 
individual fraction lead to similar cytokine pattern in LTBI and TB patients. 
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Fig. 26: Cellular T-cell cytokine profiles after 16h of restimulation with Beijing fractions. 
PBMC from a) one patient with active pulmonary TB and b) two LTBI were restimulated with 
fractionated Beijing whole cell lysate as already described and analyzed by flow cytometry. For each 
individual fraction the percentage of CD4+ CD154+ T cells expressing IFNγ (IFNγ sp), TNFα (TNFα 
sp), both cytokines (IFNγ/TNFα dp) or none of these cytokines (CD154 sp) is shown. Bars indicate 
arithmetic mean and error bars represent standard deviation. 
 
 
Simultaneous analysis of three cytokines 
In order to investigate the cytokine profile for three cytokines simultaneously the combination 
of staining antibodies was modified. To include a third cytokine the staining for CD154 had to 
be renounced. This seems unproblematic since former experiments revealed a strong 
correlation of cytokine expression with CD154 expression. Frequencies of T cells expressing 
effector cytokines without co-expression of CD154 were either not detectable or close to 
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detection limits in this assay. Together with the same 16h restimulation procedure a more 
detailed picture of cellular cytokine pattern after incubation with Beijing fractions could be 
documented. Figure 27 shows the absolute amount of CD3+ CD4+ T cells expressing IFNγ, 
TNFα, IL2 or each possible combination of these cytokines using PBMC from a TB patient. 
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Fig. 27: Cellular T-cell cytokine profiles after 16h of restimulation with Beijing fractions. 
PBMC from a patient with active pulmonary TB were restimulated with fractionated Beijing whole 
cell lysate as already described and analyzed by flow cytometry. For each individual fraction the 
percentage of CD3+ CD4+ T cells expressing IFNγ (IFNγ sp), TNFα (TNFα sp), IL2 (IL2 sp) or every 
possible combination of these cytokines is shown. Background values of unstimulated PBMC were 
subtracted during data analysis. 
 
All 14 fractions elicited cytokine production by PBMC but the height of the CD4+ T-cell 
response varied from fraction to fraction. This phenomenon was already observed by the more 
limited analysis of IFNγ expression after in vitro restimulation and ICS (fig. 8+9). Differences 
in the cytokine pattern could be measured, especially with regard to IFNγ/TNFα dp and INFγ 
sp cells, which is consistent with the former results. Most striking is the high proportion of 
IFNγ sp cells for fractions 2-4 in combination with a low amount of poly-functional T cells. 
Each Beijing fraction seems to be characterized by a specific cytokine pattern which is 
slightly different from the remaining fractions. These differences can also be found between 
fractions with a comparable over-all CD4 T-cell response (e.g. fraction 2 versus fraction 4). 
 
6.3.2 Effect of interleukin 7 
Another observation made in the study of cellular cytokine profiles was the effect of 
interleukin 7 (IL7) to promote poly-cytokine producing T cells. IL7 is continuously produced 
and released by human keratinocytes, adherent bone marrow stroma cells as well as thymic 
cells (Melchers, et al., 1992; Park, et al., 1992). The respective membrane bound 76 kDa 
receptor (CD127) is mainly expressed on activated T cells, pre B cells and bone marrow 
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macrophages. An unrelated 90 kDa receptor variant is also expressed on naïve human T cells, 
but the effect of IL7 on PBMC directly correlates with the expression of CD127 (Armitage, et 
al., 1992). Signaling through CD127 promotes proliferation and cellular activation, which 
designates IL7 as a homeostatic growth factor (Guimond, et al., 2005). IL7 enhances the 
secretion of Th1 cytokines, namely IFNγ and TNFα, by PBMC and can enhance the in vitro 
generation of cytolytic T lymphocytes (Alderson, et al., 1990; van Roon, et al., 2003). These 
findings hint to the investigation of cytokine profiles in presence of sub-optimal doses of IL7. 
Therefore low concentrations of recombinant IL7 (5ng/ml) were chosen since at this 
concentration IL7 does not lead to proliferation or cytokine production in PBMC without 
further antigenic stimuli (data not shown). The cellular “three cytokine” profile was 
determined after 16h co-incubation of PBMC from a TB patient with 10µg/ml Beijing lysate 
in presence and absence of IL7 (fig. 28). To ensure that IL7 alone had no effect an 
unstimulated medium control also treated with 5ng/ml IL7 was included. Each individual 
medium control (+/- IL7) was used to subtract background levels during data analysis for 
lysate and lysate+IL7.  
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Fig. 28: Modified cytokine profile after 16h of restimulation with Beijing whole cell lysate in 
presence of IL7.  
PBMC from a patient with active pulmonary TB were restimulated with Beijing whole cell lysate as 
already described and analyzed by flow cytometry. Cells were either incubated with lysate alone or 
together with 5ng/ml recombinant IL7. The percentage of CD3+ CD4+ T cells expressing IFNγ (IFNγ 
sp), TNFα (TNFα sp), IL2 (IL2 sp) or every possible combination of these cytokines is shown. 
Background values were subtracted during data analysis. 
 
Cellular cytokine pattern detected by ICS and FACS analysis are shown in figure 28. Most 
evident is an increase of the over-all CD4+ T-cell response towards Beijing lysate after low 
dose IL7 treatment. The percentage of cytokine positive cells rose from ~0.4% CD3+ CD4+ to 
~0.55% CD3+ CD4+. In addition to the elevated amount of cytokine positive cells in presence 
of IL7, the relative cellular distribution (cytokine profile) was also altered. The proportion of 
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triple positive (tp) T cells expressing IFNγ/TNFα/IL2 (blue) as well as dp T cells producing 
IFNγ/TNFα (yellow) was increased regarding the absolute amount as well as the relative 
proportion in relation to the whole CD4+ T-cell response. In this patient sub-optimal doses of 
IL7 promoted T cells with a poly-cytokine profile leading to an increased over-all memory 
response against M. tuberculosis Beijing lysate in vitro. 
 
The identical experiment was done for six patients with active pulmonary TB and the results 
are illustrated in figure 29. All patients were restimulated with Beijing lysate in presence and 
absence of IL7. The CD4+ recall response was measured by the expression of INFγ/TNFα/IL2 
by ICS and FACS analysis. In all cases an increased percentage of IFNγ/TNFα/IL2 tp and 
INFγ/TNFα dp cells after treatment with IL7 could be confirmed (fig 29a). The analysis 
shows the summary of both subsets. While the absolute increase mediated by IL7 can be seen 
on the left panel, the relative increase is depicted on the right. Depending on the donor the 
effect was more or less pronounced and caused an increase in IFNγ/TNFα/IL2 triple positive 
and IFNγ/TNFα dp cells up to +121%. 
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Fig. 29: Analysis of poly-functional T cells after restimulation with Beijing lysate in presence 
and absence of IL7.  
PBMC from six patients with active pulmonary TB were restimulated with Beijing whole cell lysate 
as already described and analyzed by flow cytometry. Cells were either incubated with lysate alone or 
together with 5ng/ml recombinant IL7. The sum of T cells expressing IFNγ and TNFα (IFNγ/TNFα 
dp) or IFNγ, TNFα and IL2 (IFNγ, TNFα, IL2 tp) is shown as percentage of all CD4+ T cells. 
Background values were subtracted during data analysis. 
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6.4 Functional in vitro assays 
Characteristic cytokine profiles as well as the positive effect of IL7 on poly-functional  
T cells bring a new aspect into play. Their amount represents the quality of the immune 
response independent from the over-all T-cell frequency. Such qualitative differences could 
be important for protection of the host against infections (Seder, et al., 2008). But questions 
regarding the in vivo relevance cannot be answered by descriptive clinical studies. It is crucial 
to understand the impact of T cell sub-populations with different functional properties on the 
outcome of infection and their role in protecting the host efficiently. Since the typical course 
of disease and especially the latent stage of infection differ in mice and humans, functional in 
vitro assays are needed. They should allow direct evaluation of positive and adverse effects of 
different stimuli (e.g. cytokines) or T cell sub-populations (e.g. poly-functional T cells) on the 
ability of immune cells to kill intracellular mycobacteria. 
 
6.4.1 Methodology 
To establish a functional in vitro assay human monocyte-derived macrophages infected with 
mycobacteria were chosen as “target cells”. The use of primary cells rather than immortalized 
human macrophage cell lines allows the generation of autologous M. tuberculosis-specific 
PBMC as “effector cells”. An additional feature of this assay is the use of eGFP expressing 
mycobateria. This allows final read-out of bacterial load by FACS analysis instead of plating 
bacilli on agar medium followed by determination of colony forming units (CFU) three weeks 
later. The advantage in time saved by direct FACS analysis is an added bonus but the initial 
idea was to include phenotypic markers for macrophages and T cells to gain additional 
information about the survival of macrophages. In combination with bacterial growth analysis 
this approach aims at discriminating between killing of intracellular mycobacteria with or 
without macrophage collateral damage. Additionally this approach should allow the analysis 
of infected macrophages with high and low mycobacterial burden. Figure 30 gives a 
schematic overview about the assay. It is characterized by two simultaneous processes: i) the 
generation of monocyte-derived macrophages for infection with eGFP expressing 
mycobacteria, ii) the long term incubation of autologous PBMC with different specific and 
unspecific stimuli (i.e. cytokines, M. tuberculosis lysate, M. tuberculosis derived proteins).  
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The final assay is carried out by co-incubation of infected macrophages (targets) together with 
activated autologous PBMC (effectors) at different ratios for 16h-36h. Initially, FACS 
analysis and determination of CFU was done in parallel as a proof of principle. 
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Fig. 30: Schematic overview of the in vitro killing assay. 
The in vitro killing assay is characterized by two parallel steps dealing on the one hand with the 
generation of monocyte-derived macrophages (upper part) and the stimulation of autologous PBMC to 
gain effector cells (lower part) on the other hand. After 4-6d the final assay is performed by infecting 
macrophages with eGFP expressing mycobacteria. The infected macrophages represent targets and 
were co-incubated for 16h to 36h with different amounts of autologous effector PBMC. To evaluate 
the ability to kill intracellular mycobacteria, FACS analysis is performed after co-culure, verified by 
conventional counting of colony forming units (CFU) on plates. 
 
A unique feature of this assay is the analysis of flow cytometric data after co-culture (fig. 31): 
the staining for phenotypic markers together with the characteristic size (FSC) and granularity 
(SSC) provide a tool for clear-cut discrimination of PBMC and macrophages. In a first step 
the proportion of eGFP expressing cells within the macrophage gate is determined. A marker 
for differentiated macrophages (i.e. CD14 or CD11b) is used in parallel. The amount of 
eGFP+ macrophages is then compared between unstimulated PMBC and PBMC activated by 
M. tuberculosis lysate or Th1 cytokines. A reduced percentage of eGFP+ marcophages goes 
along with a lower bacterial load compared with unstimulated PBMC. This reduction can be 
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due to specific killing of intracellular mycobacteria with survival of macrophages (conversion 
from eGFP+ to eGFP-) or caused by the death of infected macrophages. To address this issue 
effector:target ratios (E:T ratio) were calculated in terms of absolute number of PBMC 
divided by absolute number of macrophages. Since the number of PBMC remains constant 
throughout the whole assay, a change in the E:T ratio can only be explained by an altered 
number of vital macrophages. Consequently an increase in the E:T ratio represents killing of 
macrophages. The reduction of bacterial burden can be easily verified by determination of 
CFU and serve as an intrinsic control, but the information about the collateral damage of 
infected macrophages is a unique feature of this assay. To establish the assay eGFP 
expressing BCG was used as a surrogate, but in later stages it can be replaced either by 
carboxyfluorescein diacetate1 (CFDA) labeled M. tuberculosis or recombinant H37Rv 
expressing eGFP. 
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Fig. 31: Schematic overview of data analysis.  
Following co-culture, cells were stained for characteristic phenotypic markers in order to identify 
leukocytes (effector cells) and macrophages (target cells.) Unstimulated PBMC were compared to 
cells activated by M. tuberculosis lysate (MTB) or cells activated by IL2 (lymphokine activated killer 
cells, LAK). a) A reduction of eGFP+ macrophages reflects either specific killing of intracellular 
mycobacteria or killing of infected macrophages. b) Discrimination is possible by calculating the ratio 
of effector PBMC (constant) and target macrophages (variable). Consequently an increase in the 
effector:target ratio (E:T ratio) compared to the unstimulated control indicates killing of macrophages. 
                                                 
1 CFDA is a membrane permeable florescent dye which is cleaved by proteases in the cytosole and stays inside 
the cell afterwards. It is mainly used for proliferation assays (dilution of the CFDA signal) but due to its stability 
CFDA can also serve as a cellular tracker. 
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6.4.2 Functional properties of different T-cell populations 
Preliminary experiments should proof that a reduced proportion of eGFP+ macrophages after 
co-culture with different effector PBMC can be detected by flow cytometry. Therefore 
monocyte-derived macrophages were infected at a low MOI of 5 for 4h with eGFP-BCG. 
After infection the target cells were incubated for 16h in presence of unstimulated autologous 
PBMC or PBMC which had been activated by M. tuberculosis lysate and high doses of IL2. 
The high concentrations of IL2 lead to the generation of lymphokine activated killer cells 
(LAK) which should reduce bacterial burden by unspecific killing. In all cases 10 times more 
effector PBMC than macrophages (initial E:T ratio = 10) were applied. These conditions 
characterized by a low MOI and high concentration of effector cells were chosen to facilitate 
reduction of bacterial load which is needed to evaluate the feasibility of the new flow 
cytometry-based killing assay. 
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Fig. 32: FACS analysis of macrophages after co-incubation with autologous PBMC.  
Monocyte-derived macrophages were infected with eGFP-BCG with a MOI of 5 for 4h. After 
extensive washing to remove extracellular mycobacteria cells were co-cultured for 16h with 
autologous PBMC (effector/target ratio: 10:1). a) Unstimulated PBMC b) PBMC activated by M. 
tuberculosis whole cell lysate (MTB) c) IL2 activated killer cells (LAK). The x-axis shows expression 
of the monocyte/macrophage marker CD14 while eGFP expression is depicted on the y-axis. 
 
FACS analysis of the preliminary experiment is shown in figure 32. Macrophages are gated 
according to their specific size and granularity in the FSC/SSC. The dot plots indicate CD14 
expression on the x-axis and expression of eGFP on the y-axis. The upper right quadrant 
represents the amount of eGFP+ macrophages as percentage of all gate events. After co-
culture with unsimulated PBMC 10.75% of all CD14+ macrophages were also eGFP+. 
Compared to unstiumlated PBMC the incubation with PBMC activated by M. tuberculosis 
lysate led to decreased proportion of eGFP+ CD14+ macrophages (8.53% eGFP+ 
macrophages).  
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The most pronounced reduction was achieved by IL2 activated LAK cells. In this case only 
4.42% of all CD14+ macrophages were also eGFP+. 
Next a direct comparison of FACS data and CFU was employed to guarantee that the 
proportion of eGFP+ macrophages correlates with bacterial growth on plates. To reduce assay 
to assay variation, effector PBMC were replaced by rifampicine or streptomycin in order to 
reduce bacterial burden. Additionally mycobacteria were used at a higher MOI of 20 to 
achieve better infection efficiency and the macrophage marker CD14 was replaced by CD11b. 
This was required since preliminary experiments revealed that CD14 could be down-regulated 
after prolonged cell culture periods (data not shown). The results are depicted in figure 33 for 
FACS analysis (fig. 33a) and conventional CFU (fig. 33b). 
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Fig. 33: FACS analysis and determination of CFU after antibiotic treatment.  
Monocyte-derived macrophages were infected with eGFP-BCG with a MOI of 20 for 4h and 
incubated for 16h without antibiotics (green bar), in presence of different concentrations of 
rifampicine (Rif, red bars) or together with different concentrations of streptomycin (Strep, blue bars). 
a) FACS analysis showing the percentage of eGFP+ events among all CD11b+ events or b) 
determination of CFU on plates. Experiments were done in triplicates, bars represent mean and error 
is depicted as SD. 
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For the flow cytometry approach the proportion of eGFP+ events among all CD11b+ events 
(macrophages) is shown. Macrophages incubated without antibiotics (MF alone) were ~ 48% 
eGFP+ representing infection efficiency. Treatment with the lowest concentration of 
rifampicine (0.05µg/ml) did not reduce this amount, but rising concentration subsequently 
reduced the percentage of eGFP+ macrophages to ~ 30%. In general streptomycin also caused 
a dose-dependent reduction to levels comparable to rifampicine but at higher absolute 
concentrations (~ 30% eGFP+ macrophages at 100µg/ml streptomycin). The gradual decrease 
of bacterial load could be confirmed by CFU. For both antibiotics a similar kinetic depending 
on the concentration of the drug was observed. Interestingly the number of CFU for untreated 
macrophages was ~ 73 at a dilution of 1:1000 while lowest doses of rifampicine (0.05µg/ml) 
were sufficient to reduce the CFU to ~33 at the same dilution. This is in contrast to the FACS 
analysis which did not document a reduction in eGFP+ macrophages after treatment with 0.05 
µg/ml rifampicine.  
 
Since FACS analysis and CFU seem to correlate, PBMC activated by M. tuberculosis lysate 
and the Th1 cytokine IFNγ were included to the assay (fig. 34). In addition to five different 
concentrations of rifampicine (0.01µg/ml – 0.5µg/ml) the effect of unstimulated PBMC and 
lysate-activated PBMC in presence and absence of 50U/ml recombinant IFNγ was also tested. 
PBMC were all applied at the same initial E:T ratio of 10-1. The broad range of different 
rifampicine concentrations leads to a typical titration curve based on the FACS data. The 
lowest concentration has no significant effect on the bacterial load while increasing doses 
gradually decreased the bacterial burden. The maximal effect was already observed at 
0.3µg/ml with a reduction in the proportion of eGFP+ macrophages from ~ 21% to ~ 2%. 
Similar to the previous experiment determination of CFU confirmed the subsequent reduction 
of bacterial burden by rifampicine in a dose-dependent manner. In contrast to the FACS data 
lowest concentrations (0.001µg/ml) were already sufficient to decrease mycobacterial CFU on 
plates. If target macrophages were incubated in presence of unstimulated autologous PBMC 
for 16h a slight reduction of eGFP+ macrophages could be shown (from ~21% to ~18%). The 
most intense reduction was achieved by autologous PBMC stimulated with M. tuberculosis 
lysate (from ~21% to ~13.5%). Hence the priming with lysate has an additive effect to other 
immune processes also carried out by unstimulated (naïve) PBMC. These general findings 
could be verified by conventional CFU but it is worth to mention that in a few cases equal 
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bacterial levels by FACS analysis turned out to be different based on CFU. Most striking is 
the dissimilarity of FACS analysis and CFU for the correlation between medium control (MF) 
and macrophages treated with IFNγ (MF+IFN). FACS data did not correlate with the growth 
of bacteria on plates. 
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Fig. 34: FACS analysis and determination of CFU after treatment with antibiotics and 
incubation with autologous PBMC, respectively.  
Monocyte-derived macrophages were infected with eGFP-BCG with a MOI of 20 for 4h and 
incubated with different effector PBMC, antibiotics or cytokines for 16h. Green bars show infected 
macrophages without treatment (MF) and after co-culture with unstimulated PBMC (unstim.) or 
PBMC activated by M. tuberculosis lysate (MTB). Red bars show the same conditions in presence of 
50U/ml recombinant IFNγ. We also included five different concentrations of rifampicine (Rif, blue 
bars). If autologous PBMC were applied the effector:target ratio was 10:1. Read-out was as either a) 
FACS analysis showing the percentage of eGFP+ events among all CD11b+ events or b) determination 
of CFU on plates. Experiments were done in triplicates, bars represent mean and error is depicted as 
SD. 
 
In summary, the results support a general correlation of FACS analysis and CFU. Moreover 
the ideal titration curve regarding different concentrations of antibiotics demonstrates the 
potential of the assay. A slight killing effect of unstimulated PBMC and a more pronounced 
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effect of lysate-activated PBMC was observed. Preliminary results also argue for the killing 
ability of LAK cells measured by FACS. Within the next experiments E:T ratios were 
calculated to monitor macrophage survival and different amounts of effector PBMC were 
applied to investigate whether their effect is dose-dependent.  
 
Figure 35 shows flow cytometric data, CFU and E:T ratios of macrophages co-cultured with 
unstimulated PBMC, IL2 activated LAK cells or PBMC primed with M. tuberculosis lysate. 
Either five times more or ten times more effector PBMC than macrophages were initially 
applied at the beginning of co-culture period.  
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Fig. 35: FACS analysis and determination of CFU after incubation with autologous PBMC.  
Monocyte-derived macrophages were infected with eGFP-BCG with a MOI of 20 for 4h and 
incubated for 16h together with unstimulated autologous PBMC (green bars, unstim.), with PBMC 
activated by M. tuberculosis lysate (red bars, MTB-lysate) or with LAK cells stimulated by 100 U/ml 
IL2 (blue bars). Autologous PBMC were applied at an initial effector:target ratio of 5:1 and 10:1, 
respectively. Read-out was as either a) FACS analysis measuring eGFP+ events among all CD11b+ 
macrophages, b) determination of CFU on plates or c) the final effector:target ratio at the end of co-
culture by calculating the ratio of CD4+ events/CD11b+ events based on FACS analysis. Experiments 
were done in triplicates, bars represent mean and error is depicted as SD. 
 
Unstimulated PBMC (E:T = 5:1) led to ~75% eGFP+ macrophages among the whole 
population of CD11b+ cells. This proportion is slightly reduced to ~60% by doubling the 
amount of unstimulated PBMC (E:T = 10:1). In contrast, LAK cells already reduced the 
amount of eGFP+ macrophages to ~60% at an initial E:T ratio of 5-1, which decreased to 
~50% after application of ten times more LAK cells than macrophages (E:T = 10:1). Finally 
lysate-activated PBMC had the strongest killing effect based on the detection of eGFP+ 
macrophages. Five times more effector PBMC than macrophages (E:T = 5:1) caused a 
decrease to ~50% and an E:T ratio of 10-1 led to ~25% eGFP+ macrophages. These results 
gained by flow cytomertry could be verified by parallel determination of CFU on plates.  
In this experiment the E:T ratio was calculated as the quotient of CD4+ events divided by 
CD11b+ events. For unstimulated PBMC the quotient at the end of co-culture was ~2.5 and ~5 
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depending on the initial amount of effector PBMC. For the same conditions, IL2 activated 
LAK cells led to final quotients of ~10 and ~16.5, respectively. Since the amount of CD4+ 
cells remained constant, the only explanation for an increase in the E:T quotient is massive 
killing of macrophages. An intermediate quotient of ~5 and ~8 was observed for lysate-
activated PBMC, representing slight side damage to macrophages. 
It is worth to underline that the novel assay allows discrimination between different killing 
mechanisms. Lysate-activated PBMC for instance, applied at an E:T ratio of 5:1, reduced the 
bacterial burden to the same level of LAK cells at an E:T ratio of 10:1. This holds true for 
FACS analysis as well as CFU. Bacterial growth analysis alone would show a uniform 
picture, while flow cytometry-based calculation of E:T ratios revealed a side damage of 
macrophages three times higher for LAK cells compared to lysate-activated PBMC. In other 
words, flow cytometry provides useful information about qualitative differences in the in vitro 
killing of intracellular mycobacteria. 
 
In order to verify these findings with PBMC from another uninfected (TST negative) donor, a 
similar experimental setup was used which included LAK cells induced by different 
concentrations of IL2 (10U/ml, 50U/ml, 100 U/ml). Unstimulated PBMC, LAK cells as well 
as PBMC activated by M. tuberculosis lysate were applied at an initial E:T ratios of 2.5:1; 5:1 
and 10:1. Determination of the proportion of eGFP+ macrophages and the calculation of E:T 
quotients (CD45+ events/CD11b+ events) are given in figure 36. As expected the co-culture 
together with different amounts of unstimulated autologous PBMC gradually reduced the 
percentage of eGFP+ macrophages from ~75% to ~52%. The application of lysate-activated 
PBMC led to a subsequent reduction from ~50% to ~10% in a dose-dependent manner. In 
contrast, the lowest concentration of IL2 of 10U/ml did not induce LAK cells effectively since 
the proportions of eGFP+ macrophages were comparable to those of unstimulated PBMC. 
50U/ml was sufficient for the induction of LAK cells and especially at high concentrations 
(E:T ratio of 10:1) these cells were able to reduce the bacterial load, represented as percentage 
of eGFP+ CD11b+ cells (reduction to ~30%). The highest concentration of 100U/ml IL2 did 
reduce the amount of eGFP+ macrophages most efficiently. The decrease in bacterial burden 
was comparable to PBMC activated by M. tuberculosis lysate. Regarding the E:T quotients 
the incubation with lysate-activated PBMC did not cause more damage to macrophages than 
the incubation with unstimulated PBMC. A higher initial E:T ratio also correlates with a 
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higher E:T quotient at the end of the assay. Hence information about collateral damage of 
macrophages was obtained by comparing each particular E:T quotient to the value of 
unstimulated PBMC.  
GFP+
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
0
10
20
30
40
50
60
70
80
90
unstim.
MTB-lysate
IL2-10 U/ml
%
 C
D
11
b+
IL2-50 U/ml
IL2-100 U/ml
Effector/Target ratio
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
2,5
-1 5-1 10
-1
0.0
2.5
5.0
7.5
unstim.
MTB-lysate
IL2-10 U/ml
C
D
45
+  
/ C
D
11
b+
IL2-50 U/ml
IL2-100 U/ml
a
b
%
 C
D
11
b+
C
D
45
+  
/ C
D
11
b+
 
Fig. 36: FACS analysis after incubation with autologous PBMC.  
Monocyte-derived macrophages were infected with eGFP-BCG with a MOI of 20 for 4h and 
incubated for 16h together with unstimulated autologous PBMC (green bars, unsitm.), with PBMC 
activated by M. tuberculosis lysate (red bars, MTB-lysate) or with PBMC stimulated by different 
amounts of IL2 (blue bars, orange bars, violet bars). Autologous PBMC were applied at an initial 
effector:target ratio of 2,5:1; 5:1 and 10:1. Read-out was either: a) FACS analysis measuring eGFP+ 
events among all CD11b+ macrophages, b) the final effector:target ratio at the end of co-culture by 
calculating the ratio of CD45+ events/CD11b+ events based on FACS data. Experiments were done in 
triplicates, bars represent mean and error is depicted as SD 
 
PBMC activated by M. tuberculosis lysate or low doses of IL2 (10U/ml) did not cause 
collateral damage to macrophages (compared to unstimulated PBMC) while LAK cells 
induced by 50U/ml and 100U/ml of IL2 reduced the absolute number of viable macrophages. 
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The killing effect on macrophages did positively correlate with the number of effector PBMC 
applied. Qualitatively this independent experiment verifies the data of the first experiment. 
PBMC primed with M. tuberculosis lysate and high doses of IL2 (50U/ml+100U/ml) 
gradually reduced the bacterial burden. In case of M. tuberculosis lysate the E:Tquotient after 
co-culture does not argue for massive killing of macrophages. In contrast, PBMC activated by 
high concentrations of IL2 reduced the amount of viable marcophages, especially if high 
amounts of effector PBMC were used. 
 
In summary, the in vitro killing assay was performed for different donors and with PBMC 
activated by various stimuli. Figure 37 gives a complete overview of all experiments 
performed. In some cases the experiments were done with PBMC from the same donor 
(labeled in green/red). For each single experiment the table indicates whether reduction of 
intracellular mycobacteria was detectable or not after incubation with antibiotics or PBMC 
activated by lysate and IL2, respectively. Most important for the feasibility of the new assay is 
the correlation of FACS data and CFU; the observed reduction in the amount of eGFP+ 
macrophages should correlate with a reduced bacterial burden determined by bacterial growth 
on plates. This also includes the correct distribution of bacterial levels within one experiment. 
Donor 
Killing 
MTB-lysate 
Killing 
IL2 
Killing 
Antibiotics 
FACS/CFU 
Correlation 
086 - - Y Y 
086 - - Y Y 
083 Y N - - 
083 Y Y - Y 
083 N N - Y 
275 N N - N 
276 N N - Y 
227 Y Y - N 
082 Y Y - Y 
008 Y Y - Y 
183* N N - - 
570* N N - N 
 
 
Fig. 37: Overview of every in vitro killing assay performed.  
For every in vitro killing assay the table shows the identification number of the donor, whether the 
FACS analysis of GFP+ macrophages correlated with CFU on plates and finally if a reduction of 
bacterial load could be observed after i) treatment with antibiotics ii) by LAK cells or iii) by PBMC 
stimulated with M. tuberculosis lysate. Y indicates YES, N represents NO and – stands for “not 
determined”. * = altered protocol / infection with low MOI 
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Using the final protocol and an infection with a high MOI (upper part of the table) seven of 
nine killing assays showed correlation of FACS data and CFU. In two cases the bacterial 
levels gained by flow cytometry could not be verified by CFU. If the distribution of bacterial 
titers differed only for a single data set the experiment is considered a failure. Remarkably in 
some cases the generation of effector cells by incubation with IL2 and/or lysate did not reduce 
the bacterial burden although the same conditions were used. For donor 083 even the same 
PBMC under the same conditions led to different results.  
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7 Discussion 
Adaptive cellular immune responses are crucial for effective and long lasting protection 
against the intracellular pathogen M. tuberculosis. Consequently the assessment of M. 
tuberculosis-specific T memory responses is a matter of particular interest for vaccination 
strategies (Reece and Kaufmann, 2008), monitoring of treatment and clinical diagnosis 
(Lalvani, 2007). Focus of this thesis is the study of human T-cell mediated immune 
responses against infection with M. tuberculosis leading either to active disease or LTBI. By 
comparing the quantity, quality and specificity of adaptive immune responses among both 
study groups differences which contribute to the outcome of infection should be identified. 
Till today suitable markers for the discrimination of LTBI and active disease as well as 
functional differences responsible for the outcome of infection are still unknown (Jacobsen, 
et al., 2008). Major findings of this thesis are i) the identification of immunogenic M. 
tuberculosis proteins associated with dormancy, reactivation and resuscitation based on a 
novel 7 d T-cell assay; ii) comparison between donors with LTBI and TB patients revealed 
significantly higher T-cell responses against 7 of the 35 tested latency antigens in LTBI; iii) 
T-cell responses against one of the antigens, namely Rv3407, were exclusively detected in 
LTBI; iv) MHC genotyping demonstrated an over-representation of HLA-DQ8.1 within the 
sub-group of LTBI recognizing Rv3407 (9.2. HLA phenotyping, p. 123 ). 
 
7.1 Antigen identification 
The first part of this thesis deals with the identification of new M. tuberculosis antigens. It 
can be divided into two independent approaches: fractionated Beijing whole cell lysate and 
recombinant latency-associated proteins. Relevant in both cases is the comparison of T cell 
mediated memory responses in latent infection and active TB. Until today various M. 
tuberculosis-derived immunodominant proteins (e.g. ESAT6_CFP10, Ag85a/b and TB10.4) 
have been identified. Most of these antigens were characterized by restimulation of primed 
PBMC from infected individuals with culture supernatant, cytosolic lysates or other protein-
rich fractions of M. tuberculosis. Similar to that, prominent antigenic proteins like ESAT6 
and CFP10 were identified in short term culture filtrate by proteomics (Berthet, et al., 1998; 
Sorensen, et al., 1995).  
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Since ESAT6 as well as CFP-10 are not present in M. bovis BCG, IGRA for the diagnosis of 
M. tuberculosis infection rely on both these antigens (i.e. QuantiFeron GOLDTM and T-Spot 
TBTM). Even though measurement of IFNγ induced by ESAT6 and CFP10 in LTBI 
improved the diagnosis, it remained insufficient as a correlate of protection against M. 
tuberculosis (Mittrucker, et al., 2007). Nevertheless IGRA with prolonged incubation 
periods were more sensitive to detect past latent TB, discrimination of active TB and LTBI 
remains impossible by molecular test (Leyten, et al., 2007) Hence, candidate biomarkers 
which reliably predict protective immunity are urgently needed. 
The initial step was to fractionate M. tuberculosis Beijing whole cell lysate according to 
molecular size. The hyper-virulent clinical isolate of M. tuberculosis called Beijing was used 
to mirror the situation in high-endemic areas (Wong, et al., 2007). The potential to elicit 
antigen-specific immune responses in LTBI and TB patients was then measured by flow 
cytometry after 16h in vitro restimulation for each separate fraction. Qualitative and 
quantitative differences in antigen recognition among both study groups should be 
documented. 
ICS revealed detectable amounts of IFNγ expressing CD4+ T cells in LTBI after incubation 
with each of the 11 fractions (fig. 8, p.51). There were only minor differences between the 
separate fractions. In comparison to LTBI the frequencies of IFNγ+ CD4+ T cells were 
significantly higher in TB patients. This phenomenon can be explained by the different 
stages of the disease (latency versus active TB) which are possibly accompanied by a 
different activation status of the immune system. It is worth to speculate that active TB goes 
along with a higher abundance of M. tuberculosis antigens due to replicating bacteria and 
promote priming of T-helper cells. Nevertheless the relevant reports in the literature are 
inconsistent. In comparison to LTBI increased levels of IFNγ production after incubation 
with ESAT6 and CFP10 could be measured in PBMC from TB patients (Arend, et al., 2000; 
Chee, et al., 2007). In contrast to this, depressed IFNγ levels after restimulation with PPD 
have been reported by others (Hirsch, et al., 1999). Obviously the particular antigen used for 
in vitro restimulation is crucial for these studies. This might explain why IFNγ responses in 
the periphery are increased after incubation with certain M. tuberculosis proteins while PPD 
induced responses appear to be static. Additionally the absolute level of IFNγ in cell culture 
supernatants does not have to correlate with the relative frequency of IFNγ expressing T 
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cells, since gradual differences in the cellular IFNγ amount can be measured by flow 
cytometry (data not shown). In summary, T-cell kinetics in humans after exposure to M. 
tuberculosis and the changes during therapy seem to be complex and vary between 
individuals. For instance, longitudinal studies after point-exposure to TB revealed individual 
differences in the adaptive T-cell response among untreated donors (Ewer, et al., 2006). 
Anyway the intention to document pronounced T-cell responses towards single Beijing 
fractions was not successful. Although some fractions (i.e. Frak-3; Frak-4; Frak-11) elicited 
higher frequencies of IFNγ expressing CD4+ T-cells in some TB patients compared to the 
average of all fractions, these findings were not consistent. Furthermore intermediate recall 
responses were detected for some fractions (i.e. Frak-8; Frak-9; Frak-10; Frak-12) in some 
donors which did not allow clear-cut identification of potential candidates.  
Despite possible contaminations within the crude bacterial lysate (e.g. TLR ligands or 
endotoxins) an insufficient separation of the whole cell lysate by gel filtration could be 
responsible for these observations. The most likely explanation is crude separation of 
immunogenic proteins by gel filtration since the majority of cytosolic protein yield was 
recovered within 4 out of 24 fractions (fig 6, p. 48). This would also be an explanation for 
the observed gradual differences in the strength of the recall response. One could imagine 
that such a crude isolation in combination with the relatively huge genome of M. 
tuberculosis (4294 genes) does not allow the identification of single antigenic proteins or an 
effective comparison of M. tuberculosis-specific T-cell responses between LTBI and TB 
patients. In order to achieve a better separation of antigenic proteins within the fractions an 
ion exchange chromatography was performed following gel filtration. The intention was to 
further separate the individual fractions according to the charge properties of polar 
molecules. In preliminary experiments no better separation of the cytosolic protein fraction 
could be achieved by this strategy (data not shown).  
Moreover this study relies on ICS followed by FACS analysis; consequently it includes 
various effector cytokines but cannot be performed in high-endemic areas where FACS 
analyzers are still missing. Therefore this approach can be considered as a pilot study and 
especially the assay conditions have to be adjusted. To evaluate a specific candidate or 
fraction, detection of IFNγ in the supernatant could be a feasible way which fits the 
conditions in developing countries. 
 
                                                                                                                                   Discussion 
 
 91
7.2 Latency-associated antigens 
As already mentioned the vast majority of individuals is capable of controlling M. 
tuberculosis infection by specific cellular immunity leading to LTBI. The latent stage of 
infection is thought to be associated with a dormancy state of the pathogen including the 
expression of exclusive dormancy related antigens, i.e. DosR encoded proteins (Park, et al., 
2003). DosR antigens as well as factors involved in the reactivation and resuscitation of 
dormant bacilli are candidate biomarkers for LTBI and susceptibility to disease (Biketov, et 
al., 2000; Chan and Flynn, 2004). To verify the hypothesis that LTBI is also linked to 
specific T-helper cell responses against such latency-associated proteins, T-cell responses 
were studied after short-term in vitro restimulation of PBMC from LTBI. IFNγ expressing 
memory T cells were only detectable after incubation with PPD and known 
immunodominant proteins like ESAT6_CFP10, TB10.4 or Ag85a/b (fig. 12, p. 57). The 
whole panel of dormancy-, reactivation- and resuscitation-associated proteins (fig. 10, 54) 
did not induce detectable expression of IFNγ in CD4+ memory T cells after 16h of 
restimulation (fig. 12, 57). There is increasing evidence that short-term assays efficiently 
detect recent M. tuberculosis infection while in vitro stimulation for several days is more 
sensitive for LTBI (Arend, et al., 2007; Cehovin, et al., 2007; Weir, et al., 1999). Since our 
own previous experiments indicated that a 16-h restimulation before measurement is optimal 
for intracellular cytokine detection (Mueller, et al., 2008), 7d of stimulation were combined 
with restimulation 16h prior to analysis.  
Indeed prominent T-cell responses towards the majority of latency-associated proteins as 
well as amplified T-cell responses towards classical immunodominant proteins were 
detected by this assay (fig. 13, 59). Consequently the novel 7d assay allows detection of T-
memory responses which are missed by 16-h short-term restimulation. Different reasons 
may contribute to the superiority of the optimized assay. Obviously CD45RO+ memory 
populations which are present in the periphery at very low frequencies benefit from 
protracted incubation times, possibly by proliferation leading to detectable T-cell responses 
after 7d. It is also worth to speculate that a suppressive effect of regulatory T cells could be 
overcome by these culture conditions. Finally a different cellular phenotype / maturation 
stage of T cells specific for M. tuberculosis latency antigens could be an explanation for the 
altered restimulation prerequisites of this T-cell subset.  
                                                                                                                                   Discussion 
 
 92 
As an initial step to address this question, relative and absolute changes in the proportion of 
cytokine expressing T cells induced by latency-associated antigens and classical 
immunodominant proteins were compared between 16h and 7d in individual donors. The 
relative increase (ratio of T-cell frequencies after 16h and 7d) was significantly higher in 
latency-associated antigens as compared to classical immunodominant proteins (fig. 15a, p. 
62). In contrast, the absolute increase (absolute difference between 16h and 7d) in T-cell 
proportions induced by latency-associated antigens was comparable to that of 
immunodominant antigens (fig.15b, p. 62). These results argue against a boost of T-cell 
responses as the only mechanism involved, since this would also result in absolute 
differences in comparison to classical antigens. In other words, CD45RO+ memory T cells 
which either recognizes classical immunodominant antigens or latency-associated antigens 
do not seem to follow the same kinetic. An impressive example is Rv0569 which did not 
induce detectable IFNγ expression in T cells after 16h while the 7d responses even exceeded 
those induced by ESAT6_CFP10 (the most immunogenic antigen after 16h restimulation).  
 
In connection with the new restimulation conditions for the detection of T-cell responses 
towards M. tuberculosis latency-associated antigens, the use of ICS, IFNγ ELISA and 
proliferation assays as readout methods has been evaluated. It turned out that all three assays 
lead to robust, reliable and comparable results (fig. 13, p. 59), while ICS had by far the 
highest specificity (lowest ‘background’ in TST negative uninfected donors; fig. 14, p. 61). 
In accordance with a previous study (Leyten, et al., 2006) IFNγ was detected in the 
supernatants of PBMC from LTBI stimulated with latency antigens (fig. 13, p. 59). Notably, 
and in contrast to ICS, IFNγ was also detected in supernatants of PBMC from some 
uninfected donors after stimulation with latency antigens (Fig. 14, p. 61).  
The second round of restimulation did not cause this higher background in uninfected 
donors since supernatants collected at day 6 from a subgroup of uninfected donors showed 
similar IFNγ levels as compared to the day 7 time point after restimulation (data not shown). 
The possibility that other immune cell populations (i.e. NKT cells, CD8+ T cells) were the 
source of cytokines was excluded by flow cytometry (data not shown). Therefore a possible 
explanation would be exhaustion or induced killing of these cells (e.g. by apoptosis) due to 
restimulation 16h prior to analysis (Alsharifi, et al., 2008; Krammer, et al., 2007). 
Alternatively, these donors may have been false negatives in the T-Spot TB© (although there 
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is no evidence for this assumption) or these responses may reflect cross-reactivity towards 
antigens expressed by commensal bacteria (Regner, 2001). 
 
Based on the optimized assay, specific memory responses of CD4+ T cells after incubation 
with most of the tested latency-associated antigens could be documented in LTBI (fig. 13, p. 
59). Hence eleven latency-antigens eliciting highest T-cell responses in LTBI (i.e. Rv0569, 
Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, Rv1884c, Rv2450c and 
Rv3407) were selected. The amount of IFNγ expressing CD4+ CD45RO+ T cells was 
compared in patients with active pulmonary TB, LTBI and TST negative donors after 7d of 
restimulation with these antigens. Seven of the tested antigens (i.e. Rv1733c, Rv2003, 
Rv2005c, Rv0140, Rv1009, Rv2450c and Rv3407) induced significantly higher amounts of 
IFNγ expressing memory T cells in LTBI compared to TB patients (p< 0.03; fig. 17, p. 64). 
For Rv1733c, Rv2003, Rv2005c, Rv0140 and Rv3407 these differences were even highly 
significant (p< 0.001; fig. 17, p. 64). People with LTBI in the present study are health care 
workers at different medical centers in Germany and they can be considered long-term M. 
tuberculosis exposed. All of them remained healthy for years within this environment and 
therefore their immune response seems to be efficient in containing the pathogen. T-cell 
responses specifically indicating LTBI argue for their important role in immunity to TB. Of 
course longitudinal studies regarding the progression of LTBI are needed in addition to this 
cross-sectional study. Anyway, this is an initial step towards improved detection of 
“subdominant” antigens in different diseases where reliable biomarkers are still missing and 
T-cell responses against immunodominant antigens are insufficient for protection. 
 
Different latency-associated antigens elicited T-cell responses in distinct LTBI. Therefore 
we set an arbitrary threshold of positive T-cell response (0.20 %, i.e. 10-fold higher than the 
assumed flow cytometric detection threshold of 0.02 %) and determined the minimal cluster 
of latency-associated antigens which induced a positive response in a maximal proportion of 
LTBI. Rv1733c and Rv3407 together induced T cell responses in 71.4% of tested LTBI. In 
contrast, only one of 20 TB patients responded to these proteins (fig 38). 
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Figure 38. IFNγ expressing T cells after 7d restimulation with Rv1733c and Rv3407.  
The sum of the T-cell response elicited by both latency-associated antigens is shown for LTBI and 
TB patients as percentage of IFNγ+ CD4+ CD45RO+ T cells. PBMC were analysed by ICS after 7d 
and two rounds of restimulation with either Rv1733c or R3407. The dotted line indicates an 
arbitrary cut-off of 0.3%. 
 
Discrimination analysis 
To determine whether T-cell responses against latency-associated M. tuberculosis antigens 
are sufficient for classification of TB patients and LTBI, we included eleven latency 
antigens (i.e. Rv0569, Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, 
Rv1884c, Rv2450c and Rv3407) together with ESAT6_CFP-10, PPD and SEB in a 
discrimination approach. Random forest analysis together with leave-1-out cross-validations 
across all possible combinations were applied to determine the prediction accuracy and 
relative importance of each factor for classification (fig. 39a). This analysis revealed a cross-
validated prediction accuracy of 83% between TB patients and LTBI. The resuscitation-
associated antigen Rv3407 was by far the most influential factor for classification (fig. 39b) 
(Mollenkopf, et al., 2004) 
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Figure 39. Random forest analysis together with leave-1-out crossvalidations.  
Discrimination approach of TB patients and LTBI based on 11 subdominant antigens (i.e. Rv0569, 
Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, Rv1884c, Rv2450c and Rv3407) 
together with ESAT-6_CFP10, PPD and SEB. a) Discrimination approach of TB patients and LTBI. 
Each bar represents an individual donor. TB patients are shown on the left (red bars), LTBI on the 
right side (blue bars). The vertical axis indicates the prediction threshold calculated by the random 
forest analysis. Below the threshold a TB-case is predicted, above the threshold an LTBI-case. The 
prediction probability is represented as the bar height. (b) Mean decrease of class impurity over all 
trees measured as Gini index indicates the relative importance of each factor for classification. 
 
Based on the cross-sectional study, Rv3407 was the only latency-associated antigen which is 
recognized in LTBI, but in none of the TB cases. Consequently Rv3407 is the most 
important factor for discrimination of LTBI and TB patients (fig. 39). To characterize the 
distinct epitope within Rv3407 overlapping peptide pools were designed. The identification 
of four different immunogenic peptides by the synthetic matrix pools (fig. 20, p. 67) render 
the existence of a single ‘super-epitope’ recognized by the majority of LTBI unlikely. In this 
context it is worth to mention that in most cases more than a single ‘vertical’ and a single 
‘horizontal’ pool elicited positive T-cell responses as defined by the arbitrary threshold of 
0.2% IFNγ+ CD4+ CD45RO+ T cells. To approach this issue the pool which led to the 
highest frequency of IFNγ expressing T cells was used for the identification of the 
immunogenic peptide. Of course other combinations are possible for some of the LTBI 
leading to different distinct peptides. Additionally the 7d/two rounds restimulation assay 
which has been designed for protein antigens seems to be suboptimal for stimulation with 
peptides. Only six out of ten LTBI which had been preselected for their response to Rv3407 
protein also had measurable responses against the overlapping peptide pools. Moreover, 
only the minority of tested LTBI possessed prominent CD4+ memory responses which 
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allowed the identification of a single epitope. Possible explanations for the observed 
dissimilarities between proteins and peptides are i) different pathways of antigen processing 
and presentation; ii) differences in antigen availability; iii) an altered level of T-cell 
activation by proteins and peptides. Large particular antigens are taken up and processed by 
APC leading to TAP-dependent presentation of the containing epitopes to T cells (see 3.2 
Adaptive immune responses). This pathway follows its own dynamic and can be influenced 
on different levels by signal molecules, e.g. cytokines. The surface expression of MHC 
molecules as well as molecules involved in antigen processing can be regulated. In contrast, 
small peptides are loaded directly to MHC molecules on the cell surface without 
participating in the classical antigen processing pathway. They compete exogenously with 
other peptides for MHC binding and can replace peptides with low binding affinity 
(Ackerman and Cresswell, 2004; Hosken, et al., 1989). Consequently the presentation of 
high affinity peptides follows another kinetic and cannot be regulated directly by the APC.  
Intertwined with these differences in processing and presentation is the different amount of 
available antigen. Intermediate protein concentrations used for restimulation (5 – 10µg/ml) 
lead to a limited availability of potential epitopes while high concentrations of 15-mer 
synthetic peptides (1 – 5µg/ml) needed for in vitro restimulation provide high amounts of 
potential T-cell epitopes. All these dissimilarities could result in differences regarding the 
signal strength sensed by the TCR.  
One could speculate that long-term stimulation together with a second round of 
restimulation lead to activation induced cell death or T-cell anergy for peptides which is not 
the case for proteins.  
 
Despite the suboptimal assay conditions it could be shown that distinct peptide epitopes in 
different LTBI were recognized by antigen-specific T cells. Ongoing studies will determine 
whether this is due to differences in the HLA-phenotype. At this stage high resolution MHC 
genotyping by polymerase-chain-reaction (PCR) was performed for nine donors with LTBI 
which recognize Rv3407 protein (9.2. HLA phenotyping, p.123). These preliminary results 
indicate that there are no significant differences in the distribution of MHC class I haplotype 
from the reference group (German/European population). For MHC class II an elevated 
amount of donors carrying the HLA-DQA1*0301/DQB1*0302 allele was detected [78% 
compared to 9.9% for the average of the German population (Kimiyoshi, 1991)]. Regardless 
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of the distinct epitope recognized within Rv3407 the fact that HLA-DQ8.1 (synonym for the 
combination of HLA-DQA1*0301/DQB1*0302) is overrepresented among a subgroup of 
LTBI give rise to new questions and speculations. Especially because memory responses 
towards Rv3407 mediated by CD4+ T cells seem to correlate with latent infection and 
possibly with long-term protection against active pulmonary TB.  
Genetic factors determining susceptibility or resistance to M. tuberculosis infections have 
been studied extensively. Recent findings indicate that susceptibility to mycobacterial 
infections is caused by mutations affecting the function of the IFNγ as well as the IL12 
receptor (Levin and Newport, 1999). Moreover susceptibility to TB has been linked to a 
loss-of-function polymorphism in the human P2X7 gene which impairs the ability of 
macrophages to kill intracellular M. tuberculosis (Britton, et al., 2007). Activation of the 
P2X7 receptor, an ATP-gated Ca2+ channel, leads to the formation of pores, the activation of 
phospholipase D and the induction of apoptosis with death of the infecting mycobacteria.  
Molecular defects affecting the regulatory subunit of the NFκB inhibitor (IκB) kinase 
complex also predispose to server mycobacterial infection (Orange and Geha, 2003). This 
results in an impaired NFκB activation and reduced responsiveness to TLR activation and 
TNFα. 
Genes encoding the vitamin D3 receptor, natural resistance-associated macrophage protein 
(NRAMP1) and mannose binding lectin (MBL) have been associated with TB susceptibility 
in multiple studies (Fernando and Britton, 2006). All these polymorphisms can be linked to 
functional deficiencies of the host immune system. Vitamin D3 is an immunomodulatory 
hormone that can activate human monocytes and suppresses the growth of mycobacteria 
(Rook, et al., 1986; Tsoukas, et al., 1984). NRAMP1 plays an important role in macrophages 
responses to intracellular infections, including the increased production of RNI and ROI, the 
regulation of MHC II molecules as well as the production of pro-inflammatory cytokines 
(Blackwell, et al., 2000). Finally MBL is a complement-activating protein and opsonizing 
agent (Janeway, 2005). Single studies also reported an association of susceptibility to TB 
with TLR-2 and IL1Rα mutations as well as TAP2 polymorphisms (Bellamy, et al., 1998; 
Ogus, et al., 2004; Rajalingam, et al., 1997). 
Despite genetic predisposition factors which affect basic immunological functions some 
links to the HLA genotype have been reported so far. HLA-C, the main ligands for killer 
inhibitory receptors (KIR), are divided in two allotypes. The group 1 allotypes were found to 
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be more prevalent among patients with TB, which suggests a possible inhibition of NK cell 
activity against the infected target cells (Bothamley, 1999). In a case-control study of an 
Indian population, susceptibility to TB was found to be associated with HLA-DR2 
(Bothamley, et al., 1989; Rajalingam, et al., 1996). Additionally a Cambodian study showed 
a significant association of HLA-DQB*0503 allele and susceptibility to TB (Goldfeld, et al., 
1998). Recently a new X-linked recessive form of Mendelian susceptibility to mycobacterial 
disease has been reported (Bustamante, et al., 2007).  
A link to HLA-DQ8.1 has not been found so far. Since this analysis focuses on a subgroup 
of LTBI which possibly possess an advantageous phenotype of adaptive immunity, the 
overrepresentation of DQ8.1 could be missed considering the entire group of LTBI. This 
issue has to be addressed in large-cohort studies to receive more reliable data. 
 
For some of the patients with active pulmonary TB the T-cell response against latency-
associated M. tuberculosis proteins could be compared at the beginning of treatment and six 
weeks later after sputum conversion. This comparison revealed two essential facts i) These 
patients did not show a homogenous T-cell kinetic. Some of them had a static T-cell 
response characterized by the absence of T-cell mediated recognition for any of the latency 
antigens at both time points (fig. 21a, p. 69); others possessed increased amounts of IFNγ-
expressing memory T cells at the later time point while T-cell responses for the latency 
antigens where next to detection limits at the beginning of treatment (fig. 21 b-d, p. 69).  
ii) There is also heterogeneity regarding the latency-associated antigens. In each individual 
TB patient with increased T-cell responses after sputum conversion a different subset of 
antigens was affected. Nevertheless the DosR encoded proteins Rv1734, Rv2003 and 
Rv2006 were consistently found among this subset (fig. 21 b-d, p. 69). 
It is important to mention that in most patients the increase in T cell mediated recognition of 
the latency-associated antigens correlated with an increased IFNγ response towards the 
conventional immunodominant antigen ESAT6_CFP10 (fig. 21 c-d, p. 69). In conclusion the 
observed increase in T-cell recognition of the DosR encoded proteins could be due to a 
generally boosted T-cell response towards M. tuberculosis derived proteins along treatment. 
Death of mycobacteria and the presentation of their antigenic components might lead to 
increased antigen availability. Hence improved T-cell priming after prolonged 
administration of antibiotics could be an explanation for our observations. One might also 
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speculate that the increasing pressure by the combination of antibiotics and adaptive 
immune responses drive the pathogen into the dormant stages of its life cylce. The up-
regulation of DosR encoded proteins could lead to the induction of specific CD4+ T-cell 
responses. Some controversial reports regarding the kinetic of M. tuberculosis-specific 
immune responses along therapy have been discussed already (e.g. (Ewer, et al., 2006)). 
There are also some studies which documenter an elevated frequency of RD1-specific CD4+ 
T cells at the beginning of treatment which levels off at later time points (Chee, et al., 2007; 
Veenstra, et al., 2007). Clearly this is in contrast with the results of this thesis. 
Based on the present data it is impossible to claim which kind of T-cell response directed 
against which latency-associated antigen is really beneficial for the outcome of infection. 
Anyway it could be shown that TB patients (as well as LTBI) do not possess a homogenous 
T-cell response after M. tuberculosis infection and that there are fundamental differences in 
T-cell mediated recognition of latency-associated M. tuberculosis proteins. The cross-
sectional comparison of LTBI and TB patients (fig. 17, p. 64) indicate that some latency-
associated antigens are potential correlates of immunity to TB but this needs further 
evaluation. 
 
Since childhood TB is often associated with severe courses of disease it is worth to study T-
cell responses towards the pre-selected latency antigens in small children (below the age of 
six). The criteria for ‘real’ LTBI in these children is much more complicated compared to 
adults because infection with M. tuberculosis is treated immediately with antibiotics. This 
prophylactic treatment does not allow the identification of long-term resistant donors and 
blurs the boundaries between LTBI and active TB.  
Indeed a situation different from that in adults could be observed; the preliminary study 
revealed T cell mediated recognition of all but one latency antigens in both study groups in 
the majority of tested individuals (fig. 22, p. 70). The only exception was Rv3407 which was 
exclusively recognized in LTBI and not in children with pulmonary TB. Interestingly the 
median of the amount of IFNγ expressing memory T cells for six of the latency-associated 
proteins was higher in TB patients than LTBI. Such a reverse situation compared to adults 
might be due to differences in the maturation stage of the immune system and/or antibiotic 
treatment. Perhaps the prophylactic therapy in children prevents a ‘real’ latency stage from 
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being evolved and consequently antigens associated with M. tuberculosis dormancy are not 
highly expressed. 
 
7.3 Characterization of T-cell subsets 
To further study the T-cell recognition of fractionated Beijing whole cell lysate, the 
associated cellular cytokine profiles were analyzed for each fraction. Therefore ICS 
followed by FACS analysis was used to detect either two or three cytokines simultaneously. 
This staining procedure allowed quantification of the amount of multi-functional T-cell 
proportions for each fraction. For the combination of IFNγ and TNFα no significant 
differences in the cytokine profiles were observed after restimulation of PBMC from donors 
with LTBI (fig. 25, p. 74). The vast majority of M. tuberculosis-specific CD4+ CD154+ T 
cells produced both cytokines in parallel and dissimilarities between the 11 fractions were 
absent. In contrast, patients with active TB had a reduced amount of IFNγ/TNFα dp T cells 
while the amount of CD4+ CD154+ T cells expressing neither IFNγ nor TNFα was 
increased. Even more each fraction elicited a slightly altered cytokine profile with different 
proportions of multi-functional T cells. This is an interesting finding since the amount of 
multi-functional T cells is thought to contribute to the outcome of viral and bacterial 
infections. It has been reported that the amount of IFNγ+ IL2+ CD4+ T cells in HIV infected 
“Long-term-non-progressors” as well as individuals receiving anti-retroviral therapy is 
increased compared to progressors. The progressors predominantly had IFNγ sp T cells 
being specific for HIV encoded proteins (Boaz, et al., 2002; Harari, et al., 2004; Younes, et 
al., 2003). Similar results were found during chronic hepatitis C virus infection (Semmo, et 
al., 2005). More recent studies showed that a high amount of poly-functional T cells 
producing IFNγ and TNFα correlate with non-progressive HIV-2 infection and possibly a 
good clinical outcome (Duvall, et al., 2008). Also in cytomegalovirus infection extensive 
FACS analysis identified protective multi-functional CD4+ T cells which produce MIP-1β, 
TNFα and IFNγ in the absence of IL2 (Casazza, et al., 2006). These CD4+ T cells have a 
terminally differentiated phenotype and possess direct cytotoxic activity mediated by 
perforine and granzymes.  
Remarkably, the degree of protection against Leishmania major infection in mice is 
predicted by the frequency of CD4+ T cells simultaneously producing IFNγ, IL2 and TNFα. 
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Initial studies in humans revealed a shifted dominance to IFNγ/IL2 dp T cells during 
treatment of active TB (Millington, et al., 2007).  
Conflicting to this report in the literature differences based on the expression of IFNγ/IL2 
were absent while differences based on IFNγ/TNFα could be observed by this study (fig.26, 
p. 76). In contrast to this thesis, Millington et. al. used ESAT6_CFP10 for restimulatiuoin of 
T cells instead of M. tuberculosis lysate. Obviously the number of individuals tested for the 
expression of IFNγ/IL2 (n=3) and IFNg/TNFa (n=7) is too small to allow definitive 
statements. Additionally T-cell responses towards fractions can possibly lead to different 
results compared to those achieved by incubation with single immunogenic proteins (i.e. 
ESAT6_CFP10). Anyway the present findings emphasize the role of qualitative aspects of 
adaptive immune responses revealed by flow cytometry.  
For further delineation of antigen-specific T-cell subsets recognizing fractionated Beijing 
lysate cytokine profiles of IFNγ, TNFα and IL2 were analyzed after restimulation (fig. 27, p. 
77). This revealed a characteristic cytokine profile for each fraction with variable amounts of 
IFNγ/TNFα/IL2 tp and IFNγ/TNFα dp CD4+ T cells. These findings accentuate the impact 
of multi-functional T-cell proportions and introduce a new aspect to our analysis, namely the 
quality of T-cell responses. However, the importance of these T-cell subsets in vivo as well 
as their impact on host defense against M. tuberculosis cannot be addressed by such 
experiments. Follow up studies of “Long-term-non-progressors” and progressors are needed 
to clarify this point. Since this kind of study is going beyond the scope of this PhD thesis a 
new functional in vitro assay was designed to evaluate the effects of different T-cell subsets 
on mycobacteria-infected macrophages. The results of this approach will be discussed later. 
 
Beforehand it is worth to mention that low concentrations of IL7 were able to increase the 
amount of IFNγ/TNFα/IL2 tp and IFNγ/TNFα dp CD4+ T cells after restimulation with 
Beijing whole cell lysate. For six patients with active pulmonary TB increased proportions 
of both T-cell subsets were observed (fig.29, p. 79). The responsiveness to IL7 seems to 
vary between donors leading to an increase of ~30% to ~120% for both T-cell sub-
populations compared to the incubation with Beijing lysate alone. IL7 is a growth factor and 
continuously secreted by bone marrow stromal cells, thymic cells and keratinocytes. It is 
well known to promote survival of B cells (Melchers, et al., 1992), but it also plays an 
important role in T-cell homeostasis and maturation. The expression level of the associated 
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high affinity receptor (IL7Rα) has been proposed to contribute to T-cell expansion, 
contraction and memory development (Kaech, et al., 2003; Ma, et al., 2006).  
Another theory suggests that deprivation of IL7 in combination with its limited availability 
account for these T-cell dynamics (Mazzucchelli and Durum, 2007).  
The addition of recombinant IL7 at low amounts should optimize cell culture conditions for 
short-term restimulation of PBMC in this thesis. Especially a better T-cell survival and an 
improved responsiveness of CD8+ T cells should be achieved by IL7. Surprisingly a specific 
effect of this cytokine on multi-functional T cells could be observed which gave rise to new 
questions. It has been reported that in vitro incubation with IL7 increases the production of 
Th1 cytokines by mononuclear cells in patients with rheumatoid arthritis (van Roon, et al., 
2003). Furthermore the administration of recombinant IL7 enhances survival of M. 
tuberculosis infected mice (Maeurer, et al., 2000). In animal experiments IL7 synergizes 
with IL15 and the transfer of spleenocytes from treated to untreated mice also increased 
survival (Maeurer, et al., 2000). All these hints together suggest an intertwined role of IL7 
and multi-functional T cells. Since high effectiveness is crucial for the success of 
vaccination strategies the generation of a recombinant BCG vaccine expressing IL7 could be 
a promising approach.  
 
7.4 Functional in vitro assays 
To address the relevance of IL7 and functional aspects of different T-cell subsets, novel in 
vitro assays are needed. They should allow rapid quantification of viable intracellular 
mycobacteria as well as assessment of T cell/macrophage interactions. Especially the 
contribution of different T-cell subset to killing of mycobacteria should be measureable. 
Monocyte-derived macrophages were used as target cells for infection with eGFP expressing 
mycobacteria since they are very similar to the primary host cell of M. tuberculosis in vivo. 
Macrophage-like cell lines were no alternative due to the use of autologous PBMC as 
effector cells. The conventional method for determination of bacterial titers is plating 
bacteria on agar medium and counting of CFU. This method is on the one hand error-prone 
and on the other hand incapable of providing information about side damage to host 
macrophages. Some novel assays have been established to gain insights into direct killing 
mechanisms of T cells (Snyder, et al., 2003). None of these approaches is able to provide 
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information on survival of target cells and killing of mycobacteria simultaneously. The 
direct FACS analysis of eGFP+ macrophages in combination with staining for lineage 
markers allows quantification of vital macrophages and determination of bacterial burden in 
parallel. 
As an initial step to address the feasibility of the in vitro killing assay we compared the 
results gained by flow cytometry to conventional determination of CFU on plates. Therefore 
BCG infected monocyte-derived macrophages were incubated with different concentrations 
of rifampicine and streptomycin, respectively (fig. 33, p. 84). A dose dependent reduction of 
the bacterial load could be observed by flow cytometry and CFU after treatment with both 
antibiotics. Interestingly the FACS approach detected generally higher bacterial titers after 
incubation with antibiotics compared to CFU. Probably this is due to long-term effects after 
treatment with antibiotics which inhibit the growth on plates and cannot be observed 
immediately after cell culture. Nevertheless the dose dependent reduction of intracellular 
mycobacteria was detectable by flow cytometry and the new method seems to be less error-
prone than conventional CFU. Since killing by autologous effector PBMC is likely to be a 
direct effect (Stenger, 2001), the dissimilarity of FACS and CFU regarding bacteriostatic 
effects will be irrelevant for our questions. Hence the flow cytometry-based assay provides 
direct and reliable information about immediate killing of intracellular mycobacteria.  
Consequently infected macrophages were co-cultured with PBMC activated by M. 
tuberculosis lysate and unstimulated PBMC, respectively (fig.34, p. 86). The incubation 
with unstimulated PBMC (PBMC/macrophage ratio = 10:1) already reduced the amount of 
intracellular bacteria. Notably the bactericidal effect was much stronger if PBMC activated 
by M. tuberculosis lysate were used. The same tendency was observed by FACS analysis 
and CFU, but in contrast to flow cytometry the CFU data suffered from a higher standard 
error which impaired the ability to detect minor changes in bacterial titers. Similar results 
regarding the direct or indirect killing effect of autologous PBMC were observed within 
independent experiments using PBMC from another donor (fig. 32, p. 83). The detection of 
eGFP+ macrophages by flow cytometry documented the killing effect of autologous PBMC 
activated by M. tuberculosis lysate. The killing effect was even more pronounced for IL2 
stimulated LAK cells (fig. 32, p. 83). 
In order to show that autologous effector PBMC decrease the bacterial load in a dose-
dependent manner different amounts of PBMC were added to infected macrophages (fig. 35, 
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p. 87). Initially an effector/target ratio of 5-1 and 10-1 was applied. To get an impression 
about the killing mechanism the ratio of CD4+ T cells and CD11b+ macrophages was 
calculated at the end of the assay. Since the amount of T cells remains constant during the 
co-culture period an increase in the final effector/target ratio measured by flow cytometry 
indicates killing of macrophages (for further details see 6.4.1 Methodology, p. 80). This 
allows a quantification of side damage to macrophages and is a unique feature of the novel 
assay. In comparison to unstimulated PBMC, FACS and CFU both documented a dose-
dependent reduction of intracellular mycobacteria by autologous PBMC activated by M. 
tuberculosis or IL2. The strength of the killing effect was comparable and high amounts of 
lysate-activated PBMC were even more potent than LAK cells. Both methods seem to lead 
to identical results at first glance. Taking the calculation of final effector/target ratios into 
account, more detailed information was gained by FACS analysis than by CFU alone. It 
turned out that PBMC stimulated by M. tuberculosis lysate caused slight side damage to 
infected macrophages while LAK cells killed significantly more macrophages under the 
same conditions. Consequently the inclusion of modern flow cytometry provided valuable 
information about killing mechanisms and revealed qualitative differences.  
These findings demonstrated the potential of lysate-activated PBMC to reduce the bacterial 
burden without massive side damage to macrophages. The observed killing effect was as 
strong as the effect mediated by LAK cells. Discrimination between both killing 
mechanisms was possible since LAK cells caused significant side damage to macrophages 
which was not the case for lysate-activated PBMC. Remarkably, increasing amounts of 
effector PBMC led to an increased killing of mycobacteria and IL2 concentrations above 
10U/ml were needed to induce LAK cells. 
Detailed information about the underlying molecular mechanisms of LAK cells and lysate 
activated PBMC are rare in the literature. The generation of LAK cells by high dose 
treatment with recombinant IL2 induces more unspecific ways of killing carried out mainly 
by NK cells (Hiserodt, 1993). It is also known that IL2 acts as an antigen-unspecific 
proliferation factor for T cells and allows clonal expansion (Burchill, et al., 2007). Although 
IL2 activated LAK cells were extensively used for adoptive immunotherapy against cancer 
in the past, the molecular basis of the interactions between LAK cells and their target cells 
has not yet been elucidated in detail. The involvement of Fc-receptors on LAK cells 
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suggests antibody-dependent cytotoxicity, but perforin as well as granzymes also seem to 
play a role (Hank, et al., 1988).  
The killing mechanism mediated by M. tuberculosis lysate-activated PBMC remains elusive, 
as well. Two possible explanations may account for the killing effects of these cells: i) MHC 
restricted recognition of conventional peptides or unconventional (glycol-) lipids presented 
via CD1d; ii) nonspecific activation of PBMC, e.g. by residual TLR ligands within the 
lysate. To distinguish between both mechanisms a block of MHC-I and MHC-II had been 
performed by antibodies. Unfortunately the effector/target co-culture period of 36 hours was 
too long for such blocking experiments and significantly reduced survival of effector PBMC 
(data not shown). Alternatively different T-cell populations were isolated and applied 
separately to the infected macrophages. Using the MACS technology CD4+ and CD8+ T 
cells as well as CD56+ NK cells were purified after stimulation with M. tuberculosis lysate. 
CD56+ NK cells did not have a stronger killing effect than unstimulated PBMC but the 
results for CD4+ and CD8+ T cells were less clear (data not shown). Consequently M. 
tuberculosis lysate was used as a surrogate stimulus during the initial phase of this assay 
which can be replaced by recombinant immunodominant proteins of M. tuberculosis like 
TB10.4 or Ag85a/b in the future. 
 
Considering the whole set of performed experiments, there are some crucial points of 
criticism which impair the potential of this novel assay. For all experiments based on 
antibiotics the direct quantification of eGFP+ macrophages by flow cytometry correlated 
with determination of CFU on plates (fig.37, p. 90). In contrast, among all eight experiments 
based on autologous PBMC only six showed a correlation of FACS analysis and CFU data. 
In some cases killing of bacteria was detected by measuring eGFP+ macrophages which 
could not be verified by CFU and vice versa. Moreover for the same donor and identical 
culture conditions killing by autologous effector PBMC could be measured in some cases 
and not in others (donor 083; fig. 37, p. 90). Possibly the generation of monocyte-derived 
macrophages lead to a heterogeneous target cell population which was more or less 
susceptible for infection with mycobacteria. An example is the variable proportion of CD16 
expressing macrophages among the target cell population. Such assay to assay variations 
could be misleading and interfere with the evaluation of T-cell help. 
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Similar problems were observed by other groups working on functional in vitro assays (Prof. 
S. Stenger, personal communication). The exchange of monocyte-derived macrophages by 
end-differentiated alveolar macrophages may be a possible solution. These lung-resident 
macrophages can be obtained by bronchoalveolar lavage, but they are only present in low 
absolute numbers in these samples. Ethical questions may also arise since this kind of 
medical examination is not free of risk and needs a therapeutic indication. Additionally it 
would be difficult to collect peripheral blood form a patient in the clinic 7d prior to the 
lavage in order to generate autologous effects cells.  
 
Despite all difficulties, the dose-dependent decrease in bacterial burden after treatment with 
antibiotics proof the potential of this assay to directly assess the level of intracellular 
bacteria. In combination with conventional CFU, the FACS based analysis provides 
important information about the quality of the observed killing, which cannot be addressed 
by bacterial growth analysis alone. Therefore it helps to elucidate different killing 
mechanisms. On the other hand, assay to assay variations as well as high technical 
requirements (e.g. the need of FACS analyzers and equipment for cell culture) designates 
the assay for academic research but limits its applicability for field studies in developing 
countries. 
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9 Appendix 
9.1 Supplier List 
 
Supplier Location URL 
Adobe Systems GmbH Ohmstrasse 1 
D-85716 Unterschleißheim 
www.adobe.de 
Amersham Biosciences Europe GmbH Munzinger Strasse 9, D-79111 Freiburg www. amershambiosciences.com 
Applied Biosystems Division Headquarters, 850 Lincoln Centre 
Drive, Foster City, CA 94404, USA 
www.appliedbiosystems.com 
American Type Culture Collection (ATCC) P.O.Box 1549, Manassas, VA 20108, USA www.atcc.org 
Bachofer GmbH  
now: Laborbedarf Saur 
Wannweiler Straße 11, D- 72770 Reutlingen www.h-saur.de 
Bayer AG D-51368 Leverkusen www.bayer.com 
B.Braun 
Becton Dickinson GmbH 
(BD Biosciences): comprising products from 
Pharmingen and Clontech 
Postfach 1120, D-34209 Melsungen 
Tullastrasse 8-12, D-69126 Heidelberg 
www.bbraun.de 
www.bdbiosciences.com 
Biochrom Labs, Inc. 1719 South 13th Street, P.O. Box 996, Terre 
Haute, IN 47808 
USA 
www.biochrom.com 
Bio-Rad Laboratories GmbH Heidemannstrasse 164 
D-80939 München 
www.bio-rad.com 
Corning Fisher Scientific GmbH, Im Heiligen Feld 17, 
D-58239 Schwerte 
www.corning.com/lifesciences 
ebioscience AMDS und ERL, Postfach 1112,  
D-47552 Kranenburg 
www.ebioscience.com 
Eppendorf Barkhausenweg 1, D-22339 Hamburg www.eppendorf.com 
Graph Pad Software, Inc. 11452 El Camino Real, #215 San Diego, CA 
92130 USA 
www.graphpad.com 
Harvard Apparatus, Inc. 84 October Hill Road, Holliston, Ma. 01746, 
USA 
www.harvardapparatus.com 
Heraeus Instruments Kendro Laboratory Products GmbH, Robert-
Bosch-Strasse 1, D-63505 Langenselbold 
www.heraeus-instruments.de 
Hilgenberg GmbH Strauchgraben 2, D-34323 Malsfeld www.hilgenberg-gmbh.de 
IKA Labortechnik GmbH & Co.KG Janke & Kunkel-Strasse 10, D-79219 Staufen  www.ika.net 
Invitrogen GmbH: comprising products from 
Invitrogen, NOVEX and Gibco  
Technologiepark Karlsruhe, Emmy-Noether-
Strasse 10, D-76131 Karlsruhe 
www.invitrogen.com 
Integra Bioscience GmbH  Ruhberg 4, D-35463 Fernwald www.integra-bioscience.de 
Ingenuity systems Mountain View, California, USA www.ingenuity.com 
Jackson ImmunoResearch Europe Ltd Unit 4, Northfield Business Park, Northfield 
Road, Soham, Cambridgeshire, UK CB7 5UE 
www.jireurope.com 
JPT Peptide Technologies Volmerstrasse 5 (UTZ), D-12489 Berlin www.jpt.com/index.htm 
Lab-Therm Scientific 
Leica Microsystems AG 
 
Leica Mikrosysteme Vertrieb GmbH, Lilien-
www.labtherm.co.uk 
www.leica-microsystems.com 
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Supplier Location URL 
thalstrasse 39-45, D-64625 Bensheim 
Memmert GmbH & Co. KG 
Merck 
Postfach 17 20, D-91107 Schwabach 
Frankfurter Strasse 250, D-64293 Darmstadt 
www.memmert.com/de 
www.merck.de 
Metabion GmbH Lena-Christ-Strasse 44, D-82152 Martinsried www.metabion.de 
Microm International GmbH Robert-Bosch-Strasse 49, D-69190 Walldorf www.microm.de 
Microsoft Deutschland GmbH Katharina-Heinroth-Ufer 1, D-10787 Berlin www.microsoft.de 
Millipore GmbH Am Kronberger Hang 5, D-65824 Schwalbach www.millipore.de 
Mobitec Lotzestrasse 22°, D-37083 Göttingen www.mobitec.de 
Molecular Devices GmbH Gutenbergstrasse 10, D-85737 Ismaning/ 
München 
www.moleculardevices.com 
Molecular Probes Europe BV Poortgebouw, Rijnsburgerweg 10 
2333 AA Leiden, The Netherlands 
www.probes.com 
New Brunswick Scientific P.O. Box 4005, Edison, New Jersey, 08818-
4005, USA 
www.nbsc.com/ 
Nunc GmbH und Co.KG Hagenauer Straße 21A, D-65203 Wiesbaden www.nuncbrand.com 
QIAGEN GmbH QIAGEN Strasse 1, D-40724hilden www.qiagen.com 
R&D Systems GmbH Borsigstrasse 7, D-65205 Wiesbaden www.rndsystems.com 
Roche Diagnostics GmbH 
Roche Applied Science 
Sandhofer Strasse 116, D-68305 Mannheim www.roche-applied-science.com 
Carl Roth GmbH & Co.KG Schoemperlenstrasse 1-5, D-76185 Karlsruhe www.carl-roth.de 
Sartorius AG 
 
Savant 
Schleicher & Schuell BioScience GmbH  
Weender Landstrasse 94-10, D-37075 
Goettingen, Germany 
Savant, Farmingdale, NY, USA 
Hahnestrasse 3, D-37586 Dassel/ Relliehausen
www.sartorius.de 
 
www.schleicher-schuell.de 
Scientific Software Group P.O. Box 708188, Sandy, Utah 84070, USA www.scisoftware.com 
Thermo Shandon, Inc. 171 Industry Dr., Pittsburgh, PA 15275, USA www.shandon.com 
Schütt Labortechnik Rudolf-Wissell-Straße 11, D-37079 Göttingen www.schuett-labortechnik.de/ 
Sigma-Aldrich Chemie GmbH Eschenstrasse 5, D-82024 Taufkirchen bei 
München 
www.sigmaaldrich.com 
Zeiss: Unternehmensbereich Mikroskopie Rankestr. 26, D-10789 Berlin www.zeiss.de 
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9.2 HLA phenotyping 
 
 
MHC genotyping of LTBI recognizing Rv3407. 
 
 
Donor HLA-A HLA-B HLA-Cw HLA-DRB1 HLA-DQA1 HLA-DQB1 HLA-DPB1
LTBI-A 0201 / 3201 4402 / 5101 0501 / 1502 0301 / 0401 0301 / 0501 02MS / 0302 0201 / 0401 
LTBI-B 0201 / 6801 1302 / 5101 0602 / 1502 0404 / 0701 0201 / 0301 02MS / 0302 0401 / - 
LTBI-C 0201 / 2501 1801 / 4402 0501 / 1203 0401 / 1101 0303 / 0505 0301 / - 0401 / - 
LTBI-D 2902 / 6901 3508 / 5701 0701 / 1203 0403 / 0701 0201 / 0301 0302 / 0302 0401 / 0601 
LTBI-E 0201 / 3201 0801 / 1501 0304 / 0701 0401 / 1302 0102 / 0301 0302 / 0604 0401 / 0402 
LTBI-G 0101 / 6802 4402 / 5301 0401 / 0501 0402 / 1302 0102 / 0301 0302 / 0604 0401 / 0501 
LTBI-H 0201 / 0301 3501 / 3901 0401 / 1203 0101 / 0404 0101 / 0301 0302 / 0501 0301 / 0402 
LTBI-I 0201 / - 1501 / 1801 0304 / 1203 0401 / 0403 0301 / - 0302 / - 0401 / - 
LTBI-J 0301 / 2402 1501 / 4001 0303 / 0304 1103 / 1501 0102 / 0505 0301 / 0602 0401 / 1001 
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9.3 Zusammenfassung 
Adaptive Immunantworten gegen Mycobacterium tuberculosis (M. tuberculosis) sind von 
entscheidender Bedeutung für die effektive Eindämmung des Erregers sowie den Schutz vor 
einer erneuten, sekundären Tuberkulose (TB). Obwohl Schlüsselfaktoren wie die Th1 Zytoki-
ne IFNγ und TNFα bekannt sind, blieben Bemühungen zur Identifizierung eindeutiger immu-
nologischer Parameter, welche ausschlaggebend für den Krankheitsverlauf sind, bislang er-
folglos. Ein Großteil der infizierten Personen ist durch zelluläre Immunität in der Lage, die 
primäre TB zu bekämpfen und entwickelt darauf hin eine latente Tuberkulose Infektion 
(LTBI) während lediglich ~10% an aktiver TB erkranken. Ein besseres Verständnis der 
zugrunde liegenden Immunprozesse sowie die Identifikation projektiver Biomarker für TB 
sind zentrale Ziele dieser Arbeit. 
Zur Bearbeitung dieser Fragestellungen wurden adaptive Immunantworten gegen M. tubercu-
losis in gesunden Probanden mit LTBI und Patienten mit aktiver TB analysiert. Hierfür wurde 
die Erkennung unterschiedlicher Proteine des Erregers durch die Messung IFNγ exprimieren-
der CD4+ CD45RO+ Gedächtnis T Zellen untersucht. Eine Besonderheit war die Einbezie-
hung sogenannter Latenz-assoziierter Proteine, welche in Zusammenhang mit Dormanz und 
Reaktivierung des Bakteriums stehen. Optimierte Assay Bedingungen waren von Nöten, be-
vor adaptive Gedächtnis Antworten gegen diese Latenz-assoziierten Antigene mittels intrazel-
lulärer Zytokinfärbung detektiert werden konnten. Dies Art von T Zell Antwort lies sich nicht 
im Rahmen konventioneller Kurz-Zeit Stimulationen nachweisen. 7 Tage in vitro Inkubation 
in Verbindung mit einer zweimaligen Restimulation belegten eine spezifische Erkennung 
durch CD4+ CD45RO+ T Zellen für die Mehrheit der getesteten Proteine bei Spendern mit 
LTBI. Der darauf folgende Vergleich zwischen Patienten mit aktiver TB und Personen mit 
LTBI zeigte signifikant höhere T Zell Antworten für 7 der 35 M. tuberculosis Proteine wäh-
rend LTBI.  
Bemerkenswerterweise konnten spezifische T Zellen für eines der Protein, nämlich Rv3407, 
ausschließlich während LTBI gemessen werden und nicht bei Patienten mit aktiver TB.  
Diskriminanz Analysen zeigten, dass eine Unterscheidung zwischen LTBI und TB Patienten 
basierend auf T Zell Antwort gegen ausgewählte Latenz-assoziierte Antigene mit einer Ge-
nauigkeit von 82% möglich ist. Erneut erwies sich Rv3407 als der mit Abstand bedeutendste 
Faktor innerhalb der ausgewählten M. tuberculosis Proteine.  
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Durch den Einsatz synthetischer Peptidpools im Rahmen des neuen Assay konnten mehrere 
potentielle immunogene Epitope innerhalb von Rv3407 identifiziert werden. Darüber hinaus 
dokumentierte der Vergleich von T Zell Antworten nach Kurz-Zeit und Lang-Zeit Stimulation 
unterschiedliche Voraussetzungen für die in vitro Restimulation mit klassischen immundomi-
nanten Antigenen und Latenz-assoziierten Antigen. Diese Unterschiede führen zu der Hypo-
these, dass T Zellen mit Spezifität für Latenz-assoziierte M. tuberculosis Antigene einen an-
deren zellulären Phänotyp bzw. Reifungsgrad aufweisen. 
 
Ein weiterer Schwerpunkt war die Studie zellulärer Zytokinmuster von M. tuberculosis spezi-
fischen T Zellen zur Beurteilung der „Qualität“ adaptiver Immunantworten und deren mögli-
cher Beitrag zum Schutz vor dem Erreger. Diese Untersuchung belegte einen höheren Anteil 
Poly-Zytokin-produzierender T Zellen während LTBI im Vergleich zur aktiven TB. Insbe-
sondere der Anteil von IFNγ/TNFα doppelt positiver (dp) sowie IFNγ/TNFα/IL2 trippel posi-
tiver (tp) T Zellen war hiervon betroffen. Die Gabe von rekombinantem IL7 in diesem Scena-
rio führte zu einem weiteren absoluten und relativen Anstieg dieser T Zell Subpopulation. Die 
tatsächliche Relevanz dieser Beobachtungen in vivo sollte darauf hin im Rahmen neuer funk-
tionaler in vitro Assays untersucht werden. 
Die Infektion humaner Monozyten-abgeleiteter Makrophagen mit eGFP exprimierenden My-
kobakterien bildete die Grundlage für die Erforschung der funktionalen Eigenschaften unter-
schiedlicher autologer T Zell Populationen. Vorversuche belegten das Potential der neuen 
Methode zur direkten Messung intrazellulärer Mykobakterien durch die Detektion eGFP+ 
Makrophagen mittels Durchflusszytometrie. Darüber hinaus zeigte das neue in vitro Assay ein 
Dosis-abhängiges Abtöten von intrazellulären Bakterien, hervorgerufen durch autologe 
PBMC. Diese wurden zuvor entweder mit Hilfe von M. tuberculosis Lysat oder hohen Kon-
zentrationen von IL2 aktiviert. Die Bestimmung der Anzahl lebensfähiger Makrophagen zeig-
te grundlegende mechanistische Unterschiede in dem erzielten Abtötungs-Effekt beider 
PBMC Typen. Der Kollateralschaden an Makrophagen war signifikant unterschiedlich und 
derartige Auswirkungen auf das Überleben der Wirts-Zellen hätten nicht durch eine konventi-
onelle Bestimmung bakterieller Titer mittels CFU beobachtet werden können. Allerdings 
schmälerten beachtliche Assay-zu-Assay Variation den potentiellen Nutzen dieser vielver-
sprechenden, neuen Methode. Vermutlich begründet sich diese Varianz in der Heterogenität 
der eingesetzten Makrophagen Population. 
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